"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2021/072404 A1,107-595-519-999-435,2021-04-15,2021,US 2020/0055407 W,2020-10-13,US 201962913474 P;;US 201962945705 P,2019-10-10,A MACHINE LEARNING ALGORITHM FOR PREDICTING CLINICAL OUTCOMES AND IDENTIFYING DRUG TARGETS IN ISCHEMIC STROKE,"The presently-disclosed subject matter generally to methods for identifying and analyzing biomarkers to determine group effects. The presently-disclosed subject matter also relates to methods for identifying genes and proteins that increase or decrease in response to ischemic stroke damage. The disclosed subject matter further describes methods of predicting edema and infarct volume in a patient. Also described herein are methods of determining the necessity of intervention for smokers. Further disclosed herein, are methods for testing therapies for ischemic stroke.",UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH;;FRASER JUSTIN;;CHENG QIANG,,https://lens.org/107-595-519-999-435,Patent Application,yes,4,0,2,2,0,C12Q1/6883;;C12Q2600/158;;A61B5/145;;A61P9/00;;G01N33/5088;;G01N33/6827;;G01N2800/2871;;G16H50/30;;G16B20/20;;G16B40/10;;G16H50/30;;G16B25/10;;G16B40/20;;C12Q1/6883;;C12Q2600/158,C12Q1/68,,1,1,001-985-632-110-394,10.1136/neurintsurg-2018-014118;;30064997,"FRASER ET AL.: ""The Blood And Clot Thrombectomy Registry And Collaboration (BACTRAC) protocol: novel method for evaluating human stroke"", J NEUROLNTERVENT SURG, vol. 11, no. 3, March 2019 (2019-03-01), pages 265 - 270, [retrieved on 20180731]",PENDING
2,US,A1,US 2019/0391561 A1,085-441-343-626-820,2019-12-26,2019,US 201816013781 A,2018-06-20,US 201816013781 A,2018-06-20,TOOLPATH GENERATION BY DEMONSTRATION FOR COMPUTER AIDED MANUFACTURING,"Methods, systems, and apparatus, including medium-encoded computer program products, for computer aided design and manufacture of physical structures using toolpath generation by demonstration include, in one aspect, a method including: receiving a user specified path traced in reference to geometry of a modeled object to be manufactured by a computer-controlled manufacturing system, wherein the user specified path is a spatial representation of a desired toolpath; synthesizing candidate toolpaths for the geometry of the modeled object using variations of at least one toolpath parameter; measuring similarities between the candidate toolpaths and the user specified path, including comparing at least a spatial similarity between the candidate toolpaths and the user specified path; suggesting at least some of the candidate toolpaths based on the measured similarities; and determining a toolpath for use when manufacturing the modeled object in accordance with user input regarding the at least some of the candidate toolpaths.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE WILLIAM;;MATEJKA JUSTIN,AUTODESK INC (2018-06-20),https://lens.org/085-441-343-626-820,Patent Application,yes,0,1,2,2,0,G05B19/4097;;G05B2219/36252;;Y02P90/02;;G05B19/4099;;G05B2219/49007;;G05B2219/35134,G05B19/4099,,0,0,,,,ACTIVE
3,US,B2,US 11521178 B2,065-318-642-083-791,2022-12-06,2022,US 201815925632 A,2018-03-19,US 201815925632 A;;US 201762501360 P,2017-05-04,Techniques for crowdsourcing and dynamically updating computer-aided schedules,"In various embodiments, a scheduling application automatically determines the timing of linearly dependent events. In operation, the scheduling application detects that a first event included in an original scheduled sequence of events has not completed by a scheduled completion time based on a current time. The scheduling application then determines that a second event included in the original scheduled sequence of events has a dependency on the completion of the first event. Subsequently, the scheduling application updates one or more temporal properties associated with the second event based on the current time to generate a third event. The scheduling application then generates, via a processor, a modified scheduled sequence of events that includes the third event instead of the second event. Advantageously, automatically adjusting the timing of linear dependent events based on the current time reduces inefficiencies associated with conventional scheduling techniques.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK,AUTODESK INC (2018-03-16),https://lens.org/065-318-642-083-791,Granted Patent,yes,21,0,2,2,0,G06Q10/1095;;G06Q10/107;;G06Q10/1095;;G06F3/0482;;G06Q10/107,G06Q10/10;;G06F3/0482,,1,1,044-123-433-147-54X,10.1007/s11423-007-9078-x,"Yoon, Seung Won, and Scott D. Johnson. “Phases and patterns of group development in virtual learning teams.” Educational Technology Research and Development 56.5-6 (2008): 595-618. (Year: 2008).",ACTIVE
4,US,B2,US 10332285 B2,017-068-998-467-817,2019-06-25,2019,US 201514732611 A,2015-06-05,US 201514732611 A,2015-06-05,Techniques for automatic and dynamic opacity settings for scatterplots,"An opacity engine for automatically and dynamically setting an opacity level for a scatterplot based on a predetermined value for a mean opacity level of utilized pixels (MOUP) in the scatterplot. The opacity engine may automatically set the opacity level for the scatterplot to produce the predetermined MOUP value in the scatterplot. A utilized pixel in the scatterplot comprises a pixel displaying at least one data point representing data. The MOUP value in the scatterplot may be equal to the sum of the final opacity levels of all utilized pixels in the chart, divided by the number of utilized pixels in the chart. The predetermined MOUP value may be between 35%-45%, such as 40%. The opacity engine may adjust the determined opacity level for charts having relatively low over-plotting factors.",AUTODESK INC,MATEJKA JUSTIN FRANK;;ANDERSON FRASER;;FITZMAURICE GEORGE,AUTODESK INC (2015-06-04),https://lens.org/017-068-998-467-817,Granted Patent,yes,1,0,4,4,0,G06T11/206;;G06T11/206,G06T11/20,,10,7,007-393-951-835-404;;115-928-714-603-865;;115-928-714-603-865;;055-519-339-568-292;;079-426-080-477-372;;007-393-951-835-404;;006-469-299-651-410,10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086;;10.1145/1753326.1753357;;10.1145/1753326.1753357;;10.1145/1357054.1357127;;10.1145/1842993.1842999;;10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086;;10.1145/964965.808606,"Mayorga et al. (“Splatterplots: Overcoming Overdraw in Scatter Plots”, EEE Transactions on Visualization and Computer Graphics, vol. 19, No. 9, Sep. 2013.;;Heer et al. Crowdsourcing Graphical Perception: Using Mechanical Turk to Assess Visualization Design. ACMCHI, 203-212. CHI 2010.;;Few et al. “Solutions to the Problem of Over-Plotting in graphs,”, Visual Business Intelligence Newsletter, Sep./Oct. 2008.;;Fast, M. “What the heck is PITCHf/x”, The Hardball times annual, 2010, 153-8.;;Few, S. Solutions to the problem of Over-plotting in Graphs. Visual Business intelligence Newsletter, 2008.;;Heer, J. and Bostock, M. Crowdsourcing Graphical Perception: “Using Mechanical Turk to Assess Visualization Design”. ACM CHI 10, 2010, 203-212.;;Kittur, A., Chi, E.H., and Suh, B, Crowdsourcing User Studies with Mechanical Turk. ACM CHI (2008), 453-456.;;Luboschik, M., Radloff, A., and Schumann, H. A New Weaving Technique for Handling Overlapping Regions. ACM AVI (2010), 25-32.;;Mayorga, A. and Gleicher, M. Splatterplots: Overcoming Overdraw in Scatter Plots. IEEE Transactions on Visualization and Computer Graphics 19, 9 (2013) 1526-1538.;;Porter, T. and Duff, T. “Compositing Digital Images”, ACM SIGGRAPH (1984), 253-259.",ACTIVE
5,US,A1,US 2019/0311510 A1,173-562-819-106-734,2019-10-10,2019,US 201916450683 A,2019-06-24,US 201916450683 A;;US 201514732611 A,2015-06-05,TECHNIQUES FOR AUTOMATIC AND DYNAMIC OPACITY SETTINGS FOR SCATTERPLOTS,"An opacity engine for automatically and dynamically setting an opacity level for a scatterplot based on a predetermined value for a mean opacity level of utilized pixels (MOUP) in the scatterplot. The opacity engine may automatically set the opacity level for the scatterplot to produce the predetermined MOUP value in the scatterplot. A utilized pixel in the scatterplot comprises a pixel displaying at least one data point representing data. The MOUP value in the scatterplot may be equal to the sum of the final opacity levels of all utilized pixels in the chart, divided by the number of utilized pixels in the chart. The predetermined MOUP value may be between 35%-45%, such as 40%. The opacity engine may adjust the determined opacity level for charts having relatively low over-plotting factors.",AUTODESK INC,MATEJKA JUSTIN FRANK;;ANDERSON FRASER;;FITZMAURICE GEORGE,AUTODESK INC (2015-06-04),https://lens.org/173-562-819-106-734,Patent Application,yes,1,0,4,4,0,G06T11/206;;G06T11/206,G06T11/20,,3,2,115-928-714-603-865;;007-393-951-835-404,10.1145/1753326.1753357;;10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086,"Heer et al. ""Crowdsourcing Graphical Perception: Using Mechanical Turk to Assess Visualization Design"". ACMCHI, 203–212. CHI 2010. (Year: 2010);;Mayorga et al. ""Splatterplots: Overcoming Overdraw in Scatter Plots"", EEE TRANSACTIONS ON VISUALIZATION AND COMPUTER GRAPHICS, VOL. 19, NO. 9, SEPTEMBER 2013 (Year: 2013);;Few et al., ""Solutions to the Problem of Over-Plotting in graphs,"", Visual Business Intelligence Newsletter, September/October 2008 (Year: 2008)",ACTIVE
6,US,A1,US 2016/0358351 A1,055-570-820-713-947,2016-12-08,2016,US 201514732611 A,2015-06-05,US 201514732611 A,2015-06-05,TECHNIQUES FOR AUTOMATIC AND DYNAMIC OPACITY SETTINGS FOR SCATTERPLOTS,"An opacity engine for automatically and dynamically setting an opacity level for a scatterplot based on a predetermined value for a mean opacity level of utilized pixels (MOUP) in the scatterplot. The opacity engine may automatically set the opacity level for the scatterplot to produce the predetermined MOUP value in the scatterplot. A utilized pixel in the scatterplot comprises a pixel displaying at least one data point representing data. The MOUP value in the scatterplot may be equal to the sum of the final opacity levels of all utilized pixels in the chart, divided by the number of utilized pixels in the chart. The predetermined MOUP value may be between 35%-45%, such as 40%. The opacity engine may adjust the determined opacity level for charts having relatively low over-plotting factors.",AUTODESK INC,MATEJKA JUSTIN FRANK;;ANDERSON FRASER;;FITZMAURICE GEORGE,AUTODESK INC (2015-06-04),https://lens.org/055-570-820-713-947,Patent Application,yes,2,3,4,4,0,G06T11/206;;G06T11/206,G06T11/20,,6,4,115-928-714-603-865;;007-393-951-835-404;;007-393-951-835-404;;115-928-714-603-865,10.1145/1753326.1753357;;10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086;;10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086;;10.1145/1753326.1753357,"Heer et al. Crowdsourcing Graphical Perception: Using Mechanical Turk to Assess Visualization Design. ACMCHI, 203-212. CHI 2010.;;Few et al. "" Solutions to the Problem of Over-Plotting in graphs,"", Visual Business Intelligence Newsletter, September/October 2008.;;Mayorga et al. (""Splatterplots: Overcoming Overdraw in Scatter Plots"", EEE TRANSACTIONS ON VISUALIZATION AND COMPUTER GRAPHICS, VOL. 19, NO. 9, SEPTEMBER 2013;;Mayorga et al. (""Splatterplots: Overcoming Overdraw in Scatter Plots"", EEE TRANSACTIONS ON VISUALIZATION AND COMPUTER GRAPHICS, VOL. 19, NO. 9, SEPTEMBER 2013;;Heer et al. Crowdsourcing Graphical Perception: Using Mechanical Turk to Assess Visualization Design. ACMCHI, 203-212. CHI 2010.;;Few et al. "" Solutions to the Problem of Over-Plotting in graphs,"", Visual Business Intelligence Newsletter, September/October 2008.",ACTIVE
7,US,B2,US 10838400 B2,051-137-145-117-929,2020-11-17,2020,US 201816013781 A,2018-06-20,US 201816013781 A,2018-06-20,Toolpath generation by demonstration for computer aided manufacturing,"Methods, systems, and apparatus, including medium-encoded computer program products, for computer aided design and manufacture of physical structures using toolpath generation by demonstration include, in one aspect, a method including: receiving a user specified path traced in reference to geometry of a modeled object to be manufactured by a computer-controlled manufacturing system, wherein the user specified path is a spatial representation of a desired toolpath; synthesizing candidate toolpaths for the geometry of the modeled object using variations of at least one toolpath parameter; measuring similarities between the candidate toolpaths and the user specified path, including comparing at least a spatial similarity between the candidate toolpaths and the user specified path; suggesting at least some of the candidate toolpaths based on the measured similarities; and determining a toolpath for use when manufacturing the modeled object in accordance with user input regarding the at least some of the candidate toolpaths.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE WILLIAM;;MATEJKA JUSTIN,AUTODESK INC (2018-06-20),https://lens.org/051-137-145-117-929,Granted Patent,yes,8,0,2,2,0,G05B19/4097;;G05B2219/36252;;Y02P90/02;;G05B19/4099;;G05B2219/49007;;G05B2219/35134,G05B19/4099,,5,3,118-462-364-965-82X;;004-986-063-874-83X;;082-867-705-936-762,10.14778/1454159.1454226;;10.1016/j.procs.2016.08.106;;10.1016/b978-024081193-2.50005-0,"Anderson, “Objective Surgical Skill Evaluation,” (2010) University of Alberta, Department of Computing Science, 105 pages.;;Ding et al., “Querying and Mining of Time Series Data: Experimental Comparison of Representations and Distance Measures,” Proceedings of the VLDB Endowment (2008) 1(2):1542-1552.;;Vaughan and Gabrys, “Comparing and Combining Time Series Trajectories Using Dynamic Time Warping,” Procedia Computer Science (2016) 96:465-474.;;Unknown author, “PowerMill Getting Started Tutorial,” (Sep. 4, 2017) [online] (retrieved from https://knowledge.autodesk.com/support/powermill/getting-started/caas/simplecontent/content/powermill-getting-started-tutorial.html), 10 pages.;;Unknown author, “Learning—Adaptive Clearing Toolpaths,” (May 30, 2018) [online] (retrieved from http://help.autodesk.com/view/fusion360/ENU/?guid=GUID-E9EBAB0B-5DF4-4168-BA58-AEA055D980F5), 7 pages.",ACTIVE
8,US,A1,US 2018/0322471 A1,145-967-389-621-794,2018-11-08,2018,US 201815925632 A,2018-03-19,US 201815925632 A;;US 201762501360 P,2017-05-04,TECHNIQUES FOR CROWDSOURCING AND DYNAMICALLY UPDATING COMPUTER-AIDED SCHEDULES,"In various embodiments, a scheduling application automatically determines the timing of linearly dependent events. In operation, the scheduling application detects that a first event included in an original scheduled sequence of events has not completed by a scheduled completion time based on a current time. The scheduling application then determines that a second event included in the original scheduled sequence of events has a dependency on the completion of the first event. Subsequently, the scheduling application updates one or more temporal properties associated with the second event based on the current time to generate a third event. The scheduling application then generates, via a processor, a modified scheduled sequence of events that includes the third event instead of the second event. Advantageously, automatically adjusting the timing of linear dependent events based on the current time reduces inefficiencies associated with conventional scheduling techniques.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK,AUTODESK INC (2018-03-16),https://lens.org/145-967-389-621-794,Patent Application,yes,21,3,2,2,0,G06Q10/1095;;G06Q10/107;;G06Q10/1095;;G06F3/0482;;G06Q10/107,G06Q10/10,,1,1,044-123-433-147-54X,10.1007/s11423-007-9078-x,"Yoon, Seung Won, and Scott D. Johnson. ""Phases and patterns of group development in virtual learning teams."" Educational Technology Research and Development 56.5-6 (2008): 595-618. (Year: 2008)",ACTIVE
9,US,B2,US 10580178 B2,155-968-378-133-813,2020-03-03,2020,US 201916450683 A,2019-06-24,US 201916450683 A;;US 201514732611 A,2015-06-05,Techniques for automatic and dynamic opacity settings for scatterplots,"An opacity engine for automatically and dynamically setting an opacity level for a scatterplot based on a predetermined value for a mean opacity level of utilized pixels (MOUP) in the scatterplot. The opacity engine may automatically set the opacity level for the scatterplot to produce the predetermined MOUP value in the scatterplot. A utilized pixel in the scatterplot comprises a pixel displaying at least one data point representing data. The MOUP value in the scatterplot may be equal to the sum of the final opacity levels of all utilized pixels in the chart, divided by the number of utilized pixels in the chart. The predetermined MOUP value may be between 35%-45%, such as 40%. The opacity engine may adjust the determined opacity level for charts having relatively low over-plotting factors.",AUTODESK INC,MATEJKA JUSTIN FRANK;;ANDERSON FRASER;;FITZMAURICE GEORGE,AUTODESK INC (2015-06-04),https://lens.org/155-968-378-133-813,Granted Patent,yes,1,0,4,4,0,G06T11/206;;G06T11/206,G06T11/20,,7,5,007-393-951-835-404;;115-928-714-603-865;;055-519-339-568-292;;079-426-080-477-372;;006-469-299-651-410,10.1109/tvcg.2013.65;;pmc4048834;;23846097;;23530086;;10.1145/1753326.1753357;;10.1145/1357054.1357127;;10.1145/1842993.1842999;;10.1145/964965.808606,"Few et al., “Solutions to the Problem of Over-Plotting in graphs,”, Visual Business Intelligence Newsletter, Sep./Oct. 2008 (Year: 2008).;;Mayorga et al. “Splatterplots: Overcoming Overdraw in Scatter Plots”, EEE Transactions on Visualization and Computer Graphics, vol. 19, No. 9, Sep. 2013 (Year: 2013).;;Heer et al. “Crowdsourcing Graphical Perception: Using Mechanical Turk to Assess Visualization Design”. ACMCHI, 203-212. CHI 2010. (Year: 2010).;;Fast, Mike, “What the heck is PITCHf/x”, The Hardball Times Annual, 2010, pp. 1-6.;;Kittur et al., “Crowdsourcing User Studies with Mechanical Turk”, ACM CHI (2008), pp. 453-456.;;Luboschik et al., “A New Weaving Technique for Handling Overlapping Regions”, ACM AVI (2010), pp. 25-32.;;Porter et al., “Compositing Digital Images”, ACM SIGGRAPH, vol. 18, No. 3, Jul. 1984, pp. 253-259.",ACTIVE
10,US,A1,US 2023/0243849 A1,109-925-339-628-129,2023-08-03,2023,US 202117927389 A,2021-05-26,US 202117927389 A;;US 202063030259 P;;US 2021/0034279 W,2020-05-26,Identifying Risk of Cerebra Edema,Tools for identifying risk of cerebral edema in a stroke patient are provided and include a method that involves identifying risk of cerebral edema when cytokines and chemokines are detected in a systemic blood sample from the subject.,UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH R;;FRASER JUSTIN F;;CHENG QIANG,UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2020-06-11),https://lens.org/109-925-339-628-129,Patent Application,yes,0,0,3,3,0,G01N2800/50;;G01N2800/2871;;G01N33/6893;;G01N2333/4724;;G01N2333/7155;;G01N2333/523;;G01N33/6893;;G01N2333/7155;;G01N2333/7158;;G01N2800/2871;;G01N2800/50,G01N33/68,,0,0,,,,PENDING
11,US,B1,US 11736312 B1,038-357-380-390-259,2023-08-22,2023,US 202217654934 A,2022-03-15,US 202217654934 A;;US 202016943652 A,2020-07-30,Variable termination in a vehicle communication bus,"Disclosed are systems, methods, and non-transitory computer-readable media for variable termination in a vehicle communication bus. To provide compatibility with multiple vehicles, a device may include a software selectable terminator resistor that can be programmatically enabled or disabled to add or remove resistance as needed. For example, the software selectable terminator resistor may be enabled when the device is added as an end node in a high-speed communication bus and operates as a terminator resistor. Alternatively, the software selectable terminator resistor may be disabled when the device is added as an intermediate node positioned between terminator resistors in the high-speed communication bus.",SAMSARA NETWORKS INC,XIAO JUSTIN TINGAO;;WALKER BENEDICT FRASER;;YANG XIN,SAMSARA INC (2020-08-09),https://lens.org/038-357-380-390-259,Granted Patent,yes,17,0,3,3,0,H04L2012/40215;;H04L2012/40273;;H04L12/40169;;H04L12/40;;H04L2012/40273;;H04L2012/40215,H04L12/40,,6,0,,,"“U.S. Appl. No. 16/943,652, Non Final Office Action dated Nov. 4, 2021”, 13 pgs.;;“U.S. Appl. No. 16/943,652, Response filed Nov. 19, 2021 to Non Final Office Action dated Nov. 4, 2021”, 10 pgs.;;“U.S. Appl. No. 16/943,652, Notice of Allowance dated Dec. 17, 2021”, 9 pgs.;;U.S. Appl. No. 16/943,652 U.S. Pat. No. 11,310,069, filed Jul. 30, 2020, Variable Termination in a Vehicle Communication Bus.;;U.S. Appl. No. 16/985,649, filed Aug. 5, 2020, Variable Multiplexer for Vehicle Communication Bus Compatibility.;;“U.S. Appl. No. 16/985,649, Non Final Office Action dated Jan. 19, 2023”, 11 pgs.",ACTIVE
12,US,B2,US 11310069 B2,151-426-564-390-897,2022-04-19,2022,US 202016943652 A,2020-07-30,US 202016943652 A,2020-07-30,Variable termination in a vehicle communication bus,"Disclosed are systems, methods, and non-transitory computer-readable media for variable termination in a vehicle communication bus. To provide compatibility with multiple vehicles, a device may include a software selectable terminator resistor that can be programmatically enabled or disabled to add or remove resistance as needed. For example, the software selectable terminator resistor may be enabled when the device is added as an end node in a high-speed communication bus and operates as a terminator resistor. Alternatively, the software selectable terminator resistor may be disabled when the device is added as an intermediate node positioned between terminator resistors in the high-speed communication bus.",SAMSARA NETWORKS INC,XIAO JUSTIN TINGAO;;WALKER BENEDICT FRASER;;YANG XIN,SAMSARA INC (2020-08-09),https://lens.org/151-426-564-390-897,Granted Patent,yes,12,3,3,3,0,H04L2012/40215;;H04L2012/40273;;H04L12/40169;;H04L12/40;;H04L2012/40273;;H04L2012/40215,H04L12/40,,0,0,,,,ACTIVE
13,US,A1,US 2022/0038301 A1,048-020-781-774-367,2022-02-03,2022,US 202016943652 A,2020-07-30,US 202016943652 A,2020-07-30,VARIABLE TERMINATION IN A VEHICLE COMMUNICATION BUS,"Disclosed are systems, methods, and non-transitory computer-readable media for variable termination in a vehicle communication bus. To provide compatibility with multiple vehicles, a device may include a software selectable terminator resistor that can be programmatically enabled or disabled to add or remove resistance as needed. For example, the software selectable terminator resistor may be enabled when the device is added as an end node in a high-speed communication bus and operates as a terminator resistor. Alternatively, the software selectable terminator resistor may be disabled when the device is added as an intermediate node positioned between terminator resistors in the high-speed communication bus.",SAMSARA NETWORKS INC,XIAO JUSTIN TINGAO;;WALKER BENEDICT FRASER;;YANG XIN,SAMSARA INC (2020-08-09),https://lens.org/048-020-781-774-367,Patent Application,yes,0,2,3,3,0,H04L2012/40215;;H04L2012/40273;;H04L12/40169;;H04L12/40;;H04L2012/40273;;H04L2012/40215,H04L12/40,,0,0,,,,ACTIVE
14,US,A1,US 2023/0134886 A1,091-312-634-414-162,2023-05-04,2023,US 202017768181 A,2020-10-13,US 202017768181 A;;US 201962913474 P;;US 201962945705 P;;US 2020/0055407 W,2019-10-10,A MACHINE LEARNING ALGORITHM FOR PREDICTING CLINICAL OUTCOMES AND IDENTIFYING DRUG TARGETS IN ISCHEMIC STROKE,"The presently-disclosed subject matter generally to methods for identifying and analyzing biomarkers to determine group effects. The presently-disclosed subject matter also relates to methods for identifying genes and proteins that increase or decrease in response to ischemic stroke damage. The disclosed subject matter further describes methods of predicting edema and infarct volume in a patient. Also described herein are methods of determining the necessity of intervention for smokers. Further disclosed herein, are methods for testing therapies for ischemic stroke.",UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH R;;FRASER JUSTIN F;;CHENG QIANG,UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2022-09-08),https://lens.org/091-312-634-414-162,Patent Application,yes,0,0,2,2,0,C12Q1/6883;;C12Q2600/158;;A61B5/145;;A61P9/00;;G01N33/5088;;G01N33/6827;;G01N2800/2871;;G16H50/30;;G16B20/20;;G16B40/10;;G16H50/30;;G16B25/10;;G16B40/20;;C12Q1/6883;;C12Q2600/158,G16H50/30;;C12Q1/6883;;G16B25/10;;G16B40/20,,0,0,,,,PENDING
15,WO,A3,WO 2021/242877 A3,022-377-802-851-05X,2022-01-06,2022,US 2021/0034279 W,2021-05-26,US 202063030259 P,2020-05-26,IDENTIFYING RISK OF CEREBRA EDEMA,Tools for identifying risk of cerebral edema in a stroke patient are provided and include a method that involves identifying risk of cerebral edema when cytokines and chemokines are detected in a systemic blood sample from the subject.,UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH R;;FRASER JUSTIN F;;CHENG QIANG,,https://lens.org/022-377-802-851-05X,Search Report,yes,3,0,3,3,0,G01N2800/50;;G01N2800/2871;;G01N33/6893;;G01N2333/4724;;G01N2333/7155;;G01N2333/523;;G01N33/6893;;G01N2333/7155;;G01N2333/7158;;G01N2800/2871;;G01N2800/50,G01N33/68,,1,1,006-874-637-337-678,10.3171/2016.8.peds16326;;27858578,"ZHU XIAO, MCDOWELL MICHAEL M., NEWMAN WILLIAM C., MASON GARY E., GREENE STEPHANIE, TAMBER MANDEEP S.: ""Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report"", JOURNAL OF NEUROSURGERY. PEDIATRICS, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, US, vol. 19, no. 2, 1 February 2017 (2017-02-01), US , pages 249 - 253, XP055895708, ISSN: 1933-0707, DOI: 10.3171/2016.8.PEDS16326",PENDING
16,WO,A2,WO 2021/242877 A2,051-190-278-297-196,2021-12-02,2021,US 2021/0034279 W,2021-05-26,US 202063030259 P,2020-05-26,IDENTIFYING RISK OF CEREBRA EDEMA,Tools for identifying risk of cerebral edema in a stroke patient are provided and include a method that involves identifying risk of cerebral edema when cytokines and chemokines are detected in a systemic blood sample from the subject.,UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH R;;FRASER JUSTIN F;;CHENG QIANG,,https://lens.org/051-190-278-297-196,Patent Application,yes,0,0,3,3,0,G01N2800/50;;G01N2800/2871;;G01N33/6893;;G01N2333/4724;;G01N2333/7155;;G01N2333/523;;G01N33/6893;;G01N2333/7155;;G01N2333/7158;;G01N2800/2871;;G01N2800/50,G01N33/53,,0,0,,,,PENDING
17,US,B2,US 11921414 B2,150-618-674-352-955,2024-03-05,2024,US 17390772,2021-07-30,,,Reflection-based target selection on large displays with zero latency feedback,"One embodiment of the invention disclosed herein provides a system that includes a mirror apparatus with a first surface to which a half-silvered mirror film is applied, where the mirror apparatus transmits a transmitted image from a second surface to the first surface. The system further includes a servo-controlled dimmer that adjusts a level of ambient light associated with the mirror apparatus. The system further includes a motion sensing device that tracks positions of a plurality of points associated with an object; wherein the object is situated on the half-silvered mirror film side of the mirror apparatus. The system further includes a computing device including a memory that stores instructions that, when executed by a processor included in the computing device, cause the processor to control the servo-controlled dimmer to adjust the ambient light such that both the transmitted image and a reflected image is visible on the first surface.","AUTODESK, INC.",Fraser Anderson;;Tovi Grossman;;Justin Frank Matejka;;George Fitzmaurice,AUTODESK INC (2014-06-25),https://lens.org/150-618-674-352-955,Granted Patent,yes,12,0,1,1,0,G03B21/62;;G03B21/10,G03B21/62;;G03B21/10,,0,0,,,,UNKNOWN
18,US,A1,US 2015/0098143 A1,159-209-726-778-043,2015-04-09,2015,US 201414315609 A,2014-06-26,US 201414315609 A;;US 201361886539 P,2013-10-03,REFLECTION-BASED TARGET SELECTION ON LARGE DISPLAYS WITH ZERO LATENCY FEEDBACK,"One embodiment of the invention disclosed herein provides a system that includes a mirror apparatus with a first surface to which a half-silvered mirror film is applied, where the mirror apparatus transmits a transmitted image from a second surface to the first surface. The system further includes a servo-controlled dimmer that adjusts a level of ambient light associated with the mirror apparatus. The system further includes a motion sensing device that tracks positions of a plurality of points associated with an object; wherein the object is situated on the half-silvered mirror film side of the mirror apparatus. The system further includes a computing device including a memory that stores instructions that, when executed by a processor included in the computing device, cause the processor to control the servo-controlled dimmer to adjust the ambient light such that both the transmitted image and a reflected image is visible on the first surface.",AUTODESK INC,ANDERSON FRASER;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2014-06-25),https://lens.org/159-209-726-778-043,Patent Application,yes,18,11,3,3,0,G03B21/62;;G03B21/62;;G03B21/10;;G03B21/10,G02B5/08,359/839,0,0,,,,ACTIVE
19,US,B2,US 11086207 B2,104-358-622-483-754,2021-08-10,2021,US 201414315609 A,2014-06-26,US 201414315609 A;;US 201361886539 P,2013-10-03,Reflection-based target selection on large displays with zero latency feedback,"One embodiment of the invention disclosed herein provides a system that includes a mirror apparatus with a first surface to which a half-silvered mirror film is applied, where the mirror apparatus transmits a transmitted image from a second surface to the first surface. The system further includes a servo-controlled dimmer that adjusts a level of ambient light associated with the mirror apparatus. The system further includes a motion sensing device that tracks positions of a plurality of points associated with an object; wherein the object is situated on the half-silvered mirror film side of the mirror apparatus. The system further includes a computing device including a memory that stores instructions that, when executed by a processor included in the computing device, cause the processor to control the servo-controlled dimmer to adjust the ambient light such that both the transmitted image and a reflected image is visible on the first surface.",AUTODESK INC,ANDERSON FRASER;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2014-06-25),https://lens.org/104-358-622-483-754,Granted Patent,yes,12,0,3,3,0,G03B21/62;;G03B21/62;;G03B21/10;;G03B21/10,G03B21/62;;G03B21/10,,0,0,,,,ACTIVE
20,US,A1,US 2015/0099252 A1,057-291-429-312-578,2015-04-09,2015,US 201414315574 A,2014-06-26,US 201414315574 A;;US 201361886534 P,2013-10-03,ENHANCING MOVEMENT TRAINING WITH AN AUGMENTED REALITY MIRROR,One embodiment of the invention disclosed herein provides techniques for controlling a movement training environment. A movement training system retrieves a movement object from a set of movement objects. The movement training system attains first motion capture data associated with a first user performing a movement based on the movement object. The movement training system generates a first articulable representation based on the first motion capture data. The movement training system compares at least one first joint position related to the first articulable representation with at least one second joint position related to a second articulable representation associated with the movement object. The movement training system calculates a first similarity score based on a difference between the at least one first joint position and the at least one second joint position.,AUTODESK INC,ANDERSON FRASER;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2014-06-25),https://lens.org/057-291-429-312-578,Patent Application,yes,19,95,2,2,0,G06T7/0014;;G06T2207/30196;;G06T2207/30221;;G06T11/00;;G06T7/251;;G09B19/003;;G09B5/02;;G16H20/30;;G06V40/23;;G09B19/003;;G09B5/02;;G06T7/0014;;G06T2207/30196;;G06T2207/30221;;G06T11/00;;G06T7/251;;G06V40/23;;G16H20/30,A63B24/00;;G09B5/02;;G09B19/00;;G16H20/30,434/257;;434/247,1,0,,,"Anderson et al. ""You Move: Enhancing Movement Training with an augmented Mirror"", UIST'13, October 8-11 2013, Vision, St. Andrews, UK",ACTIVE
21,US,B2,US 10134296 B2,066-571-598-292-451,2018-11-20,2018,US 201414315574 A,2014-06-26,US 201414315574 A;;US 201361886534 P,2013-10-03,Enhancing movement training with an augmented reality mirror,One embodiment of the invention disclosed herein provides techniques for controlling a movement training environment. A movement training system retrieves a movement object from a set of movement objects. The movement training system attains first motion capture data associated with a first user performing a movement based on the movement object. The movement training system generates a first articulable representation based on the first motion capture data. The movement training system compares at least one first joint position related to the first articulable representation with at least one second joint position related to a second articulable representation associated with the movement object. The movement training system calculates a first similarity score based on a difference between the at least one first joint position and the at least one second joint position.,AUTODESK INC,ANDERSON FRASER;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2014-06-25),https://lens.org/066-571-598-292-451,Granted Patent,yes,19,25,2,2,0,G06T7/0014;;G06T2207/30196;;G06T2207/30221;;G06T11/00;;G06T7/251;;G09B19/003;;G09B5/02;;G16H20/30;;G06V40/23;;G09B19/003;;G09B5/02;;G06T7/0014;;G06T2207/30196;;G06T2207/30221;;G06T11/00;;G06T7/251;;G06V40/23;;G16H20/30,G09B5/02;;G06K9/00;;G06T7/00;;G06T7/246;;G06T11/00;;G09B19/00;;G16H20/30,,1,0,,,"Anderson et al. “You Move: Enhancing Movement Training with an augmented Mirror”, UIST'13, Oct. 8-11, 2013, Vision, St. Andrews, UK.",ACTIVE
22,US,A1,US 2021/0356854 A1,102-328-592-720-922,2021-11-18,2021,US 202117390772 A,2021-07-30,US 202117390772 A;;US 201414315609 A;;US 201361886539 P,2013-10-03,REFLECTION-BASED TARGET SELECTION ON LARGE DISPLAYS WITH ZERO LATENCY FEEDBACK,"One embodiment of the invention disclosed herein provides a system that includes a mirror apparatus with a first surface to which a half-silvered mirror film is applied, where the mirror apparatus transmits a transmitted image from a second surface to the first surface. The system further includes a servo-controlled dimmer that adjusts a level of ambient light associated with the mirror apparatus. The system further includes a motion sensing device that tracks positions of a plurality of points associated with an object; wherein the object is situated on the half-silvered mirror film side of the mirror apparatus. The system further includes a computing device including a memory that stores instructions that, when executed by a processor included in the computing device, cause the processor to control the servo-controlled dimmer to adjust the ambient light such that both the transmitted image and a reflected image is visible on the first surface.",AUTODESK INC,ANDERSON FRASER;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2014-06-25),https://lens.org/102-328-592-720-922,Patent Application,yes,0,1,3,3,0,G03B21/62;;G03B21/62;;G03B21/10;;G03B21/10,G03B21/62;;G03B21/10,,0,0,,,,ACTIVE
23,US,S,US D0746227 S,157-328-738-847-99X,2015-12-29,2015,US 201329477008 F,2013-12-18,US 201329477008 F,2013-12-18,Battery charger,,LEMIRE-ELMORE JUSTIN BRUCE;;CAMERON ROBERT FRASER;;CAMPBELL ROBERT J;;GRIN TECHNOLOGIES LTD,LEMIRE-ELMORE JUSTIN BRUCE;;CAMERON ROBERT FRASER;;CAMPBELL ROBERT JAMES,,https://lens.org/157-328-738-847-99X,Design Right,no,0,10,2,2,0,,,1302;;D13/107,0,0,,,,ACTIVE
24,US,A1,US 2017/0034228 A1,142-223-734-856-869,2017-02-02,2017,US 201615183602 A,2016-06-15,US 201615183602 A;;US 201562197486 P,2015-07-27,SHARING COMPUTER APPLICATION ACTIVITIES,"Information regarding application usage on an actor device may be provided through activity notifications and activity reports. An activity notification describing current application activity on an actor device is sent, via wireless connection, to an observer device which displays the activity notification. Activity notifications provide different granularity levels of information based on a received level selection or based on a distance (proximity) between the actor device and the observer device. An activity report representing the history of application usage on an actor device may be displayed on the actor device. For example, the activity report may be triggered to by displayed when the actor device is placed flat. The activity report provides a graphical representation of the application usage on the actor device for a predetermined time period of prior usage. The graphical representation may comprise a plurality of stripes, each stripe representing a particular application or application type.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK;;ENS BARRETT;;ANDERSON FRASER,AUTODESK INC (2016-06-14),https://lens.org/142-223-734-856-869,Patent Application,yes,8,7,4,4,0,H04L65/403;;H04L67/535;;H04L65/403;;H04L67/535;;H04L43/045;;H04L43/06,H04L29/06;;G06F3/0484;;G06F17/30,,0,0,,,,ACTIVE
25,US,B2,US 11677691 B2,156-828-882-959-384,2023-06-13,2023,US 202117193734 A,2021-03-05,US 202117193734 A;;US 202063000684 P,2020-03-27,Computer-based techniques for obtaining personalized assistance with software applications,"In various embodiments, a mentor application automatically obtains assistance with software applications. The mentor application generates a computer-generated help request associated with a first user of a software application. Based on the computer-generated help request and a set of user contexts associated with a set of users, the mentor application computes match scores. Each match score predicts how suitable a particular user is for servicing the computer-generated help request. Based on the match scores, the mentor application transmits at least one help request notification to at least one user included in the set of users to determine a second user to service the computer-generated help request. The mentor application then establishes a computer connection between the first user and the second user through which an interactive help session between the first user and the second user is held.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE;;GROSSMAN TOVI;;JOSHI NIKHITA;;MATEJKA JUSTIN FRANK,AUTODESK INC (2021-03-01),https://lens.org/156-828-882-959-384,Granted Patent,yes,6,0,2,2,0,H04N7/155;;H04N7/147;;G06Q30/016;;H04L51/02;;H04M3/5191;;H04M3/4217;;H04M3/5233;;H04L51/216;;H04L51/02;;H04N7/147;;H04N7/155;;H04M3/42221;;H04M2201/40;;H04M3/5191;;H04M3/5233;;H04M3/563;;G06F3/1454;;H04L51/216,H04L51/02;;G06F3/14;;H04L51/216;;H04M3/42;;H04M3/51;;H04M3/523;;H04M3/56;;H04N7/14;;H04N7/15,,44,33,011-008-582-336-95X;;134-368-694-392-648;;133-224-069-444-589;;032-690-545-278-62X;;059-628-630-838-399;;022-592-803-939-012;;047-606-909-992-104;;116-119-881-340-624;;018-190-010-574-491;;114-693-774-408-885;;000-667-726-708-012;;138-352-679-740-789;;137-228-565-856-56X;;001-146-463-632-134;;080-402-751-094-890;;003-828-335-930-998;;124-317-654-620-199;;056-797-605-495-054;;021-817-836-143-107;;108-223-726-039-858;;081-679-955-566-069;;068-720-384-692-256;;060-647-054-175-919;;073-808-749-668-441;;011-502-749-077-94X;;107-673-920-784-888;;011-204-901-208-559;;061-703-325-709-733;;098-680-261-102-855;;024-893-553-791-650;;005-505-978-809-274;;003-492-746-432-938;;059-330-849-434-928,10.1145/91474.91485;;10.1145/240080.240203;;10.1145/501516.501539;;10.1109/msr.2013.6624015;;10.1145/143457.143471;;10.1007/bf00122575;;10.1145/3025453.3025972;;10.1145/2858036.2858512;;10.1145/1978942.1979400;;10.1109/vlhcc.2018.8506568;;10.1145/2207676.2208620;;10.2307/1884324;;10.1145/32206.32212;;10.1145/358916.358947;;10.1145/2047196.2047215;;10.1145/1753326.1753552;;10.1145/1518701.1518803;;10.1109/vlhcc.2015.7357201;;10.1145/223904.223915;;10.1145/1772690.1772735;;10.1145/2858036.2858266;;10.1109/vlhcc.2015.7357216;;10.1145/1348549.1348556;;10.1145/3290605.3300570;;10.1145/223355.223677;;10.1145/99332.99356;;10.1145/2047196.2047218;;10.1145/1622176.1622214;;10.1145/358916.358994;;10.1145/1297144.1297165;;10.1145/108844.108906;;10.1145/2187980.2188202;;10.1007/s10606-005-9007-7,"Ackerman et al., “Answer Garden: A Tool for Growing Organizational Memory”, Proceedings of the conference on Office information systems—, ACM Press, http://doi.org/10.1145/91474.91485, 1990, pp. 31-39.;;Ackerman et al., “Answer Garden 2: Merging Organizational Memory with Collaborative Help”, Proceedings of the 1996 ACM conference on Computer supported cooperative work-CSCW '96, ACM Press, http://doi.org/10.1145/240080.240203, 1996, pp. 97-105.;;Ames, Andrea L., “Just What They Need, Just When They Need It: An Introduction to Embedded Assistance”, Proceedings of the 19th annual international conference on Computer documentation—SIGDOC'01, ACM Press, http://doi.org/10.1145/501516.501539, Oct. 21-24, 2001, pp. 111-115.;;Asaduzzaman et al., “Answering Questions about Unanswered Questions of Stack Overflow”, 10th Working Conference on Mining Software Repositories (MSR), IEEE, http://doi.org/10.1109/MSR.2013.6624015, 2013, pp. 97-100.;;Berlin et al., “Consultants and Apprentices: Observations about Learning and Collaborative Problem Solving”, Proceedings of the 1992 ACM conference on Computer-supported cooperative work—CSCW '92, ACM Press, http://doi.org/10.1145/143457.143471, 1992, pp. 130-137.;;Camerer et al., “Recent Developments in Modeling Preferences:Uncertainty and Ambiguity”, Journal of Risk and Uncertainty, vol. 5, No. 4, http://doi.org/10.1007/BF00122575, 1992, pp. 325-370.;;Carroll et al., “Paradox of the Active User”, In Interfacing Thought: Cognitive Aspects of Human-Computer Interaction, MIT Press, Cambridge, MA, USA, 1987, pp. 80-111.;;Chen et al., “Codeon: On-Demand Software Development Assistance”, Proceedings of the 2017 CHI Conference on Human Factors in Computing Systems—CHI '17, ACM Press, http://doi.org/10.1145/3025453.3025972, May 6-11, 2017, pp. 6220-6231.;;Chen et al., “Towards Providing On-Demand Expert Support for Software Developers”, Proceedings of the 2016 CHI Conference on Human Factors in Computing Systems-CHI '16, ACM Press, http://doi.org/10.1145/2858036.2858512, May 7-12, 2016, pp. 3192-3203.;;Chilana et al., “Modern Software Product Support Processes and the Usage of Multimedia Formats”, Proceedings of the 2011 annual conference on Human factors in computing systems—CHI '11, ACM Press, http://doi.org/10.1145/1978942.1979400, May 7-12, 2011, pp. 3093-3102.;;Chilana et al., “Supporting Remote Real-Time Expert Help:Opportunities and Challenges for Novice 3D Modelers”, 2018 IEEE Symposium on Visual Languages and Human-Centric Computing (VL/HCC), IEEE, http://doi.org/10.1109/VLHCC.2018.8506568, 2018, pp. 157-166.;;Chilana et al., “LemonAid: Selection-Based Crowdsourced Contextual Help for Web Applications”, Proceedings of the 2012 ACM annual conference on Human Factors in Computing Systems—CHI '12, ACM Press, http://doi.org/10.1145/2207676.2208620, May 5-10, 2012, pp. 1549-1558.;;Codementor, “Codementor | Get live 1:1 coding help, hire a developer, & more”, Retrieved Sep. 1, 2021, from https://www.codementor.io, 2021, 9 pages.;;Ellsberg, Daniel, “Risk, Ambiguity, and the Savage Axioms”, The Quarterly Journal of Economics, vol. 75, No. 4, http://doi.org/10.2307/1884324, Nov. 1961, pp. 643-669.;;Furnas et al., “The Vocabulary Problem in Human-System Communication”, Communications of the ACM, vol. 30, No. 11, http://doi.org/10.1145/32206.32212, Nov. 1987, pp. 964-971.;;Fussell et al., “Coordination of Communication: Effects of Shared Visual Context on Collaborative Work”, Proceedings of the 2000 ACM conference on Computer supported cooperative work—CSCW '00, ACM Press, http://doi.org/10.1145/358916.358947, Dec. 2-6, 2000, pp. 21-30.;;Goldman et al., “RealTime Collaborative Coding in a Web IDE”, Proceedings of the 24th annual ACM symposium on User interface software and technology—UIST '11, ACM Press, http://doi.org/10.1145/2047196.2047215, Oct. 16-19, 2011, pp. 155-164.;;Grossman et al., “ToolClips: An Investigation of Contextual Video Assistance for Functionality Understanding”, Proceedings of the 28th international conference on Human factors in computing systems—CHI '10, ACM Press, http://doi.org/10.1145/1753326.1753552, Apr. 10-15, 2010, pp. 1515-1524.;;Grossman et al., “A Survey of Software Learnability:Metrics, Methodologies and Guidelines”, Proceedings of the 27th international conference on Human factors in computing systems—CHI 09, ACM Press, http://doi.org/10.1145/1518701.1518803, Apr. 7, 2019, pp. 649-658.;;Guo et al., “Codechella: Multi-User Program Visualizations for Real-Time Tutoring and Collaborative Learning”, 2015 IEEE Symposium on Visual Languages and Human-Centric Computing (VL/HCC), IEEE, http://doi.org/10.1109/VLHCC.2015.7357201, 2015, pp. 79-87.;;Harrison, Susan M., “A Comparison of Still, Animated, or Nonillustrated On-Line Help with Written or Spoken Instructions in a Graphical User Interface”, Proceedings of the SIGCHI conference on Human factors in computing systems—CHI '95, ACM Press, http://doi.org/10.1145/223904.223915, May 7-11, 1995, pp. 82-89.;;Holland, Arienne, “How Estimated Reading Times Increase Engagement With Content”, Marketing Land, Retrieved Sep. 1, 2021 from https://martech.org/estimated-reading-times-increase-engagement/, Apr. 14, 2014, 12 pages.;;Horowitz et al., “The Anatomy of a Large-Scale Social Search Engine”, Proceedings of the 19th international conference on World wide web—WWW '10, ACM Press, http://doi.org/10.1145/1772690.1772735, Apr. 26-30, 2010, pp. 431-440.;;Hudson et al., “Understanding Newcomers to 3D Printing:Motivations, Workflows, and Barriers of Casual Makers”, Proceedings of the 2016 CHI Conference on Human Factors in Computing Systems—CHI '16, ACM Press, http://doi.org/10.1145/2858036.2858266, May 7-12, 2016, pp. 384-396.;;Hudson et al., “Understanding Triggers for Clarification Requests in Community-Based Software Help Forums”, 2015 IEEE Symposium on Visual Languages and Human-Centric Computing (VL/HCC), IEEE, http://doi.org/10.1109/VLHCC.2015.7357216, 2015, pp. 189-193.;;Jacobs, Aaron, “accessibility: Extension module that wraps the Accessibility API for Mac Os X”, Retrieved Sep. 1, 2021 from https://github.com/atheriel/accessibility, 2021, 2 pages.;;Java et al., “Why We Twitter: Understanding Microblogging Usage and Communities”, Proceedings of the 9th WebKDD and 1st SNA-KDD 2007 workshop on Web mining and social network analysis-WebKDD/SNA-KDD '07, ACM Press, http://doi.org/10.1145/1348549.1348556, Aug. 12, 2007, pp. 56-65.;;Kiani et al., “Beyond “One-Size-Fits-All”: Understanding the Diversity in How Software Newcomers Discover and Make Use of Help Resources”, Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems—CHI '19, ACM Press, http://doi.org/10.1145/3290605.3300570, May 4-9, 2019, pp. 1-14.;;Knabe, Kevin, “Apple Guide: A Case Study in User-Aided Design of Online Help”, Conference companion on Human factors in computing systems—CHI '95, ACM Press, http://doi.org/10.1145/223355.223677, May 7-11, 1995, pp. 286-287.;;Konnikova, Maria, “A List of Reasons Why Our Brains Love Lists”, Retrieved Sep. 1, 2021 from https://www.newyorker.com/tech/elements/a-list-ofreasons-why-our-brains-love-lists, Dec. 2, 2013, 4 pages.;;Mackay, Wendy E., “Patterns of Sharing Customizable Software”, Proceedings of the 1990 ACM conference on Computer-supported cooperative work—CSCW '90, ACM Press, http://doi.org/10.1145/99332.99356, Oct. 1990, pp. 209-221.;;Matejka et al., “IP-QAT: In-Product Questions, Answers & Tips”, Proceedings of the 24th annual ACM symposium on User interface software and technology—UIST '11, ACM Press, http://doi.org/10.1145/2047196.2047218, Oct. 16-19, 2011, pp. 175-184.;;Matejka et al., “Ambient Help”, Proceedings of the 2011 annual conference on Human factors in computing systems—CHI '11, ACM Press, http://doi.org/10.1145/1978942.1979349, May 7-12, 2011, pp. 2751-2760.;;Matejka et al., “CommunityCommands:Command Recommendations for Software Applications”, Proceedings of the 22nd annual ACM symposium on User interface software and technology—UIST '09, ACM Press, http://doi.org/10.1145/1622176.1622214, Oct. 4-7, 2009, pp. 193-202.;;McDonald et al., “Expertise Recommender: A Flexible Recommendation System and Architecture”, Proceedings of the 2000 ACM conference on Computer supported cooperative work—CSCW '00, ACM Press, http://doi.org/10.1145/358916.358994, Dec. 2-6, 2000, pp. 231-240.;;Medium, “Read Time and You”, Here's how read time is calculated, Retrieved Aug. 31, 2021 from https://blog.medium.com/read-time-and-youbc2048ab620c, Jun. 4, 2014, 2 pages.;;Novick et al., “Toward a More Accurate View of When and How People Seek Help with Computer Applications”, Proceedings of the 25th annual ACM international conference on Design of communication—SIGDOC'07, ACM Press, http://doi.org/10.1145/1297144.1297165, Oct. 22-24, 2007, pp. 95-102.;;Palmiter et al., “An Evaluation of Animated Demonstrations for Learning Computer-based Tasks”, Proceedings of the SIGCHI conference on Human factors in computing systems Reaching through technology—CHI '91, ACM Press, http://doi.org/10.1145/108844.108906, 1991, pp. 257-263.;;Riahi et al., “Finding Expert Users in Community Question Answering”, Proceedings of the 21st international conference companion on World Wide Web—WWW '12 Companion, ACM Press, http://doi.org/10.1145/2187980.2188202, Apr. 16-20, 2012, pp. 791-798.;;Twidale, Michael B., “Over the Shoulder Learning: Supporting Brief Informal Learning”, Computer Supported Cooperative Work (CSCW), vol. 14, No. 6, http://doi.org/10.1007/s10606-005-9007-7, 2005, pp. 505-547.;;Wilner, Christina, “5 surprising Benefits of using Time Estimates in your To-do List”, Amazing Marvin, Retrieved Aug. 31, 2021 from https://blog.amazingmarvin.com/5-benefits-of-usingtime-estimates-in-your-to-do-list/, 2019, 16 pages.;;Stack Overflow, “How do I ask a good question?”, Help Center, Retrieved Aug. 31, 2021 from https://stackoverflow.com/help/how-to-ask, 2021, 3 pages.;;Twitter, “Rogue ?. Bigham on Twitter: @deliprao haha, tweets are way better. first, you did the tiniest amount (at least) of background on me. second, they're short! easier to read, and incentivizes getting to the point, third, my response is expected to be short, so need to ask something that gets to the heart of it!” / Twitter, Retrieved Aug. 31, 2021 from https://twitter.com/jeffbigham/status/1165383660666859520, Aug. 25, 2019, 2 pages.;;Nielsen, Jakob, “Powers of 10: Time Scales in User Experience”, Nielsen Norman Group, Retrieved Aug. 31, 2021 from https://www.nngroup.com/articles/powers-of-10-timescales-in-ux/, Oct. 4, 2009, 8 pages.",ACTIVE
26,US,B2,US 11190560 B2,079-111-090-577-098,2021-11-30,2021,US 201615183549 A,2016-06-15,US 201615183549 A;;US 201562197486 P,2015-07-27,Sharing computer application activities,"Information regarding application usage on an actor device may be provided through activity notifications and activity reports. An activity notification describing current application activity on an actor device is sent, via wireless connection, to an observer device which displays the activity notification. Activity notifications provide different granularity levels of information based on a received level selection or based on a distance (proximity) between the actor device and the observer device. An activity report representing the history of application usage on an actor device may be displayed on the actor device. For example, the activity report may be triggered to by displayed when the actor device is placed flat. The activity report provides a graphical representation of the application usage on the actor device for a predetermined time period of prior usage. The graphical representation may comprise a plurality of stripes, each stripe representing a particular application or application type.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK;;ENS BARRET;;ANDERSON FRASER,AUTODESK INC (2016-06-14),https://lens.org/079-111-090-577-098,Granted Patent,yes,25,0,4,4,0,H04L65/403;;H04L67/535;;H04L65/403;;H04L67/535;;H04L43/045;;H04L43/06,H04L29/06;;H04L12/26;;H04L29/08,,47,38,004-335-695-186-497;;105-016-255-858-636;;005-474-756-101-116;;050-468-086-246-981;;012-536-262-262-328;;051-921-364-937-846;;144-895-579-023-174;;014-391-449-308-558;;023-105-323-588-423;;084-122-800-144-022;;008-273-472-060-808;;095-997-113-033-292;;110-736-233-056-399;;060-563-518-879-976;;152-517-695-613-018;;092-025-960-005-203;;068-405-640-520-788;;038-536-666-593-864;;089-966-342-712-249;;032-157-252-247-875;;064-603-800-890-457;;088-953-187-459-335;;178-409-451-838-910;;107-673-557-081-204;;014-045-946-807-508;;020-782-006-857-107;;012-341-113-064-088;;036-929-518-978-337;;069-552-009-871-654;;109-329-713-687-444;;094-005-825-101-504;;095-329-544-580-841;;004-731-574-337-994;;033-272-576-404-435;;059-141-986-068-124;;174-394-177-317-543;;016-333-124-969-347;;047-484-498-131-39X,10.1145/2628363.2628381;;10.1145/2702123.2702336;;10.1145/2207676.2208576;;10.1145/286498.286799;;10.1037/10096-006;;10.1007/s00779-011-0377-1;;10.1145/2556288.2557352;;10.1145/143457.143468;;10.1145/2639189.2670249;;10.1007/bf01305320;;10.1145/2493190.2493234;;10.1023/a:1021271517844;;10.1145/240080.240298;;10.1145/2207676.2208296;;10.1145/964696.964713;;10.1145/2632048.2632079;;10.1145/2638728.2641711;;10.1145/2677199.2688816;;10.1145/1056808.1056956;;10.1145/2677199.2680557;;10.1145/1753846.1753874;;10.1145/1124772.1124902;;10.1145/2396636.2396642;;10.1145/2380116.2380121;;10.1016/b978-155860808-5/50010-1;;10.1080/01449290310001638496;;10.1080/01449290410001712744;;10.1145/1851600.1851647;;10.1145/1124772.1124952;;10.1145/1718918.1718987;;10.1145/2702123.2702247;;10.1145/2702123.2702164;;10.1145/1054972.1055074;;10.1145/1753326.1753458;;10.1145/2556288.2557219;;10.1145/2660267.2660319;;10.1145/2556288.2556984;;10.1109/visual.2004.35,"Ahlström, D., Hasan, K. and Irani, P. 2014. Are you comfortable doing that? acceptance studies of around device gestures in and for public settings. MobileHCI '14, 193-202.;;Anderson, F., Grossman, T., Wigdor, D. and Fitzmaurice, G. 2015. Supporting Subtlety with Deceptive Devices and Illusory Interactions. CHI'15, 10 pages, in press.;;Bailly, G., Müller, J., Rohs, M., Wigdor, D, and Kratz, S. 2012. ShoeSense: a new perspective on gestural interaction and wearable applications. CHI '12, 1239-1248.;;Borovoy, R., Martin, F., Resnick, M. and Silverman, B. 1998. GroupWear: nametags that tell about relationships. CHI '98, 329-330.;;Clark, H.H. and Brennan, S.E. 1991. Grounding in Communication. In Perspectives on Socially Shared Cognition, Lauren B. Resnick, John M. Levine and Stephanie D. Teasley (eds.). American Psychological Association, Washington, 127-149.;;Cowan, L.G., Weibel, N. Griswold, W.G., Pina, L.R. and Hollan, J.D. 2012. Projector phone use: practices and social implications. Personal Ubiquitous Comput. 16, 1 (Jan. 2012), 53-63.;;Denning, T., Dehlawi, Z. and Kohno, T. 2014. In situ with bystanders of augmented reality glasses: perspectives on recording and privacy-mediating technologies. CHI '14, 2377-2386.;;Dourish, P. and Bellotti, V. 1992. Awareness and coordination in shared workspaces. CSCW '92, 107-114.;;Fortmann, J., Moller, H., Heuten, W. and Boll, S. How to present information on wrist-worn point-light displays. NordiCHI '14, 955-958.;;Greenberg, S., Boyle, M., and Laberge, J. PDAs and shared public displays: Making personal information public, and public information personal. Personal Technologies, 3, 1-2 (1999), 54-64.;;Grubert, J. and Schmalstieg, D. 2013. Playing it real again: a repeated evaluation of magic lens and static peephole interfaces in public space. MobileHCI '13, 99-102.;;Gutwin, C. and Greenberg, S. 2002. A descriptive framework of workspace awareness for real-time groupware. CSCW 11, 3 (Nov. 2002), 411-446.;;Gutwin, C., Roseman, M. and Greenberg, S. 1996. A usability study of awareness widgets in a shared workspace groupware system. CSCW '96, 258-267.;;Harrison, C., Horstman, J., Hsieh, G. and Hudson, S. 2012. Unlocking the expressivity of point lights. CHI '12, 1683-1692.;;Hinckley, K. 2003. Synchronous gestures for multiple persons and computers. UIST '03, 149-158.;;Hoyle, R., Templeman, R., Armes, S., Anthony, D., Crandall, D. and Kapadia, A. 2014. Privacy behaviors of lifeloggers using wearable cameras. UbiComp '14, 571-582.;;Jung, J. and Philipose, M. 2014. Courteous Glass. UbiComp '14 Adjunct Proceedings, 1307-1312.;;Kan, V., Fujii, K., Amores, J., Jin, C.L.Z., Maes, P. and Ishii, H. 2015. Social textiles: Social affordances and icebreaking interactions through wearable social messaging. TEI '15, 619-624.;;Kanis, M., Winters, N., Agamanolis, S., Gavin, A. and Cullinan, C. 2005. Toward wearable social networking with iBand. CHI '05, 1521-1524.;;Kao, H.L. and Schmandt, H.L. 2015 MugShots: A mug display for front and back stage social interaction in the workplace. In TEI '15, 57-60.;;Ko, J.C., Chan, L.W. and Hung, Y.P. 2010. Public issues on projected user interface. CHI EA '10, 2873-2882.;;Liu, C.M. and Donath, U.S. 2006. Urbanhermes: Social signaling with electronic fashion. CHI '06, 885-888.;;Marquardt, N., Ballendat, T., Boring, S., Greenberg, S. and Hinckley, K. 2012. Gradual engagement: Facilitating information exchange between digital devices as a function of proximity. ITS '12, 31-40.;;Marquardt, N., Hinckley, K. and Greenberg, S. 2012. Cross-device interaction via micro-mobility and F-formations. UIST'12, 13-22.;;Monk, A. 2003. Common ground in electronically mediated communication: Clark's theory of language use. HCI Models, Theories, and Frameworks. J.M. Carrol (ed.). Kaufmann, San Francisco, 265-290.;;Monk, A., Carroll, J., Parker, S. and Blythe, M. 2004. Why are mobile phones annoying? Behaviour & Information Technology, 23, 1 (Jan. 2004), 33-41.;;Monk, A., Fellas, E. and Ley, E. 2004. Hearing only one side of normal and mobile phone conversations, Behaviour & Information Technology, 23, 5, 301-305.;;Montero, C.S., Alexander, J., Marshall, M.T. and Subramanian, S. 2010. Would you do that? Understanding social acceptance of gestural interfaces. MobileHCI '10, 275-278.;;Morris, M.R., Huang, A., Paepcke, A. and Winograd, T. 2006. Cooperative gestures: multi-user gestural interactions for co-located groupware. CHI '06, 1201-1210.;;Morris, M.R., Lombardo, J. and Wigdor, D. 2010. WeSearch: Supporting collaborative search and sensemaking on a tabletop display. CSCW '10, 401-410.;;Pearson, J., Robinson, S. and Jones, M. 2015. It's about time: Smartwatches as public displays. CHI '15, 10 pages, in press.;;Portnoff, R.S., Lee, L.N., Egelman, S., Mishra, P., Leung, D. and Wagner, D. 2015. Somebody's Watching Me? Assessing the Effectiveness of Webcam Indicator Lights. CHI '15, 2015.;;Reeves, S., Benford, S., O'Malley, C. and Fraser, M. 2005. Designing the spectator experience. CHI '05, 741-750.;;Rico, J. and Brewster, S. 2010. Usable gestures for mobile interfaces: Evaluating social acceptability. CHI '10, 887-896.;;Reetz, A. and Gutwin, C. 2014. Making big gestures: Effects of gesture size on observability and identification for co-located group awareness. CHI '14, 4087-4096.;;Roesner, F., Molnar, D., Moshchuk, A., Kohno, T. and Wang, H. 2014. World-driven access control for continuous sensing. CCS '14, 1169-1181.;;Serrano, M., Ens, B. and Irani, p. 2014. Exploring the use of hand-to-face input for interacting with head-worn displays. CHI'14, 3181-3190.;;Wang, L. and Mueller, K. 2004. Generating subresolution detail in images and volumes using constrained texture synthesis. VIS '04, 75-82.;;Non-Final Office Action for U.S. Appl. No. 15/183,602, dated Feb. 14, 2018, 18 pages.;;Final Rejection received for U.S. Appl. No. 15/183,602, dated Sep. 18, 2018, 35 pages.;;Non-Final Rejection received for U.S. Appl. No. 15/183,602, dated Apr. 18, 2019, 29 pages.;;Final Rejection received for U.S. Appl. No. 15/183,602, dated Nov. 6, 2019, 35 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/183,602, dated Apr. 29, 2020, 28 pages.;;Final Office Action for U.S. Appl. No. 15/183,602; dated Oct. 26, 2020; 31 pages.;;Non-Final Office Action for U.S. Appl. No. 15/183,602; dated Feb. 10, 2021; 28 pages.;;Final Rejection received for U.S. Appl. No. 15/183,602 dated Jun. 15, 2021, 44 pages.;;Notice of Allowance and Fees Due received for U.S. Appl. No. 15/183,602, dated Oct. 1, 2021, 10 pages.",ACTIVE
27,US,A1,US 2021/0306286 A1,057-105-730-861-590,2021-09-30,2021,US 202117193734 A,2021-03-05,US 202117193734 A;;US 202063000684 P,2020-03-27,COMPUTER-BASED TECHNIQUES FOR OBTAINING PERSONALIZED ASSISTANCE WITH SOFTWARE APPLICATIONS,"In various embodiments, a mentor application automatically obtains assistance with software applications. The mentor application generates a computer-generated help request associated with a first user of a software application. Based on the computer-generated help request and a set of user contexts associated with a set of users, the mentor application computes match scores. Each match score predicts how suitable a particular user is for servicing the computer-generated help request. Based on the match scores, the mentor application transmits at least one help request notification to at least one user included in the set of users to determine a second user to service the computer-generated help request. The mentor application then establishes a computer connection between the first user and the second user through which an interactive help session between the first user and the second user is held.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE;;GROSSMAN TOVI;;JOSHI NIKHITA;;MATEJKA JUSTIN FRANK,AUTODESK INC (2021-03-01),https://lens.org/057-105-730-861-590,Patent Application,yes,1,1,2,2,0,H04N7/155;;H04N7/147;;G06Q30/016;;H04L51/02;;H04M3/5191;;H04M3/4217;;H04M3/5233;;H04L51/216;;H04L51/02;;H04N7/147;;H04N7/155;;H04M3/42221;;H04M2201/40;;H04M3/5191;;H04M3/5233;;H04M3/563;;G06F3/1454;;H04L51/216,H04L12/58;;G06F3/14;;H04M3/42;;H04M3/51;;H04M3/523;;H04M3/56;;H04N7/14;;H04N7/15,,0,0,,,,ACTIVE
28,US,A1,US 2017/0034291 A1,102-259-088-186-891,2017-02-02,2017,US 201615183549 A,2016-06-15,US 201615183549 A;;US 201562197486 P,2015-07-27,SHARING COMPUTER APPLICATION ACTIVITIES,"Information regarding application usage on an actor device may be provided through activity notifications and activity reports. An activity notification describing current application activity on an actor device is sent, via wireless connection, to an observer device which displays the activity notification. Activity notifications provide different granularity levels of information based on a received level selection or based on a distance (proximity) between the actor device and the observer device. An activity report representing the history of application usage on an actor device may be displayed on the actor device. For example, the activity report may be triggered to by displayed when the actor device is placed flat. The activity report provides a graphical representation of the application usage on the actor device for a predetermined time period of prior usage. The graphical representation may comprise a plurality of stripes, each stripe representing a particular application or application type.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK;;ENS BARRET;;ANDERSON FRASER,AUTODESK INC (2016-06-14),https://lens.org/102-259-088-186-891,Patent Application,yes,12,1,4,4,0,H04L65/403;;H04L67/535;;H04L65/403;;H04L67/535;;H04L43/045;;H04L43/06,H04L29/08;;H04L12/26,,0,0,,,,ACTIVE
29,US,B2,US 11323495 B2,095-893-500-326-961,2022-05-03,2022,US 201615183602 A,2016-06-15,US 201615183602 A;;US 201562197486 P,2015-07-27,Sharing computer application activities,"Information regarding application usage on an actor device may be provided through activity notifications and activity reports. An activity notification describing current application activity on an actor device is sent, via wireless connection, to an observer device which displays the activity notification. Activity notifications provide different granularity levels of information based on a received level selection or based on a distance (proximity) between the actor device and the observer device. An activity report representing the history of application usage on an actor device may be displayed on the actor device. For example, the activity report may be triggered to by displayed when the actor device is placed flat. The activity report provides a graphical representation of the application usage on the actor device for a predetermined time period of prior usage. The graphical representation may comprise a plurality of stripes, each stripe representing a particular application or application type.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK;;ENS BARRETT;;ANDERSON FRASER,AUTODESK INC (2016-06-14),https://lens.org/095-893-500-326-961,Granted Patent,yes,25,0,4,4,0,H04L65/403;;H04L67/535;;H04L65/403;;H04L67/535;;H04L43/045;;H04L43/06,G06F15/16;;H04L43/045;;H04L43/06;;H04L65/403;;H04L67/50,,46,38,004-335-695-186-497;;105-016-255-858-636;;005-474-756-101-116;;050-468-086-246-981;;012-536-262-262-328;;051-921-364-937-846;;144-895-579-023-174;;014-391-449-308-558;;023-105-323-588-423;;084-122-800-144-022;;008-273-472-060-808;;095-997-113-033-292;;110-736-233-056-399;;060-563-518-879-976;;152-517-695-613-018;;092-025-960-005-203;;068-405-640-520-788;;038-536-666-593-864;;089-966-342-712-249;;032-157-252-247-875;;064-603-800-890-457;;088-953-187-459-335;;178-409-451-838-910;;107-673-557-081-204;;014-045-946-807-508;;020-782-006-857-107;;012-341-113-064-088;;036-929-518-978-337;;069-552-009-871-654;;109-329-713-687-444;;094-005-825-101-504;;095-329-544-580-841;;004-731-574-337-994;;033-272-576-404-435;;059-141-986-068-124;;174-394-177-317-543;;016-333-124-969-347;;047-484-498-131-39X,10.1145/2628363.2628381;;10.1145/2702123.2702336;;10.1145/2207676.2208576;;10.1145/286498.286799;;10.1037/10096-006;;10.1007/s00779-011-0377-1;;10.1145/2556288.2557352;;10.1145/143457.143468;;10.1145/2639189.2670249;;10.1007/bf01305320;;10.1145/2493190.2493234;;10.1023/a:1021271517844;;10.1145/240080.240298;;10.1145/2207676.2208296;;10.1145/964696.964713;;10.1145/2632048.2632079;;10.1145/2638728.2641711;;10.1145/2677199.2688816;;10.1145/1056808.1056956;;10.1145/2677199.2680557;;10.1145/1753846.1753874;;10.1145/1124772.1124902;;10.1145/2396636.2396642;;10.1145/2380116.2380121;;10.1016/b978-155860808-5/50010-1;;10.1080/01449290310001638496;;10.1080/01449290410001712744;;10.1145/1851600.1851647;;10.1145/1124772.1124952;;10.1145/1718918.1718987;;10.1145/2702123.2702247;;10.1145/2702123.2702164;;10.1145/1054972.1055074;;10.1145/1753326.1753458;;10.1145/2556288.2557219;;10.1145/2660267.2660319;;10.1145/2556288.2556984;;10.1109/visual.2004.35,"Ahlström, D., Hasan, K. and Irani, P. 2014. Are you comfortable doing that? acceptance studies of around device gestures in and for public settings. MobileHCI '14, 193-202.;;Anderson, F., Grossman, T., Wigdor, D. and Fitzmaurice, G. 2015. Supporting Subtlety with Deceptive Devices and Illusory Interactions. CHI'15, 10 pages, in press.;;Bailly, G., Müller, J., Rohs, M., Wigdor, D, and Kratz, S. 2012. ShoeSense: a new perspective on gestural interaction and wearable applications. CHI '12, 1239-1248.;;Borovoy, R., Martin, F., Resnick, M. and Silverman, B. 1998. GroupWear: nametags that tell about relationships. CHI 98, 329-330.;;Clark, H.H. and Brennan, S.E. 1991. Grounding in Communication. In Perspectives on Socially Shared Cognition, Lauren B. Resnick, John M. Levine and Stephanie D. Teasley (eds.). American Psychological Association, Washington, 127-149.;;Cowan, L.G., Weibel, N. Griswold, W.G., Pina, L.R. and Hollan, J.D. 2012. Projector phone use: practices and social implications. Personal Ubiquitous Comput. 16, 1 (Jan. 2012), 53-63.;;Denning, T., Dehlawi, Z. and Kohno, T. 2014. In situ with bystanders of augmented reality glasses: perspectives on recording and privacy-mediating technologies. CHI '14, 2377-2386.;;Dourish, P. and Bellotti, V. 1992. Awareness and coordination in shared workspaces. CSCW '92, 107-114.;;Fortmann, J., Müller, H., Heuten, W. and Boll, S. How to present information on wrist-wom point-light displays. NordiCHI '14, 955-958.;;Greenberg, S., Boyle, M., and Laberge, J. PDAs and shared public displays: Making personal information public, and public information personal. Personal Technologies, 3, 1-2 (1999), 54-64.;;Grubert, J. and Schmalstieg, D. 2013. Playing it real again: a repeated evaluation of magic lens and static peephole interfaces in public space. MobileHCI '13, 99-102.;;Gutwin, C. and Greenberg, S. 2002. A descriptive framework of workspace awareness for real-time groupware. CSCW 11, 3 (Nov. 2002), 411-446.;;Gutwin, C., Roseman, M. and Greenberg, S. 1996. A usability study of awareness widgets in a shared workspace groupware system. CSCW '96, 258-267.;;Harrison, C., Horstman, J., Hsieh, G. and Hudson, S. 2012. Unlocking the expressivity of point lights. CHI '12, 1683-1692.;;Hinckley, K. 2003. Synchronous gestures for multiple persons and computers. UIST '03, 149-158.;;Hoyle, R., Templeman, R., Armes, S., Anthony, D., Crandall, D. and Kapadia, A. 2014. Privacy behaviors of lifeloggers using wearable cameras. UbiComp '14, 571-582.;;Jung, J. and Philipose, M. 2014. Courteous Glass. UbiComp '14 Adjunct Proceedings, 1307-1312.;;Kan, V., Fujii, K., Amores, J., Jin, C.L.Z., Maes, P. and Ishii, H. 2015. Social textiles: Social affordances and icebreaking interactions through wearable social messaging. TEI '15, 619-624.;;Kanis, M., Winters, N., Agamanolis, S., Gavin, A. and Cullinan, C. 2005. Toward wearable social networking with Band. CHI '05, 1521-1524.;;Kao, H.L. and Schmandt, H.L. 2015 MugShots: A mug display for front and back stage social interaction in the workplace. In TEI '15, 57-60.;;Ko, J.C., Chan, L.W. and Hung, Y.P. 2010. Public issues on projected user interface. CHI EA '10, 2873-2882.;;Liu, C.M. and Donath, J.S. 2006. Urbanhermes: Social signaling with electronic fashion. CHI '06, 885-888.;;Marquardt, N., Ballendat, T., Boring, S., Greenberg, S. and Hinckley, K. 2012. Gradual engagement: Facilitating information exchange between digital devices as a function of proximity. ITS '12, 31-40.;;Marquardt, N., Hinckley, K. and Greenberg, S. 2012. Cross-device interaction via micro-mobility and F-formations. UIST'12, 13-22.;;Monk, A. 2003. Common ground in electronically mediated communication: Clark's theory of language use. HCI Models, Theories, and Frameworks. J.M. Carrol (ed.). Kaufmann, San Francisco, 265-290.;;Monk, A., Carroll, J., Parker, S. and Blythe, M. 2004. Why are mobile phones annoying? Behaviour & Information Technology, 23, 1 (Jan. 2004), 33-41.;;Monk, A., Fellas, E. and Ley, E. 2004. Hearing only one side of normal and mobile phone conversations, Behaviour & Information Technology, 23, 5, 301-305.;;Montero, C.S., Alexander, J., Marshall, M.T. and Subramanian, S. 2010. Would you do that? Understanding social acceptance of gestural interfaces. MobileHCI '10, 275-278.;;Morris, M.R., Huang, A., Paepcke, A. and Winograd, T. 2006. Cooperative gestures: multi-user gestural interactions for co-located groupware. CHI '06, 1201-1210.;;Morris, M.R., Lombardo, J. and Wigdor, D. 2010. WeSearch: Supporting collaborative search and sensemaking on a tabletop display. CSCW '10, 401-410.;;Pearson, J., Robinson, S. and Jones, M. 2015. It's about time: Smartwatches as public displays. CHI '15, 10 pages, in press.;;Portnoff, R.S., Lee, L.N., Egelman, S., Mishra, P., Leung, D. and Wagner, D. 2015. Somebody's Watching Me? Assessing the Effectiveness of Webcam Indicator Lights. CHI '15, 2015.;;Reeves, S., Benford, S., O'Malley, C. and Fraser, M. 2005. Designing the spectator experience. CHI '05, 741-750.;;Rico, J. and Brewster, S. 2010. Usable gestures for mobile interfaces: Evaluating social acceptability. CHI '10, 887-896.;;Reetz, A. and Gutwin, C. 2014. Making big gestures: Effects of gesture size on observability and identification for co-located group awareness. CHI '14, 4087-4096.;;Roesner, F., Molnar, D., Moshchuk, A., Kohno, T. and Wang, H. 2014. World-driven access control for continuous sensing. CCS '14, 1169-1181.;;Serrano, M., Ens, B. and Irani, P. 2014. Exploring the use of hand-to-face input for interacting with head-worn displays. CHI'14, 3181-3190.;;Wang, L. and Mueller, K. 2004. Generating subresolution detail in images and volumes using constrained texture synthesis. VIS '04, 75-82.;;Non-Final Office Action for U.S. Appl. No. 15/183,549, dated Jan. 12, 2018, 15 pages.;;Final Rejection received for U.S. Appl. No. 15/183,549, dated Aug. 7, 2018, 18 pages.;;Non-Final Rejection received for U.S. Appl. No. 15/183,549, dated Jan. 28, 2019, 17 pages.;;Final Rejection received for U.S. Appl. No. 15/183,549, dated Jul. 23, 2019, 19 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/183,549, dated Mar. 6, 2020, 15 pages.;;Final Office Action for U.S. Appl. No. 15/183,549; dated Sep. 9, 2020; 21 pages.;;Non-Final Office Action received for U.S. Appl. No. 15/183,549, dated Mar. 4, 2021, 37 pages.;;Notice of Allowance received for U.S. Appl. No. 15/183,549, dated Jul. 16, 2021, 32 pages.",ACTIVE
30,US,A1,US 2019/0046668 A1,043-080-703-111-341,2019-02-14,2019,US 201715999117 A,2017-02-17,US 201715999117 A;;US 201662297690 P;;US 2017/0018502 W,2016-02-19,RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE,Provided herein are monoacylglycerol lipase (MGLL) occupancy probes comprising a MGLL inhibitor containing a positron emission tomography (PET) tracer radionuclide. Also provided are methods of assessing MGLL enzyme occupancy of a MGLL inhibitor using the radiolabeled occupancy probes described herein.,ABIDE THERAPEUTICS INC,GRICE CHERYL A;;JONES TODD K;;CISAR JUSTIN S;;FRASER IAIN PETER,H. LUNDBECK A/S (2019-11-29);;LUNDBECK LA JOLLA RESEARCH CENTER INC (2019-05-28),https://lens.org/043-080-703-111-341,Patent Application,yes,0,0,3,3,0,C12N9/20;;A61B6/037;;C07B59/002;;C07D295/205;;C12Y301/01023;;A61K51/0459;;C12N9/20;;A61B6/037;;C07D295/205;;C12Y301/01023;;C07B59/002;;A61K51/0459;;C07B2200/05,A61K51/04;;A61B6/03;;C07D295/205;;C12N9/20,,0,0,,,,ACTIVE
31,US,B2,US 10463753 B2,093-479-370-149-20X,2019-11-05,2019,US 201715999117 A,2017-02-17,US 201715999117 A;;US 201662297690 P;;US 2017/0018502 W,2016-02-19,Radiolabeled monoacylglycerol lipase occupancy probe,Provided herein are monoacylglycerol lipase (MGLL) occupancy probes comprising a MGLL inhibitor containing a positron emission tomography (PET) tracer radionuclide. Also provided are methods of assessing MGLL enzyme occupancy of a MGLL inhibitor using the radiolabeled occupancy probes described herein.,LUNDBECK LA JOLLA RESEARCH CENTER INC,GRICE CHERYL A;;JONES TODD K;;CISAR JUSTIN S;;FRASER IAIN PETER,H. LUNDBECK A/S (2019-11-29);;LUNDBECK LA JOLLA RESEARCH CENTER INC (2019-05-28),https://lens.org/093-479-370-149-20X,Granted Patent,yes,55,6,3,3,0,C12N9/20;;A61B6/037;;C07B59/002;;C07D295/205;;C12Y301/01023;;A61K51/0459;;C12N9/20;;A61B6/037;;C07D295/205;;C12Y301/01023;;C07B59/002;;A61K51/0459;;C07B2200/05,A61K51/00;;A61B6/03;;A61K51/04;;A61M36/14;;C07B59/00;;C07D295/205;;C12N9/20,,33,14,046-927-273-365-367;;068-958-281-797-071;;044-756-727-739-700;;058-222-982-022-733;;040-725-620-420-719;;110-624-516-869-801;;181-758-272-997-258;;052-769-110-446-302;;105-235-812-172-822;;000-290-929-702-895;;035-230-547-171-641;;066-371-099-307-130;;069-099-515-975-736;;117-587-550-537-020,18988199;;10.1002/anie.200800222;;26694017;;10.1021/acschemneuro.5b00293;;10.1021/jo00380a030;;18096503;;10.1016/j.chembiol.2007.11.006;;pmc2692834;;22542104;;pmc3361572;;10.1016/j.chembiol.2012.03.009;;pmc3806897;;23701408;;10.1021/cb400261h;;pmc3419901;;10.1111/j.1476-5381.2012.01950.x;;22428756;;10.1016/j.bmc.2014.09.012;;25282655;;10.1007/978-0-387-38295-1_5;;10.1021/jm1013693;;21413808;;10.1021/cr950066q;;11848856;;18219308;;10.1038/nrd2468;;pmc3611965;;10.1016/j.nucmedbio.2012.03.011;;22571907;;10.1039/cs9790800563,"Miller et al. Angew. Chem. Int. Ed. 2008, 47, 8998-9033.;;Wang et al. ACS Chem Neurosci. 2016, 484-489.;;Chi et al. J. Org. Chem. 1987, 52, 658-664.;;Blankman et al. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14:1347-1356 (2007).;;Chang et al. Highly Selective Inhibitors of Monoacylglycerol Lipase Bearing a Reactive Group that is Bioisosteric with Endocannabinoid Substrates. ChemBiol 19(5):579-588 (2012).;;Chang et al. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition. ACS Chem Biol 8:1590-1599 (2013).;;Fowler. Monoacylglycerol lipase—a target for drug development? Br Pharmacol. 166:1568-1585 (2012).;;Hicks. Discovery and Preclinical Evaluation of Novel Enzyme Targeting Radiotracers for Positron Emission Tomography. Thesis. Institute of Medical Science, University of Toronto. http://gradworks.umi.com/37/16/3716105.html (245 pgs) (2015).;;Korhonen et al. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Bioorg Med Chem 22(23):6694-6705 (2014).;;Machac. Radiopharmaceuticals for Clinical Cardiac PET Imaging. Cardiac PET and PET/CT Imaging (pp. 73-82) (2007).;;Meanwell et al. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 54(8):2529-2591 (2011).;;Patani et al. Bioisosterism: A Rational Approach in Drug Design. Chem. Rev. 96:3147-3176 (1996).;;PCT/US2013/020551 International Preliminary Report on Patentability dated Jul. 17, 2014.;;PCT/US2013/020551 International Search Report dated May 21, 2013.;;PCT/US2016/022690 International Search Report and Written Opinion dated Aug. 30, 2016.;;PCT/US2017/018502 International Search Report and Written Opinion dated May 16, 2017.;;PCT/US2017/052106 International Search Report and Written Opinion dated Jan. 17, 2018.;;PCT/US2017/052106 Invitation to Pay Additional Fees dated Nov. 14, 2017.;;PubChem CID 17217128 http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=17217128 Retrieved Apr. 30, 2013 Create Date: Nov. 13, 2007 (3 pgs.).;;PubChem CID 3469875. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3469875Retrieved Mar. 4, 2013 Create Date: Sep. 8, 2005 (11 pgs.).;;PubChem CID 669902 http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=669902 Retrieved May 1, 2013 Create Date: Jul. 8, 2005 (4 pgs.).;;PubMed Compund Summary for CID 71656983, ‘SCHEMBL15100862’. Available at https://pubchem.ncbi.nlm.nih.gov/compound/71656983. U.S. National Library of Medicine (11 pgs.) (Aug. 19, 2013).;;Rautio et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7(3):255-270 (2008).;;Silverman. The Organic Chemistry of Drug Design and Drug Action. Academic Press (pp. 15-22) (1992).;;Skaddan et al. The synthesis and in vivo evaluation of [18913F-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). Nucl Med Biol 39:1058-1067 (2012).;;Thornber. Isosterism and molecular modification in drug design. Chem Soc Rev 8:563-580 (1979).;;U.S. Appl. No. 14/369,982 Office Action dated Mar. 8, 2016.;;U.S. Appl. No. 14/369,982 Office Action dated Oct. 22, 2015.;;U.S. Appl. No. 14/599,105 Office Action dated Apr. 8, 2015.;;U.S. Appl. No. 15/072,229 First Action Interview dated Sep. 19, 2016.;;U.S. Appl. No. 15/072,229 Office Action dated Jan. 10, 2017.;;U.S. Appl. No. 15/272,313 Office Action dated Apr. 10, 2017.;;U.S. Appl. No. 15/272,313 Office Action dated Aug. 25, 2017.",ACTIVE
32,WO,A1,WO 2017/143283 A1,129-802-652-485-254,2017-08-24,2017,US 2017/0018502 W,2017-02-17,US 201662297690 P,2016-02-19,RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE,Provided herein are monoacylglycerol lipase (MGLL) occupancy probes comprising a MGLL inhibitor containing a positron emission tomography (PET) tracer radionuclide. Also provided are methods of assessing MGLL enzyme occupancy of a MGLL inhibitor using the radiolabeled occupancy probes described herein.,ABIDE THERAPEUTICS INC,GRICE CHERYL A;;JONES TODD K;;CISAR JUSTIN S;;FRASER IAIN PETER,,https://lens.org/129-802-652-485-254,Patent Application,yes,3,8,3,3,0,C12N9/20;;A61B6/037;;C07B59/002;;C07D295/205;;C12Y301/01023;;A61K51/0459;;C12N9/20;;A61B6/037;;C07D295/205;;C12Y301/01023;;C07B59/002;;A61K51/0459;;C07B2200/05,A61K38/46;;C12N9/20,,3,2,069-099-515-975-736;;105-235-812-172-822,pmc3611965;;10.1016/j.nucmedbio.2012.03.011;;22571907;;10.1007/978-0-387-38295-1_5,"HICKS, DISCOVERY AND PRECLINICAL EVALUATION OF NOVEL ENZYME TARGETING RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY, 2015, XP055408892, Retrieved from the Internet <URL:http://gradworks.umi.com/37/16/3716105.html>;;SKADDAN ET AL.: ""The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH"", NUCLEAR MEDICINE AND BIOLOGY, vol. 39, October 2012 (2012-10-01), XP055408903;;MACHAC: ""Radiopharmaceuticals for Clinical Cardiac PET Imaging"", CARDIAC PET AND PET/CT IMAGING, 2007, pages 73 - 82, XP055408911",PENDING
33,US,B2,US 11772275 B2,105-074-784-978-348,2023-10-03,2023,US 201816134859 A,2018-09-18,US 201816134859 A;;US 201862711436 P,2018-07-27,Generative design techniques for robot behavior,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/105-074-784-978-348,Granted Patent,yes,9,0,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,G06F30/17;;B25J11/00;;B25J19/00;;G06N3/004;;G06N3/008;;G06N3/08;;G06N5/01;;G06N7/01;;G06N20/00,,70,39,076-493-843-283-746;;013-893-681-292-726;;100-602-041-391-84X;;172-545-482-424-559;;148-836-931-919-208;;134-010-681-419-980;;042-473-482-797-36X;;076-274-048-682-780;;087-143-628-955-908;;132-106-581-232-573;;076-476-214-478-984;;109-133-761-197-189;;025-698-952-910-402;;092-443-519-048-191;;107-963-386-498-253;;030-341-682-696-344;;005-886-186-371-712;;019-710-287-333-765;;078-217-156-016-664;;155-883-923-169-270;;008-031-166-611-550;;116-288-609-818-155;;159-356-957-183-928;;007-768-081-749-120;;064-929-420-019-723;;023-077-738-773-617;;034-708-485-676-92X;;067-951-880-435-234;;059-228-935-833-377;;108-581-033-145-682;;031-146-335-433-307;;002-592-816-604-363;;012-515-073-672-51X;;096-147-242-310-183;;106-124-279-276-838;;094-993-300-006-922;;081-083-341-882-940;;011-152-225-285-898;;100-545-354-607-72X,10.1109/cec.2000.870791;;21695266;;pmc3111458;;10.1371/journal.pone.0020989;;10.1007/978-3-319-54184-6_9;;10.1145/1457515.1409077;;10.1109/psivt.2010.85;;10.1007/978-3-540-30301-5_59;;10.1145/2501988.2502008;;10.1145/3099564.3099570;;10.1007/s10100-012-0261-8;;10.1109/iros.2012.6385576;;15350240;;10.1016/j.tics.2004.07.002;;10.1145/2897824.2925909;;10.1109/roman.2011.6005254;;10.1109/icra.2016.7487451;;10.1109/cvpr.2012.6248026;;10.1145/3173574.3173735;;10.1145/2642918.2647386;;10.1145/2601097.2601101;;10.1007/978-3-642-04380-2_33;;10.1145/2816795.2818137;;10.1145/2559636.2563720;;10.1109/cvprw.2014.121;;10.1145/2601097.2601110;;10.1145/1553374.1553475;;10.1145/2157689.2157814;;10.1109/hri.2010.5453269;;10.1145/2980179.2980242;;10.1145/2677199.2680548;;10.1145/2559636.2559672;;10.1145/1957656.1957674;;10.1145/2901790.2901845;;10.1007/s12369-014-0243-1;;10.1007/s10107-004-0559-y;;10.1145/1141911.1142010;;10.1145/2766908;;10.1145/2909824.3020221;;10.1016/j.cub.2013.11.064;;24388852;;10.1145/2983620;;10.1109/humanoids.2013.7029990,"Wang (Wang, Z., Merel, J., Reed, S., Wayne, G., de Freitas, N., & Heess, N. (2017). Robust imitation of diverse behaviors. arXiv preprint arXiv:1707.02747.) (Year: 2017).;;Kubota (Kubota, N., Nojima, Y., Baba, N., Kojima, F., & Fukuda, T. (Jul. 2000). Evolving pet robot with emotional model. In Proceedings of the 2000 Congress on Evolutionary Computation. CEC00 (Cat. No. 00TH8512) (vol. 2, pp. 1231-1237). IEEE.) (Year: 2000).;;Ziyu Wang et al., “Robust Imitation of Diverse Behaviors”, 31st Conference on Neural Information Processing Systems, 2017, 10 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,863 dated Feb. 2, 2021, 35 pages.;;Alaerts et al., 2011. “Action and emotion recognition from point light displays: an investigation of gender differences”, PloS one vol. 6, Issue 6, e20989, Jun. 2011, 9 pages.;;Aneja et al., “Modeling Stylized Character Expressions via Deep Learning”, Asian Conference on Computer Vision, Springer, 2016, pp. 136-153.;;Barnes et al., “Video Puppetry: a Performative Interface for Cutout Animation”, ACM SIGGRAPH Asia 2008 Papers (SIGGRAPH Asia '08), ACM, http://doi.org/10.1145/1457515.1409077, 2016, pp. 124:1-124:9.;;Bartram et al., “What makes motion meaningful? Affective properties of abstract motion”, Image and Video Technology (PSIVT), 2010 Fourth Pacific-Rim Symposium on, IEEE, pp. 468-474.;;Breazeal et al., “Social robots that interact with people”, In Springer handbook of robotics. Springer, 2008, 1349-1369.;;Chaudhuri et al., “AttribIt: Content Creation with Semantic Attributes”, . Proceedings of the 26th annual ACM symposium on User interface software and technology, ACM, Oct. 8-11, 2013, pp. 193-202.;;Christiano et al., “Deep Reinforcement Learning from Human Preferences”, Advances in Neural Information Processing Systems, 2017, pp. 4302-4310.;;Ciccone et al., “Authoring motion cycles”, Proceedings of the ACM SIGGRAPH/Eurographics Symposium on Computer Animation, ACM, Jul. 28-30, 2017, 9 pages.;;Csató, László, “Ranking by pairwise comparisons for Swiss-system tournaments”, Central European Journal of Operations Research 21, 4: 2013, pp. 783-803.;;Dalibard et al., “Anthropomorphism of artificial agents: a comparative survey of expressive design and motion of virtual Characters and Social Robots”, Workshop on Autonomous Social Robots and Virtual Humans at the 25th Annual Conference on Computer Animation and Social Agents (CASA 2012), 21 pages.;;Dubey et al., “Deep Learning the City: Quantifying Urban Perception at a Global Scale”, European Conference on Computer Vision, Springer, Sep. 12, 2016, 196-212.;;Emeli, Victor, “Robot Learning Through Social Media Crowdsourcing”, Intelligent Robots and Systems (IROS), 2012 IEEE/RSJ International Conference on, IEEE, Oct. 7-12, 2012, pp. 2332-2337.;;Blender Foundation, “blender.org—Home of the Blender project—Free and Open 3D Creation Software”, blender.org. Retrieved Apr. 4, 2018 from https://www.blender.org/, 23 pages.;;Gallese et al., “A unifying view of the basis of social cognition”, Trends in cognitive sciences vol. 8, No. 9: 2004, pp. 396-403.;;Gannon, Madeline “Human-Centered Interfaces for Autonomous Fabrication Machines”, Carnegie Mellon University, 2017, 198 pages.;;Glauser et al., “Rig Animation with a Tangible and Modular Input Device”, ACM Trans. Graph., vol. 35, No. 4, Article 144, DOI: http://dx.doi.org/10.1145/2897824.2925909, Jul. 2016, pp. 144:1-144:11.;;Harris et al., “Exploring the affect of abstract motion in social human-robot interaction”, RO-MAN, 2011 IEEE, pp. 441-448.;;Herbrich et al., “TrueSkillTM: a Bayesian skill rating system”, Advances in neural information processing systems, 2007, pp. 569-576.;;Knight et al., “Laban Head-Motions Convey Robot State: a Call for Robot Body Language”, 2016 IEEE International Conference on Robotics and Automation (ICRA), May 16-21, 2016, pp. 2881-2888.;;Kovashka et al., “WhittleSearch: Image Search with Relative Attribute Feedback”, Computer Vision and Pattern Recognition (CVPR), 2012 IEEE Conference on, IEEE, pp. 2973-2980.;;Koyama et al., “OptiMo: Optimization-Guided Motion Editing for Keyframe Character Animation”, 2018, 12 pages.;;Koyama et al., “Crowd-Powered Parameter Analysis for Visual Design Exploration”, Proceedings of the 27th annual ACM symposium on User interface software and technology, ACM, Oct. 5-8, 2014, pp. 65-74.;;Laffont et al., “Transient Attributes for High-Level Understanding and Editing of Outdoor Scenes”, ACM Transactions on Graphics (TOG) vol. 33, No. 4, 2014, 11 pages.;;LaFreniere et al., “Crowdsourced Fabrication”, Proceedings of the 29th Annual Symposium on User Interface Software and Technology, ACM, Oct. 16-19, 2016, pp. 15-28.;;Lee et al., “Designing with Interactive Example Galleries”, Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, ACM, Apr. 10-15, 2010, pp. 2257-2266.;;Lin et al., Evaluating Emotive Character Animations Created with Procedural Animation International Workshop on Intelligent Virtual Agents, Springer, 2009, pp. 308-315.;;Matejka et al., “Dream Lens: Exploration and Visualization of Large-Scale Generative Design Datasets”, SIGCHI (To appear), Apr. 21-26, 2018, 12 pages.;;Megaro et al., “Interactive design of 3D-printable robotic creatures”, ACM Transactions on Graphics, vol. 34, No. 6, Article 216, Nov. 2015, 9 pages.;;Mok et al., “Empathy: Interactions with Emotive Robotic Drawers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, Mar. 3-6, 2014, pp. 250-251.;;Naik et al., “Streetscore—Predicting the Perceived Safety of One Million Streetscapes”, Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition Workshops, 2014, pp. 779-785.;;O'Donovan et al., “Exploratory Font Selection Using Crowdsourced Attributes”, ACM Transactions on Graphics, vol. 33, No. 4, Article 92, Jul. 2014, 9 pages.;;Pan et al., “Unsupervised Hierarchical Modeling of Locomotion Styles”, Proceedings of the 26th Annual International Conference on Machine Learning, ACM, 2009, pp. 785-792.;;Parikh et al., “Relative Attributes”, Computer Vision (ICCV), 2011 IEEE International Conference on, IEEE, pp. 503-510.;;Reynolds, Craig W. “Steering Behaviors for Autonomous Characters”, Game developers conference, pp. 763-782.;;Ribeiro et al., “The Illusion of Robotic Life”, principles and practices of animation for robots. Human-Robot Interaction (HRI), 2012 7th ACM/IEEE International Conference on, IEEE, Mar. 5-8, 2012, pp. 383-390.;;Saerbeck et al., “Perception of Affect Elicited by Robot Motion”, Human-Robot Interaction (HRI), 2010 5th ACM/IEEE International Conference on, IEEE, 2010, pp. 53-60.;;Serrano et al., An intuitive control space for material appearance, ACM Trans. Graph., vol. 35, No. 6, Article 186, Nov. 2016, 12 pages.;;Shapiro et al., “Style Components”, Proceedings of Graphics Interface 2006, Canadian Information Processing Society, pp. 33-39.;;Slyper et al., “Mirror Puppeteering: Animating Toy Robots in Front of a Webcam”, Proceedings of the Ninth International Conference on Tangible, Embedded, and Embodied Interaction, ACM, 2015, pp. 241-248.;;Sun, Yuyin, “Toward Never-Ending Object Learning for Robots” PhD Thesis, University of Washington, 2016, 191 pages.;;Szafir et al., “Communication of intent in assistive free flyers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, 2014, pp. 358-365.;;Takayama et al., “Expressing Thought: Improving Robot Readability with Animation Principles”, Human-Robot Interaction (HRI), 2011 6th ACM/IEEE International Conference on, IEEE, pp. 69-76.;;Tan et al., “Happy Moves, Sad Grooves: Using Theories of Biological Motion and Affect to Design Shape-Changing Interfaces”, Proceedings of the 2016 ACM Conference on Designing Interactive Systems, ACM, Jun. 4-8, 2016, pp. 1282-1293.;;Venture et al., “Recognizing Emotions Conveyed by Human Gait”, International Journal of Social Robotics vol. 6, No. 4: 2014, pp. 621-632.;;Wächter et al., “On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming”, Mathematical programming vol. 106, No. 1: 2006, pp. 25-57.;;Wang et al., “The cartoon animation filter”, ACM Transactions on Graphics (TOG) vol. 25, No. 3: 2006, pp. 1169-1173.;;Yuen et al., “A survey of crowdsourcing systems”, Privacy, Security, Risk and Trust (PASSAT) and 2011 IEEE Third Inernational Conference on Social Computing (SocialCom), 2011 IEEE Third International Conference on, IEEE, pp. 766-773.;;Yumer et al., “Semantic Shape Editing Using Deformation Handles”, ACM Transactions on Graphics, vol. 34, No. 4, Article 86, Aug. 2015, 12 pages.;;Zhou et al., “Expressive robot motion timing”, Proceedings of the 2017 ACM/IEEE International Conference on Human-Robot Interaction, ACM, pp. 22-31.;;Maya | Computer Animation & Modeling Software | Autodesk. Retrieved Apr. 4, 2018 from https://www.autodesk.ca/en/products/maya/overview, Retrieved on Mar. 12, 2020, 8 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,864, dated Aug. 5, 2021, 69 pages.;;Jack et al., Dynamic Facial Expressions of Emotion Transmit an Evolving Hierarchy of Signals over Time:, Jan. 20, 2014, 6 pages.;;Wang et al., “Robust Imitation of Diverse Behaviors”, Jul. 14, 2017, 12 pages.;;Durupinar et al., “PERFORM: Perceptual Approach for Adding OCEAN Personality to Human Motion Using Laban Movement Analysis”, 16 pages.;;ROS.org | Powering the world's robots. Retrieved Apr. 4, 2018 from http://www.ros.org/, Retrieved on Mar. 12, 2020, 2 pages.;;Today in Disney History: Lucky the Dinosaur Walks on the Scene | Disney Parks Blog. Aug. 28, 2013, from https://disneyparks.disney.go.com/blog/2013/08/today-in-disney-history-lucky-the-dinosaur-walks-on-the-scene/. Retrieved on Mar. 12, 2020, 5 pages.;;Aibo. aibo. Retrieved Apr. 1, 2018 from https://us.aibo.com. Retrieved on Apr. 12, 2020, 11 pages.;;KUKA Robotics. Retrieved Apr. 1, 2018 from https://www.kuka.com/en-ca. Retrieved on Mar. 12, 2020, 5 pages.;;Final Office Action received for U.S. Appl. No. 16/134,863 dated Jun. 11, 2021, 26 pages.;;Non Final Office Action received for U.S. Appl. No. 16/134,863 dated Oct. 22, 2021, 24 pages.;;Final Office Action received for U.S. Appl. No. 16/134,863 dated Feb. 15, 2022, 17 pages.;;Erez et al., “An integrated system for real-time model predictive control of humanoid robots”, 2013 13th IEEE-RAS International Conference on Humanoid Robots (Humanoids), Oct. 15-17, 2013, pp. 292-299.;;Final Office Action received for U.S. Appl. No. 16/134,864, dated Feb. 18, 2022, 53 pages.;;Advisory Action received for U.S. Appl. No. 16/134,863 dated Sep. 9, 2021, 6 pages.;;Notice of Allowance received for U.S. Appl. No. 16/134,864, dated Jul. 11, 2022, 23 pages.;;Notice of Allowance received for U.S. Appl. No. 16/134,863 dated Jun. 2, 2022, 9 pages.",ACTIVE
34,US,B2,US 11518039 B2,105-875-046-846-191,2022-12-06,2022,US 201816134863 A,2018-09-18,US 201816134863 A;;US 201862711436 P,2018-07-27,Generative design techniques for robot behavior,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/105-875-046-846-191,Granted Patent,yes,9,0,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,B25J11/00;;B25J19/00;;G06F30/17;;G06N3/00;;G06N3/08;;G06N5/00;;G06N7/00;;G06N20/00,,66,37,100-545-354-607-72X;;013-893-681-292-726;;100-602-041-391-84X;;172-545-482-424-559;;148-836-931-919-208;;134-010-681-419-980;;076-274-048-682-780;;087-143-628-955-908;;132-106-581-232-573;;076-476-214-478-984;;109-133-761-197-189;;025-698-952-910-402;;092-443-519-048-191;;107-963-386-498-253;;030-341-682-696-344;;005-886-186-371-712;;019-710-287-333-765;;078-217-156-016-664;;155-883-923-169-270;;008-031-166-611-550;;116-288-609-818-155;;159-356-957-183-928;;007-768-081-749-120;;064-929-420-019-723;;023-077-738-773-617;;034-708-485-676-92X;;067-951-880-435-234;;059-228-935-833-377;;108-581-033-145-682;;031-146-335-433-307;;002-592-816-604-363;;012-515-073-672-51X;;096-147-242-310-183;;106-124-279-276-838;;094-993-300-006-922;;081-083-341-882-940;;011-152-225-285-898,10.1109/humanoids.2013.7029990;;21695266;;pmc3111458;;10.1371/journal.pone.0020989;;10.1007/978-3-319-54184-6_9;;10.1145/1457515.1409077;;10.1109/psivt.2010.85;;10.1007/978-3-540-30301-5_59;;10.1145/3099564.3099570;;10.1007/s10100-012-0261-8;;10.1109/iros.2012.6385576;;15350240;;10.1016/j.tics.2004.07.002;;10.1145/2897824.2925909;;10.1109/roman.2011.6005254;;10.1109/icra.2016.7487451;;10.1109/cvpr.2012.6248026;;10.1145/3173574.3173735;;10.1145/2642918.2647386;;10.1145/2601097.2601101;;10.1007/978-3-642-04380-2_33;;10.1145/2816795.2818137;;10.1145/2559636.2563720;;10.1109/cvprw.2014.121;;10.1145/2601097.2601110;;10.1145/1553374.1553475;;10.1145/2157689.2157814;;10.1109/hri.2010.5453269;;10.1145/2980179.2980242;;10.1145/2677199.2680548;;10.1145/2559636.2559672;;10.1145/1957656.1957674;;10.1145/2901790.2901845;;10.1007/s12369-014-0243-1;;10.1007/s10107-004-0559-y;;10.1145/1141911.1142010;;10.1145/2766908;;10.1145/2909824.3020221;;10.1016/j.cub.2013.11.064;;24388852;;10.1145/2983620,"Erez_2013 (An integrated system for real-time model predictive control of humanoid robots, 2013 13th IEEE-RAS International Conference on Humanoid Robots (Humanoids). Oct. 15-17, 2013 Atlanta, GA (Year: 2013).;;Wang_2017 (Robust Imitation of Diverse Behaviors, 31st Conference on Neural Information Processing Systems (NIPS 2017), Long Beach, CA, USA.) (Year: 2017).;;ROS.org | Powering the world's robots. Retrieved Apr. 4, 2018 from http://www.ros.org/, Retrieved on Mar. 12, 2020, 2 pages.;;Today in Disney History: Lucky the Dinosaur Walks on the Scene | Disney Parks Blog. Aug. 28, 2013, from https://disneyparks.disney.go.com/blog/2013/08/today-in-disney-history-lucky-the-dinosaur-walks-on-the-scene/, Retrieved on Mar. 12, 2020, 6 pages.;;Aibo. aibo. Retrieved Apr. 1, 2018 from https://us.aibo.com, Retrieved on Mar. 12, 2020, 9 pages.;;KUKA Robotics. Retrieved Apr. 1, 2018 from https://www.kuka.com/en-ca, Retrieved on Mar. 12, 2020, 5 pages.;;Alaerts et al., 2011. “Action and emotion recognition from point light displays: an investigation of gender differences”, PloS one vol. 6, Issue 6, e20989, Jun. 2011, 9 pages.;;Aneja et al., “Modeling Stylized Character Expressions via Deep Learning”, Asian Conference on Computer Vision, Springer, 2016, pp. 136-153.;;Barnes et al., “Video Puppetry: A Performative Interface for Cutout Animation”, ACM SIGGRAPH Asia 2008 Papers (SIGGRAPH Asia '08), ACM, http://doi.org/10.1145/1457515.1409077, 2016, pp. 124:1-124:9.;;Bartram et al., “What makes motion meaningful? Affective properties of abstract motion”, Image and Video Technology (PSIVT), 2010 Fourth Pacific-Rim Symposium on, IEEE, pp. 468-474.;;Breazeal et al., “Social robots that interact with people”, In Springer handbook of robotics. Springer, 2008, 1349-1369.;;Chaudhuri et al., “Attriblt: Content Creation with Semantic Attributes”, . Proceedings of the 26th annual ACM symposium on User interface software and technology, ACM, Oct. 8-11, 2013, pp. 193-202.;;Christiano et al., “Deep Reinforcement Learning from Human Preferences”, Advances in Neural Information Processing Systems, 2017, pp. 4302-4310.;;Ciccone et al., “Authoring motion cycles”, Proceedings of the ACM SIGGRAPH/Eurographics Symposium on Computer Animation, ACM, Jul. 28-30, 2017, 9 pages.;;Csató, László, “Ranking by pairwise comparisons for Swiss-system tournaments”, Central European Journal of Cperations Research 21, 4: 2013, pp. 783-803.;;Dalibard et al., “Anthropomorphism of artificial agents: a comparative survey of expressive design and motion of virtual Characters and Social Robots”, Workshop on Autonomous Social Robots and Virtual Humans at the 25th Annual Conference on Computer Animation and Social Agents (CASA 2012), 21 pages.;;Dubey et al., “Deep Learning the City: Quantifying Urban Perception At A Global Scale”, European Conference on Computer Vision, Springer, Sep. 12, 2016, 196-212.;;Emeli, Victor, “Robot Learning Through Social Media Crowdsourcing”, Intelligent Robots and Systems (IROS), 2012 EEE/RSJ International Conference on, IEEE, Oct. 7-12, 2012, pp. 2332-2337.;;Blender Foundation, “blender.org—Home of the Blender project—Free and Open 3D Creation Software”, blender.org. Retrieved Apr. 4, 2018 from https://www.blender.org/, 23 pages.;;Gallese et al., “A unifying view of the basis of social cognition”, Trends in cognitive sciences vol. 8, No. 9: 2004, pp. 396-403.;;Gannon, Madeline “Human-Centered Interfaces for Autonomous Fabrication Machines”, Carnegie Mellon University, 2017, 198 pages.;;Glauser et al., “Rig Animation with a Tangible and Modular Input Device”, ACM Trans. Graph., vol. 35, No. 4, Article 144, DOI: http://dx.doi.org/10.1145/2897824.2925909, Jul. 2016, p. 144:1-144:11.;;Harris et al., “Exploring the affect of abstract motion in social human-robot interaction”, RO-MAN, 2011 IEEE, pp. 141-448.;;Herbrich et al., “TrueSkillTM: a Bayesian skill rating system”, Advances in neural information processing systems, 2007, pp. 569-576.;;Knight et al., “Laban Head-Motions Convey Robot State: A Call for Robot Body Language”, 2016 IEEE International Conference on Robotics and Automation (ICRA), May 16-21, 2016, pp. 2881-2888.;;Kovashka et al., “WhittleSearch: Image Search with Relative Attribute Feedback”, Computer Vision and Pattern Recognition (CVPR), 2012 IEEE Conference on, IEEE, pp. 2973-2980.;;Koyama et al., “OptiMo: Optimization-Guided Motion Editing for Keyframe Character Animation”, 2018, 12 pages.;;Koyama et al., “Crowd-Powered Parameter Analysis for Visual Design Exploration”, Proceedings of the 27th annual ACM symposium on User interface software and technology, ACM, Oct. 5-8, 2014, pp. 65-74.;;Laffont et al., “Transient Attributes for High-Level Understanding and Editing of Outdoor Scenes”, ACM Transactions on Graphics (TOG) vol. 33, No. 4, 2014, 11 pages.;;Lafreniere et al., “Crowdsourced Fabrication”, Proceedings of the 29th Annual Symposium on User Interface Software and Technology, ACM, Oct. 16 -19, 2016, pp. 15-28.;;Lee et al., “Designing with Interactive Example Galleries”, Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, ACM, Apr. 10-15, 2010, pp. 2257-2266.;;Lin et al., Evaluating Emotive Character Animations Created with Procedural Animation International Workshop on Intelligent Virtual Agents, Springer, 2009, pp. 308-315.;;Matejka et al., “Dream Lens: Exploration and Visualization of Large-Scale Generative Design Datasets”, SIGCHI (To appear), Apr. 21-26, 2018, 12 pages.;;Megaro et al., “Interactive design of 3D-printable robotic creatures”, ACM Transactions on Graphics, vol. 34, No. 6, Article 216, Nov. 2015, 9 pages.;;Mok et al., “Empathy: Interactions with Emotive Robotic Drawers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, Mar. 3-6, 2014, pp. 250-251.;;Naik et al., “Streetscore—Predicting the Perceived Safety of One Million Streetscapes”, Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition Workshops, 2014, pp. 779-785.;;O'Donovan al., “Exploratory Font Selection Using Crowdsourced Attributes”, ACM Transactions on Graphics, vol. 33, No. 4, Article 92, Jul. 2014, 9 pages.;;Pan et al., “Unsupervised Hierarchical Modeling of Locomotion Styles”, Proceedings of the 26th Annual International Conference on Machine Learning, ACM, 2009, pp. 785-792.;;Parikh et al., “Relative Attributes”, Computer Vision (ICCV), 2011 IEEE International Conference on, IEEE, pp. 503-510.;;Reynolds, Craig W. “Steering Behaviors For Autonomous Characters”, Game developers conference, pp. 763-782.;;Ribeiro et al., “The Illusion of Robotic Life”, principles and practices of animation for robots. Human-Robot Interaction (HRI), 2012 7th ACM/IEEE International Conference on, IEEE, Mar. 5-8, 2012, pp. 383-390.;;Saerbeck et al., “Perception of Affect Elicited by Robot Motion”, Human-Robot Interaction (HRI), 2010 5th ACM/IEEE International Conference on, IEEE, 2010, pp. 53-60.;;Serrano et al., An intuitive control space for material appearance, ACM Trans. Graph., vol. 35, No. 6, Article 186, Nov. 2016, 12 pages.;;Shapiro et al., “Style Components”, Proceedings of Graphics Interface 2006, Canadian Information Processing Society, pp. 33-39.;;Slyper et al., “Mirror Puppeteering: Animating Toy Robots in Front of a Webcam”, Proceedings of the Ninth International Conference on Tangible, Embedded, and Embodied Interaction, ACM, 2015, pp. 241-248.;;Sun, Yuyin, “Toward Never-Ending Object Learning for Robots” PhD Thesis, University of Washington, 2016, 191 pages.;;Szafir et al., “Communication of intent in assistive free flyers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, 2014, pp. 358-365.;;Takayama et al., “Expressing Thought: Improving Robot Readability with Animation Principles”, Human-Robot Interaction (HRI), 2011 6th ACM/IEEE International Conference on, IEEE, pp. 69-76.;;Tan et al., “Happy Moves, Sad Grooves: Using Theories of Biological Motion and Affect to Design Shape-Changing Interfaces”. Proceedings of the 2016 ACM Conference on Designing Interactive Systems, ACM, Jun. 4-8, 2016, pp. 1282-1293.;;Venture et al., “Recognizing Emotions Conveyed by Human Gait”, International Journal of Social Robotics vol. 6, No. 4: 2014, pp. 621-632.;;Wächter et al., “On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming”, Mathematical programming vol. 106, No. 1: 2006, pp. 25-57.;;Wang et al., “The cartoon animation filter”, ACM Transactions on Graphics (TOG) vol. 25, No. 3:2006, pp. 1169-1173.;;Yuen et al., “A survey of crowdsourcing systems”, Privacy, Security, Risk and Trust (PASSAT) and 2011 IEEE Third Inernational Conference on Social Computing (SocialCom), 2011 IEEE Third International Conference on, IEEE, pp. 766-773.;;Yumer et al., “Semantic Shape Editing Using Deformation Handles”, ACM Transactions on Graphics, vol. 34, No. 4, Article 86, Aug. 2015, 12 pages.;;Zhou et al., “Expressive robot motion timing”, Proceedings of the 2017 ACM/IEEE International Conference on Human-Robot Interaction, ACM, pp. 22-31.;;Maya | Computer Animation & Modeling Software | Autodesk. Retrieved Apr. 4, 2018 from https://www.autodesk.ca/en/products/maya/overview, Retrieved on Mar. 12, 2020, 8 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,864, dated Aug. 5, 2021, 69 pages.;;Jack et al., Dynamic Facial Expressions of Emotion Transmit an Evolving Hierarchy of Signals over Time:, Jan. 20, 2014, 6 pages.;;Wang et al., “Robust Imitation of Diverse Behaviors”, Jul. 14, 2017, 12 pages.;;Durupinar et al., “PERFORM: Perceptual Approach for Adding OCEAN Personality to Human Motion Using Laban Movement Analysis”, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,859, dated Oct. 15, 2021, 43 pages.;;Final Office Action received for U.S. Appl. No. 16/134,859 dated Feb. 17, 2022, 19 pages.;;Kubota et al., “Evolving Pet Robot with Emotional Model”, In Proceedings of the 2000 Congress on Evolutionary Computation, vol. 2, 2000, pp. 1231-1237.;;Final Office Action received for U.S. Appl. No. 16/134,864, dated Feb. 18, 2022, 53 pages.;;Non Final Office Action received for U.S. Appl. No. 16/134,859 dated Oct. 27, 2022, 15 pages.;;Notice of Allowance received for U.S. Appl. No. 16/134,864, dated Jul. 11, 2022, 23 pages.",ACTIVE
35,US,B2,US 11518040 B2,083-558-714-605-823,2022-12-06,2022,US 201816134864 A,2018-09-18,US 201816134864 A;;US 201862711436 P,2018-07-27,Generative design techniques for robot behavior,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/083-558-714-605-823,Granted Patent,yes,9,0,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,B25J11/00;;B25J19/00;;G06F30/17;;G06N3/00;;G06N3/08;;G06N5/00;;G06N7/00;;G06N20/00,,69,38,081-816-407-660-773;;081-083-341-882-940;;013-893-681-292-726;;100-602-041-391-84X;;172-545-482-424-559;;148-836-931-919-208;;134-010-681-419-980;;042-473-482-797-36X;;076-274-048-682-780;;087-143-628-955-908;;132-106-581-232-573;;076-476-214-478-984;;109-133-761-197-189;;025-698-952-910-402;;092-443-519-048-191;;107-963-386-498-253;;030-341-682-696-344;;005-886-186-371-712;;019-710-287-333-765;;078-217-156-016-664;;155-883-923-169-270;;008-031-166-611-550;;116-288-609-818-155;;159-356-957-183-928;;007-768-081-749-120;;064-929-420-019-723;;023-077-738-773-617;;034-708-485-676-92X;;067-951-880-435-234;;059-228-935-833-377;;108-581-033-145-682;;031-146-335-433-307;;002-592-816-604-363;;012-515-073-672-51X;;096-147-242-310-183;;106-124-279-276-838;;094-993-300-006-922;;100-545-354-607-72X,10.1145/3072959.3126789;;10.1016/j.cub.2013.11.064;;24388852;;21695266;;pmc3111458;;10.1371/journal.pone.0020989;;10.1007/978-3-319-54184-6_9;;10.1145/1457515.1409077;;10.1109/psivt.2010.85;;10.1007/978-3-540-30301-5_59;;10.1145/2501988.2502008;;10.1145/3099564.3099570;;10.1007/s10100-012-0261-8;;10.1109/iros.2012.6385576;;15350240;;10.1016/j.tics.2004.07.002;;10.1145/2897824.2925909;;10.1109/roman.2011.6005254;;10.1109/icra.2016.7487451;;10.1109/cvpr.2012.6248026;;10.1145/3173574.3173735;;10.1145/2642918.2647386;;10.1145/2601097.2601101;;10.1007/978-3-642-04380-2_33;;10.1145/2816795.2818137;;10.1145/2559636.2563720;;10.1109/cvprw.2014.121;;10.1145/2601097.2601110;;10.1145/1553374.1553475;;10.1145/2157689.2157814;;10.1109/hri.2010.5453269;;10.1145/2980179.2980242;;10.1145/2677199.2680548;;10.1145/2559636.2559672;;10.1145/1957656.1957674;;10.1145/2901790.2901845;;10.1007/s12369-014-0243-1;;10.1007/s10107-004-0559-y;;10.1145/1141911.1142010;;10.1145/2766908;;10.1145/2909824.3020221;;10.1109/humanoids.2013.7029990,"Durupinar, Funda, et al. “Perform: Perceptual approach for adding ocean personality to human motion using laban movement analysis.” ACM Transactions on Graphics (TOG) 36.1 (2016). pp. 1-16. (Year: 2016).;;Jack, Rachael E., Oliver GB Garrod, and Philippe G. Schyns. “Dynamic facial expressions of emotion transmit an evolving hierarchy of signals over time.” Current biology 24.2 (2014). pp. 187-192. (Year: 2014).;;Wang, Ziyu, et al. “Robust imitation of diverse behaviors.” arXiv preprint arXiv:1707.02747 (2017). Archive Jul. 14, 2017. pp. 1-12. (Year: 2017).;;Alaerts et al., 2011. “Action and emotion recognition from point light displays: an investigation of gender differences”, PloS one vol. 6, Issue 6, e20989, Jun. 2011, 9 pages.;;Aneja et al., “Modeling Stylized Character Expressions via Deep Learning”, Asian Conference on Computer Vision, Springer, 2016, pp. 136-153.;;Barnes et al., “Video Puppetry: A Performative Interface for Cutout Animation”, ACM SIGGRAPH Asia 2008 Papers (SIGGRAPH Asia '08), ACM, http://doi.org/10.1145/1457515.1409077, 2016, pp. 124:1-124:9.;;Bartram et al., “What makes motion meaningful? Affective properties of abstract motion”, Image and Video Technology (PSIVT), 2010 Fourth Pacific-Rim Symposium on, IEEE, pp. 468-474.;;Breazeal et al., “Social robots that interact with people”, In Springer handbook of robotics. Springer, 2008, 1349-1369.;;Chaudhuri et al., “AttribIt: Content Creation with Semantic Attributes”, . Proceedings of the 26th annual ACM symposium on User interface software and technology, ACM, Oct. 8-11, 2013, pp. 193-202.;;Christiano et al., “Deep Reinforcement Learning from Human Preferences”, Advances in Neural Information Processing Systems, 2017, pp. 4302-4310.;;Ciccone et al., “Authoring motion cycles”, Proceedings of the ACM SIGGRAPH/Eurographics Symposium on Computer Animation, ACM, Jul. 28-30, 2017, 9 pages.;;Csató, László, “Ranking by pairwise comparisons for Swiss-system tournaments”, Central European Journal of Operations Research 21, 4: 2013, pp. 783-803.;;Dalibard et al., “Anthropomorphism of artificial agents: a comparative survey of expressive design and motion of virtual Characters and Social Robots”, Workshop on Autonomous Social Robots and Virtual Humans at the 25th Annual Conference on Computer Animation and Social Agents (CASA 2012), 21 pages.;;Dubey et al., “Deep Learning the City: Quantifying Urban Perception at a Global Scale”, European Conference on Computer Vision, Springer, Sep. 12, 2016, 196-212.;;Emeli, Victor, “Robot Learning Through Social Media Crowdsourcing”, Intelligent Robots and Systems (IROS), 2012 IEEE/RSJ International Conference on, IEEE, Oct. 7-12, 2012, pp. 2332-2337.;;Blender Foundation, “blender.org—Home of the Blender project—Free and Open 3D Creation Software”, blender.org. Retrieved Apr. 4, 2018 from https://www.blender.org/, 23 pages.;;Gallese et al., “A unifying view of the basis of social cognition”, Trends in cognitive sciences vol. 8, No. 9: 2004, pp. 396-403.;;Gannon, Madeline “Human-Centered Interfaces for Autonomous Fabrication Machines”, Carnegie Mellon University, 2017, 198 pages.;;Glauser et al., “Rig Animation with a Tangible and Modular Input Device”, ACM Trans. Graph., vol. 35, No. 4, Article 144, DOI: http://dx.doi.org/10.1145/2897824.2925909, Jul. 2016, pp. 144:1-144:11.;;Harris et al., “Exploring the affect of abstract motion in social human-robot interaction”, RO-MAN, 2011 IEEE, pp. 441-448.;;Herbrich et al., “TrueSkillTM: a Bayesian skill rating system”, Advances in neural information processing systems, 2007, pp. 569-576.;;Knight et al., “Laban Head-Motions Convey Robot State: A Call for Robot Body Language”, 2016 IEEE International Conference on Robotics and Automation (ICRA), May 16-21, 2016, pp. 2881-2888.;;Kovashka et al., “WhittleSearch: Image Search with Relative Attribute Feedback”, Computer Vision and Pattern Recognition (CVPR), 2012 IEEE Conference on, IEEE, pp. 2973-2980.;;Koyama et al., “OptiMo: Optimization-Guided Motion Editing for Keyframe Character Animation”, 2018, 12 pages.;;Koyama et al., “Crowd-Powered Parameter Analysis for Visual Design Exploration”, Proceedings of the 27th annual ACM symposium on User interface software and technology, ACM, Oct. 5-8, 2014, pp. 65-74.;;Laffont et al., “Transient Attributes for High-Level Understanding and Editing of Outdoor Scenes”, ACM Transactions on Graphics (TOG) vol. 33, No. 4, 2014, 11 pages.;;Lafreniere et al., “Crowdsourced Fabrication”, Proceedings of the 29th Annual Symposium on User Interface Software and Technology, ACM, Oct. 16-19, 2016, pp. 15-28.;;Lee et al., “Designing with Interactive Example Galleries”, Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, ACM, Apr. 10-15, 2010, pp. 2257-2266.;;Lin et al., Evaluating Emotive Character Animations Created with Procedural Animation International Workshop on Intelligent Virtual Agents, Springer, 2009, pp. 308-315.;;Matejka et al., “Dream Lens: Exploration and Visualization of Large-Scale Generative Design Datasets”, SIGCHI (To appear), Apr. 21-26, 2018, 12 pages.;;Megaro et al., “Interactive design of 3D-printable robotic creatures”, ACM Transactions on Graphics, vol. 34, No. 6, Article 216, Nov. 2015, 9 pages.;;Mok et al., “Empathy: Interactions with Emotive Robotic Drawers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, Mar. 3-6, 2014, pp. 250-251.;;Naik et al., “Streetscore—Predicting the Perceived Safety of One Million Streetscapes”, Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition Workshops, 2014, pp. 779-785.;;O'Donovan et al., “Exploratory Font Selection Using Crowdsourced Attributes”, ACM Transactions on Graphics, vol. 33, No. 4, Article 92, Jul. 2014, 9 pages.;;Pan et al., “Unsupervised Hierarchical Modeling of Locomotion Styles”, Proceedings of the 26th Annual International Conference on Machine Learning, ACM, 2009, pp. 785-792.;;Parikh et al., “Relative Attributes”, Computer Vision (ICCV), 2011 IEEE International Conference on, IEEE, pp. 503-510.;;Reynolds, Craig W. “Steering Behaviors for Autonomous Characters”, Game developers conference, pp. 763-782.;;Ribeiro et al., “The Illusion of Robotic Life”, principles and practices of animation for robots. Human-Robot Interaction (HRI), 2012 7th ACM/IEEE International Conference on, IEEE, Mar. 5-8, 2012, pp. 383-390.;;Saerbeck et al., “Perception of Affect Elicited by Robot Motion”, Human-Robot Interaction (HRI), 2010 5th ACM/IEEE International Conference on, IEEE, 2010, pp. 53-60.;;Serrano et al., An intuitive control space for material appearance, ACM Trans. Graph., vol. 35, No. 6, Article 186, Nov. 2016, 12 pages.;;Shapiro et al., “Style Components”, Proceedings of Graphics Interface 2006, Canadian Information Processing Society, pp. 33-39.;;Slyper et al., “Mirror Puppeteering: Animating Toy Robots in Front of a Webcam”, Proceedings of the Ninth International Conference on Tangible, Embedded, and Embodied Interaction, ACM, 2015, pp. 241-248.;;Sun, Yuyin, “Toward Never-Ending Object Learning for Robots” PhD Thesis, University of Washington, 2016, 191 pages.;;Szafir et al., “Communication of intent in assistive free flyers”, Proceedings of the 2014 ACM/IEEE international conference on Human-robot interaction, ACM, 2014, pp. 358-365.;;Takayama et al., “Expressing Thought: Improving Robot Readability with Animation Principles”, Human-Robot Interaction (HRI), 2011 6th ACM/IEEE International Conference on, IEEE, pp. 69-76.;;Tan et al., “Happy Moves, Sad Grooves: Using Theories of Biological Motion and Affect to Design Shape-Changing Interfaces”, Proceedings of the 2016 ACM Conference on Designing Interactive Systems, ACM, Jun. 4-8, 2016, pp. 1282-1293.;;Venture et al., “Recognizing Emotions Conveyed by Human Gait”, International Journal of Social Robotics vol. 6, No. 4: 2014, pp. 621-632.;;Wächter et al., “On the implementation of an interior-point filter line-search algorithm for large-scale nonlinear programming”, Mathematical programming vol. 106, No. 1: 2006, pp. 25-57.;;Wang et al., “The cartoon animation filter”, ACM Transactions on Graphics (TOG) vol. 25, No. 3: 2006, pp. 1169-1173.;;Yuen et al., “A survey of crowdsourcing systems”, Privacy, Security, Risk and Trust (PASSAT) and 2011 IEEE Third Inernational Conference on Social Computing (SocialCom), 2011 IEEE Third International Conference on, IEEE, pp. 766-773.;;Yumer et al., “Semantic Shape Editing Using Deformation Handles”, ACM Transactions on Graphics, vol. 34, No. 4, Article 86, Aug. 2015, 12 pages.;;Zhou et al., “Expressive robot motion timing”, Proceedings of the 2017 ACM/IEEE International Conference on Human-Robot Interaction, ACM, pp. 22-31.;;Maya | Computer Animation & Modeling Software | Autodesk. Retrieved Apr. 4, 2018 from https://www.autodesk.ca/en/products/maya/overview. Retrieved Mar. 12, 2020, 8 pages.;;ROS.org | Powering the world's robots. Retrieved Apr. 4, 2018 from http://www.ros.org/, Retrieved on Mar. 12, 2020, 2 pages.;;Today in Disney History: Lucky the Dinosaur Walks on the Scene | Disney Parks Blog. Aug. 28, 2013 from https://disneyparks.disney.go.com/blog/2013/08/today-in-disney-history-lucky-the-dinosaur-walks-on-the-scene/, Retrieved on Mar. 12, 2020, 6 pages.;;Aibo. aibo. Retrieved Apr. 1, 2018 from http://aibo.com/, Retrieved on Mar. 12, 2020, 9 pages.;;KUKA Robotics. Retrieved Apr. 1, 2018 from https://www.kuka.com/en-ca, Retrieved on Mar. 12, 2020, 5 pages.;;Ziyu Wang et al., “Robust Imitation of Diverse Behaviors”, 31st Conference on Neural Information Processing Systems, 2017, 10 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,863 dated Feb. 2, 2021, 35 pages.;;Non-Final Office Action received for U.S. Appl. No. 16/134,859, dated Oct. 15, 2021, 43 pages.;;Final Office Action received for U.S. Appl. No. 16/134,863 dated Jun. 11, 2021, 18 pages.;;Final Office Action received for U.S. Appl. No. 16/134,859 dated Feb. 17, 2022, 19 pages.;;Kubota et al., “Evolving Pet Robot with Emotional Model”, In Proceedings of the 2000 Congress on Evolutionary Computation, vol. 2, 2000, pp. 1231-1237.;;Non Final Office Action received for U.S. Appl. No. 16/134,863 dated Oct. 22, 2021, 24 pages.;;Final Office Action received for U.S. Appl. No. 16/134,863 dated Feb. 15, 2022, 17 pages.;;Erez et al., “An integrated system for real-time model predictive control of humanoid robots”, 2013 13th IEEE-RAS International Conference on Humanoid Robots (Humanoids), Oct. 15-17, 2013, pp. 292-299.;;Notice of Allowance received for U.S. Appl. No. 16/134,863 dated Jun. 2, 2022, 9 pages.;;Advisory Action received for U.S. Appl. No. 16/134,863 dated Sep. 9, 2021, 6 pages.;;Non Final Office Action received for U.S. Appl. No. 16/134,859 dated Oct. 27, 2022, 15 pages.",ACTIVE
36,US,B2,US 8298521 B2,080-486-463-628-721,2012-10-30,2012,US 12610008 A,2008-05-23,US 12610008 A;;US 61101303 A;;US 39350502 P,2002-07-02,Treatment for eye disorder,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU CHANGJUN;;UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU CHANGJUN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2004-02-05);;THE CALIFORNIA INSTITUTE OF TECHNOLOGY (2003-08-22),https://lens.org/080-486-463-628-721,Granted Patent,yes,46,6,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61B3/12;;A61K31/74;;A61F9/007;;G01N21/64;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,424/78.04;;424/78.02;;607/1;;607/88,34,23,011-229-550-245-518;;018-636-236-881-674;;107-508-531-015-701;;033-434-998-665-730;;084-089-089-308-125;;053-016-719-296-068;;018-880-745-144-423;;076-810-335-720-854;;000-389-333-705-876;;025-986-063-550-255;;103-159-131-889-540;;064-376-313-684-472;;005-974-518-507-955;;042-671-514-512-46X;;019-987-249-651-430;;003-040-057-179-888;;130-258-136-041-402;;016-765-849-385-372;;129-647-388-907-165;;036-870-817-434-985;;088-762-033-865-208;;094-791-135-404-955;;015-881-453-955-537,10.1136/bjo.76.3.166;;1540562;;pmc504197;;10.1115/1.1536930;;pmc2744140;;12661206;;10.1146/annurev.matsci.31.1.171;;2170292;;8424710;;10.1001/archopht.1993.01090010130039;;2409504;;10.1016/s0161-6420(85)33993-3;;11045345;;10.1007/s004170000188;;10.1001/archopht.1994.01090150132035;;8129668;;10.1021/ma0106604;;10.2165/00126839-200203030-00001;;12099157;;7775106;;11783457;;10.1007/bf02853166;;16845209;;7862410;;10.1016/s0161-6420(95)31032-9;;10.1146/annurev.bioeng.6.040803.140027;;15255762;;12657618;;10.1167/iovs.02-0496;;8433826;;10.1016/s0161-6420(13)31712-6;;10.1097/00006982-199902000-00010;;10213241;;10.1006/exer.1997.0410;;9533835;;13916018;;10.1016/0002-9394(61)90014-9;;15326159;;10.1167/iovs.04-0193;;12240211;;10.1039/b105185g;;12719068;;10.1016/s0002-9394(02)02220-1,"Bird, ""Bruch's membrane change with age,"" Br. J. Ophthalmol., 76(3):166-8, 1992.;;Downs et al., ""Viscoelastic characterization of perpapillary sciera: Material properties by quadrant in rabbit and monkey eyes,"" J. Biomech. Eng., 125:124-131, 2003.;;Fisher et al., ""Photoinitiated polymerization of biomaterials,"" Annu. Rev. Mater. Res.,31:171-81, 2001.;;Gorrsch et al., ""Hematogenous photosensitization: A mechanism for the development of Afe-related macular degeneration,"" Investigative Ophthalmology & Visual Science, 31(9):1674-1682, 1990.;;Goss et al., ""Optometric Clinical Practice Guidance: Care of the Patient with Myopia,"" Reference Guide for Clinicians, © American Optometric Association, 1997.;;Gottsch et al., ""Light-induced deposits in Bruch's membrane of protoporphyric mice,"" Arch. Ophthalmol., 111:126-129, 1993.;;Green et al., ""Pathologic features of senile macular degeneration,"" Ophthalmology, 92(5):615-627, 1985.;;Haigis et al., ""Comparison of immersion ultrasound biometry and partial coherence interferometry for introcular lens calculation according to Haigis,"" Graef's Arch. Clin. Exp. Ophthalmol, 238:765-773, 2000.;;Holz et al., ""Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane,"" Arch. Ophthalmol., 112(3):402-6, 1994.;;Jin et al., ""Effect of electrostatic interaction between Glycosaminoglycans on the shear stiffness of cartilage: a molecular model and experiments,"" Macromolecules, 34:8330-8339, 2001.;;Kaufman, ""Strengthening the corea,"" Cornea, 33(5):432-2004.;;Knapp et al., ""Theology of reconstituted type I collagen gel in confined compression,"" J. Rheol., 41(5):971-993, 1997.;;Mester et al., ""A comparison of two different formulations of diciofenac sodium 0.1 in the treatment of inflammation following cataract-intraocular lens surgery,"" Drugs R&D, 3(3):145-151, 2002.;;Moore et al., ""Age-related variation in the hydraulic conducitivity of Bruch's membrane,"" Invest. Ophthalmol. Vis. Sci., 36(7):1290-7, 1995.;;Noecker, ""Effects of common ophthalmic preservatives on ocular health,"" Advances in Therapy, 18(5):205-215, 2001.;;Nowak, ""Age-related macular degeneration (AMD): pathogenesis and therapy,"" Pharmacol. Rep., 58(3):353-63, 2006.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Jan. 6, 2005.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Apr. 28, 2005.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Jul. 26, 2005.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Nov. 2, 2005.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Jul. 19, 2006.;;Office Communication, issued in U.S. Appl. No. 10/611,013, dated Apr. 19, 2007.;;Puliafito et al., ""Imaging of macular diseases with optical coherence tomography,"" Ophthalmology, 102(2):217-229, 1995.;;Rather et al., ""Biomaterials: Where we have been and where we are going,"" Annu. Rev. Biomed. Eng., 6:41-75, 2004.;;Ruberti et al., ""Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane,"" Invest. Ophthalmol. Vis. Sci., 44(4):1753-9, 2003.;;Sheraidah et al., ""Correlation between lipids extracted from Cruch's membrane and age,"" Ophthalmology, 100(1):47-51, 1993 (Abstract Only).;;Spaide et al., ""Characterization of peroxidized lipids in Bruch's membrane,"" Retina, 19(2):141-7, 1999. (Abstract only).;;Spoert et al., ""Induction of cross-links in corneal tissue,"" Exp. Eye Res., 66:97-103, 1998.;;St. Helen et al., ""Rheology of the human sciera, 1 anelastic behavior,"" Am. J. Ophthalmol., 52:539-48, 1961.;;Tezel et al., ""Reengineering of aged Bruch's membrane to enchance retinal pigment epithelium repopulation,"" Invest. Opth. Vs. Sci., 45:3337-3348, 2004.;;Tezel et al., ""Regeneration of the inner collagenous layer (1CL) of human Bruch's membrane by cleaning and extracellular matrix protein coating: Morphometic evidence,"" Investigative Ophth. & Visual Science, 44:1-2, 2003.;;Van Hest et al., ""Protein-based materials, towards a new level of structural control,"" Chem. Commun., 1897-1904, 2001.;;Visudyne-Overview: Veterporfin for Injection, available online at http://www.visudyne.com, May 2002.;;Wollensak et al., ""Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratocous,"" Am. J. Ophthalmol., 135:620-627, 2003.",INACTIVE
37,CA,A1,CA 2491128 A1,066-318-927-800-877,2004-01-15,2004,CA 2491128 A,2003-07-01,US 39350502 P;;US 0320672 W,2002-07-02,TREATMENT FOR EYE DISORDER,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activati ng energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,FRASER SCOTT;;GALLIVAN JUSTIN P;;YU CHANGJUN;;SCHWARTZ DANIEL M;;GRUBBS ROBERT H,,https://lens.org/066-318-927-800-877,Patent Application,no,0,0,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,G01N21/64;;A61B3/12;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,,0,0,,,,DISCONTINUED
38,US,B2,US 7381404 B2,148-142-534-994-320,2008-06-03,2008,US 61101303 A,2003-07-01,US 61101303 A;;US 39350502 P,2002-07-02,Treatment for dry macular degeneration,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU CHANGJUN,CALIFORNIA INSTITUTE OF TECHNOLOGY THE (2003-08-22);;REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2004-02-05),https://lens.org/148-142-534-994-320,Granted Patent,yes,44,5,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61K31/74;;A61B3/12;;G01N21/64;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,424/78.04;;424/78.02;;607/1;;607/88,28,25,042-671-514-512-46X;;018-636-236-881-674;;107-508-531-015-701;;018-880-745-144-423;;000-389-333-705-876;;022-362-500-371-374;;111-968-254-146-472;;019-987-249-651-430;;129-647-388-907-165;;036-870-817-434-985;;094-791-135-404-955;;015-881-453-955-537;;053-016-719-296-068;;033-434-998-665-730;;084-089-089-308-125;;064-376-313-684-472;;025-986-063-550-255;;088-762-033-865-208;;003-040-057-179-888;;130-258-136-041-402;;016-765-849-385-372;;011-229-550-245-518;;076-810-335-720-854;;103-159-131-889-540;;005-974-518-507-955,7862410;;10.1016/s0161-6420(95)31032-9;;10.1115/1.1536930;;pmc2744140;;12661206;;10.1146/annurev.matsci.31.1.171;;11045345;;10.1007/s004170000188;;10.1021/ma0106604;;15220724;;10.1097/01.ico.0000114302.17937.17;;10.1122/1.550817;;10.1146/annurev.bioeng.6.040803.140027;;15255762;;10.1006/exer.1997.0410;;9533835;;13916018;;10.1016/0002-9394(61)90014-9;;12240211;;10.1039/b105185g;;12719068;;10.1016/s0002-9394(02)02220-1;;2409504;;10.1016/s0161-6420(85)33993-3;;2170292;;8424710;;10.1001/archopht.1993.01090010130039;;11783457;;10.1007/bf02853166;;10.2165/00126839-200203030-00001;;12099157;;15326159;;10.1167/iovs.04-0193;;12657618;;10.1167/iovs.02-0496;;8433826;;10.1016/s0161-6420(13)31712-6;;10.1097/00006982-199902000-00010;;10213241;;10.1136/bjo.76.3.166;;1540562;;pmc504197;;10.1001/archopht.1994.01090150132035;;8129668;;7775106;;16845209,"Puliafito et al, Ophthalmology, 1995, vol. 102, No. 2, pp. 217-229.;;Downs et al., ""Viscoelastic Characterization of Perpapilary Sclera: Material Properties by Quadrant in Rabbit and Monkey Eyes,"" J. Biomech. Eng., 125:124-131, 2003.;;Fisher et al., ""Photoinitiated Polymerization of Biomaterials,"" Annu. Rev. Mater. Res., 31: 171-81-, 2001.;;Goss et al., Optometric Clinical Practice Guideline: Care of the Patient with Myopia, Reference Guide for Clinicians, (C) American Optometric Association, 1997.;;Haigis et al., ""Comparison of immersion ultrasound biometry and partial coherence interferometry for introcular lens calculation according to Haigis,"" Graefe's Arch. Clin. Exp. Opthalmol., 238: 765-773, 2000.;;Jin et al., ""Effects of Electrostatis Interactions between Glycosaminoglycans on the Shear Stiffness of Cartilage: A Molecular Model and Experiments,"" Macromolecules, 34: 8330-8339, 2001.;;Kaufman, ""Strengthening the Corea,"" Comea, 23(5): 432, 2004.;;Knapp et al., ""Rheology of reconstituted type I collagen gel in confined compression,"" J. Rheol., 41(5): 971-993, 1997.;;Ratner et al., ""Biomaterials: Where We have Been and Where We Are Going,"" Annu. Rev. Biomed. Eng., 6: 41-75, 2004.;;Spoerl et al., ""Induction of Cross-Links in Corneal Tissue,"" Exp. Eye Res., 66: 97-103, 1998.;;St. Helen et al., ""Rheology of the Human Sclera, 1. Anelastic Behavior,"" Am. J. Ophthalmol., 52: 539-48, 1961.;;van Hest et al., ""Protein-based materials, toward a new level of structural control,"" Chem. Commun., 1897-1904, 2001.;;Wollensak et al., ""Riboflavin/Ultraviolet-A-induced Collagen Crosslinking for the Treatment of Keratocous,"" Am. J. Ophthalmol., 135: 620-627, 2003.;;Green et al, ""Pathologic Features of Senile Macular Degeneration,"" Ophthalmology vol. 92, No. 5, May 1985, pp. 615-627.;;Gorrsch et al., ""Hematogenous Photosensitization: A Mechanism for the Development of Afe-related Macular Degeneration,"" Investigative Ophthalmology & Visual Science vol. 31, No. 9, Sep. 1990, pp. 1674-1682.;;Gottsch et al., ""Light-Induced Deposits in Bruch's Membrane of Protoporphyric Mice,"" Arch Ophthalmol vol. 111, Jan. 1993, pp. 126-129.;;Visudyne-Overview: Verteporfin for Injection, www.visudyne.com, May 2002.;;Noecker, R., ""Effects of Common Ophthalmic Preservatives on Ocular Health"", Advances in Therapy, vol. 18, No. 5, (Sep./Oct. 2001) pp. 205-215.;;Mester, U., et al., ""A Comparison of Two Different Formulations of Diclofenac Sodium 0.1 in the Treatment of Inflammation Following Cataract-Intraocular Lens Surgey"", Drugs R&D, vol. 3 No. 3, (2002) pp. 145-151.;;Tezel, Th., et. al., ""Regeration of the inner collagenous layer (1CL) of human Bruch's membrane by cleaning and extracellular matrix protein coating: Morphometic evidence,"" Investigative Ophth. & Visual Science, vol. 44, p. 1-2 (May 2003).;;Tezel, T.H., et. al., ""Reengineering of Aged Bruch's Membrane to Enhance Retinal Pigment Epithelium Repopulation,"" Invest Opth. Vs. Sci. (2004) vol. 45, pp. 3337-3348.;;Ruberti JW, Curcio CA, Millican CL, Menco BP, Huang JD, Johnson M., Quick-freeze/deep-etch visualization of age-related lipid accumulation on Bruch's membrane, Invest Ophthalmol Vis Sci. Apr. 2003;44(4):1753-9.;;Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, Bird AC., Correlation between lipids extracted from Bruch's membrane and age, Ophthalmology. Jan. 1993;100(1):47-51. (Abstract Only).;;Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D., Charaterization of peroxidized lipids in Bruch's membrane, Retina. 1999;19(2):141-7. (Abstract Only).;;Bird AC., Bruch's membrane change with age, Br J Ophthalmol. Mar. 1992;76(3):166-8.;;Holz FG, Sheraidah G, Pauleikhoff D, Bird AC., Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane, Arch Ophthalmol. Mar. 1994;112(3):402-6. (Abstract Only).;;Moore DJ, Hussain AA, Marshall J., Age-related variation in the hydraulic conductivity of Bruch's membrane, Invest Ophthalmol Vis Sci. Jun. 1995;36(7):1290-7.;;Nowak J.Z., Age-related macular degeneration (AMD): pathogenesis and therapy, Pharmacol Rep. May-Jun. 2006;58(3):353-63.",EXPIRED
39,US,A1,US 2020/0034513 A1,070-807-296-794-387,2020-01-30,2020,US 201816134859 A,2018-09-18,US 201816134859 A;;US 201862711436 P,2018-07-27,GENERATIVE DESIGN TECHNIQUES FOR ROBOT BEHAVIOR,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/070-807-296-794-387,Patent Application,yes,0,0,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,B25J9/16,,0,0,,,,ACTIVE
40,US,A1,US 2020/0030988 A1,073-839-041-658-135,2020-01-30,2020,US 201816134863 A,2018-09-18,US 201816134863 A;;US 201862711436 P,2018-07-27,GENERATIVE DESIGN TECHNIQUES FOR ROBOT BEHAVIOR,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/073-839-041-658-135,Patent Application,yes,2,4,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,G06N3/00;;B25J11/00,,1,0,,,"Wang_2017 (Robust Imitation of Diverse Behaviors, 31st Conference on Neural Information Processing Systems (NIPS 2017), Long Beach, CA, USA.) (Year: 2017)",ACTIVE
41,US,A1,US 2020/0034514 A1,065-934-329-433-889,2020-01-30,2020,US 201816134864 A,2018-09-18,US 201816134864 A;;US 201862711436 P,2018-07-27,GENERATIVE DESIGN TECHNIQUES FOR ROBOT BEHAVIOR,"An automated robot design pipeline facilitates the overall process of designing robots that perform various desired behaviors. The disclosed pipeline includes four stages. In the first stage, a generative engine samples a design space to generate a large number of robot designs. In the second stage, a metric engine generates behavioral metrics indicating a degree to which each robot design performs the desired behaviors. In the third stage, a mapping engine generates a behavior predictor that can predict the behavioral metrics for any given robot design. In the fourth stage, a design engine generates a graphical user interface (GUI) that guides the user in performing behavior-driven design of a robot. One advantage of the disclosed approach is that the user need not have specialized skills in either graphic design or programming to generate designs for robots that perform specific behaviors or express various emotions.",AUTODESK INC,ANDERSON FRASER;;COROS STELIAN;;DESAI RUTA;;GROSSMAN TOVI;;MATEJKA JUSTIN FRANK;;FITZMAURICE GEORGE,AUTODESK INC (2018-09-12),https://lens.org/065-934-329-433-889,Patent Application,yes,2,1,6,6,0,B25J19/007;;G06N3/008;;G06N3/08;;G06N20/00;;G06F30/17;;G06N5/01;;G06N7/01;;B25J11/001;;G06N3/004;;G06F30/17;;G06N3/08;;G06N20/00;;G06N3/008;;B25J19/007;;G06N5/01;;G06N7/01,B25J11/00;;G06N3/00,,3,2,081-816-407-660-773;;081-083-341-882-940,10.1145/3072959.3126789;;10.1016/j.cub.2013.11.064;;24388852,"Durupinar, Funda, et al. ""Perform: Perceptual approach for adding ocean personality to human motion using laban movement analysis."" ACM Transactions on Graphics (TOG) 36.1 (2016). PP. 1-16. (Year: 2016);;Jack, Rachael E., Oliver GB Garrod, and Philippe G. Schyns. ""Dynamic facial expressions of emotion transmit an evolving hierarchy of signals over time."" Current biology 24.2 (2014). PP. 187-192. (Year: 2014);;Wang, Ziyu, et al. ""Robust imitation of diverse behaviors."" arXiv preprint arXiv:1707.02747 (2017). Archive 14 Jul 2017. PP. 1-12. (Year: 2017)",ACTIVE
42,US,A1,US 2008/0286255 A1,063-686-552-795-724,2008-11-20,2008,US 12610008 A,2008-05-23,US 12610008 A;;US 61101303 A;;US 39350502 P,2002-07-02,TREATMENT FOR EYE DISORDER,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU CHANGJUN,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2004-02-05);;THE CALIFORNIA INSTITUTE OF TECHNOLOGY (2003-08-22),https://lens.org/063-686-552-795-724,Patent Application,yes,43,2,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61K38/43;;A61B3/12;;G01N21/64;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,424/94.1,0,0,,,,EXPIRED
43,US,A1,US 2023/0267667 A1,061-634-683-199-415,2023-08-24,2023,US 202217677826 A,2022-02-22,US 202217677826 A,2022-02-22,IMMERSIVE ANALYSIS ENVIRONMENT FOR HUMAN MOTION DATA,One embodiment of a computer-implemented method for analyzing human motion data includes receiving a set of motion data that indicates one or more movements of a first person within a real-world environment; generating a virtual avatar corresponding to the first person based on the set of motion data; determining a position of the virtual avatar within an extended reality (ER) scene based on the one or more movements; and displaying the virtual avatar in the ER scene according to the determined position.,AUTODESK INC,BRUDY FREDERIK;;ANDERSON FRASER;;DACHSELT RAIMUND;;FITZMAURICE GEORGE;;MATEJKA JUSTIN FRANK;;REIPSCHLÄGER PATRICK,AUTODESK INC (2022-02-22),https://lens.org/061-634-683-199-415,Patent Application,yes,6,1,1,1,0,G06T19/00;;G06V40/23;;G06V20/20;;G06F3/011;;G06F3/013;;G06T13/40;;G06F3/011;;G06T2207/30196;;G06T7/70;;G06V40/23;;G06T19/006,G06T13/40;;G06F3/01;;G06T7/70;;G06T19/00;;G06V40/20,,0,0,,,,PENDING
44,US,A1,US 2021/0152648 A1,011-621-031-593-699,2021-05-20,2021,US 202017069334 A,2020-10-13,US 202017069334 A;;US 201962936363 P,2019-11-15,TECHNIQUES FOR ANALYZING THE PROFICIENCY OF USERS OF SOFTWARE APPLICATIONS IN REAL-TIME,"A command map GUI that illustrates command usage patterns of one or more entities. A server receives and stores command usage data from a plurality of users/clients, each user/client executing a software application having a set of commands. A current user/client displays, via a GUI, graphical representations of the command usage data received from the server. The server receives new command usage data from a user/client included in the one or more entities. In response, the server automatically updates command usage data for the one or more entities, pushes the updated command usage data to the current user/client, and causes the GUI to display graphical representations of the updated command usage data. Thus, the command usage data of the one or more entities is automatically updated and displayed in the GUI in real-time or near real-time as new commands are continually invoked by users in the one or more entities.",AUTODESK INC,MATEJKA JUSTIN FRANK;;ANDERSON FRASER;;FITZMAURICE GEORGE;;GROSSMAN TOVI;;SCHREY WARREN KARL;;SMITHERMAN CHRISTIAN,AUTODESK INC (2020-10-05),https://lens.org/011-621-031-593-699,Patent Application,yes,4,3,1,1,0,H04L67/306;;G06F11/3438;;G06F2201/805;;H04L67/535;;G06F11/3438;;G06F9/451;;G06F3/14;;H04L67/535;;H04L67/01,G06F3/14;;H04L29/08;;G06F9/451;;G06F11/34;;H04L29/06,,0,0,,,,PENDING
45,AU,A1,AU 2003/253767 A1,171-359-572-060-909,2004-01-23,2004,AU 2003/253767 A,2003-07-07,US 39350502 P;;US 0320672 W,2002-07-02,TREATMENT FOR EYE DISORDER,,THE CALIFORNIA INSTITUTE OF TECH;;UNIV CALIFORNIA,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,,https://lens.org/171-359-572-060-909,Patent Application,no,0,0,1,11,0,,A61K38/43,,0,0,,,,DISCONTINUED
46,US,A1,US 2005/0048044 A1,154-885-781-004-798,2005-03-03,2005,US 61101303 A,2003-07-01,US 61101303 A;;US 39350502 P,2002-07-02,Treatment for eye disorder,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,CALIFORNIA INSTITUTE OF TECHNOLOGY THE (2003-08-22);;REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2004-02-05),https://lens.org/154-885-781-004-798,Patent Application,yes,42,14,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61B3/12;;A61F9/007;;A61K9/127;;G01N21/64;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,424/94.1;;514/2;;X51456,0,0,,,,EXPIRED
47,WO,A1,WO 2004/004757 A1,164-746-091-961-462,2004-01-15,2004,US 0320672 W,2003-07-01,US 39350502 P,2002-07-02,TREATMENT FOR EYE DISORDER,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch&apos;s membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch&apos;s membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN;;SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,,https://lens.org/164-746-091-961-462,Patent Application,yes,4,4,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61B3/12;;G01N21/64;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,,0,0,,,,PENDING
48,WO,A8,WO 2004/004757 A8,181-160-054-309-06X,2004-10-07,2004,US 0320672 W,2003-07-01,US 39350502 P,2002-07-02,TREATMENT FOR EYE DISORDER,"The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.",UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN;;SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,,https://lens.org/181-160-054-309-06X,Patent Application,no,0,0,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,A61B3/12;;G01N21/64;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,,0,0,,,,PENDING
49,CN,A,CN 1678342 A,078-462-427-800-944,2005-10-05,2005,CN 03820811 A,2003-07-01,US 39350502 P,2002-07-02,Treatment for eye disorder,,UNIV CALIFORNIA,SCHWARTZ DANIEL M;;SCOTT FRASER;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,,https://lens.org/078-462-427-800-944,Patent Application,no,0,4,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,G01N21/64;;A61B3/12;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,,0,0,,,,DISCONTINUED
50,EP,A1,EP 1539222 A1,057-558-632-951-738,2005-06-15,2005,EP 03763073 A,2003-07-01,US 0320672 W;;US 39350502 P,2002-07-02,TREATMENT FOR EYE DISORDER,,UNIV CALIFORNIA;;CALIFORNIA INST OF TECHN,SCHWARTZ DANIEL M;;FRASER SCOTT;;GRUBBS ROBERT H;;GALLIVAN JUSTIN P;;YU C J,,https://lens.org/057-558-632-951-738,Patent Application,yes,0,0,10,11,0,A61K38/482;;A61K41/00;;A61K49/0017;;A61K49/0056;;A61P27/02;;A61P27/06;;A61K49/0056;;A61K38/482;;A61K41/00;;A61K49/0017,G01N21/64;;A61B3/12;;A61F9/007;;A61K9/127;;A61K38/46;;A61K38/48;;A61K41/00;;A61K45/00;;A61K47/48;;A61K49/00;;A61P27/02;;A61P27/06;;G01N21/17,,0,0,,,,DISCONTINUED
51,US,A1,US 2024/0036062 A1,046-260-793-092-195,2024-02-01,2024,US 202318227192 A,2023-07-27,US 202318227192 A;;US 202263393016 P,2022-07-28,IDENTIFYING RISK OF AND TREATING STROKE-INDUCED COGNITIVE IMPAIRMENT FOLLOWING THROMBECTOMY,Tools for identifying risk of and for treating vascular contributions to cognitive impairment and dementia (VCID) and stroke-induced cognitive impairment in a subject are provided and include a method and a device that involve detecting target proteins in systemic blood sample from the subject.,UNIV KENTUCKY RES FOUND,PENNYPACKER KEITH R;;FRASER JUSTIN F;;MCLOUTH CHRISTOPHER;;HARP JORDAN P;;MESSMER SARAH;;FRANK JACQUELINE A,UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2022-10-19),https://lens.org/046-260-793-092-195,Patent Application,yes,0,0,1,1,0,A61P25/28;;A61K38/26;;G01N33/6896;;G01N33/6893;;G01N33/6896;;A61K38/26;;G01N2333/4745;;G01N2800/52;;G01N2800/2814;;A61P25/28,G01N33/68;;A61K38/26;;A61P25/28,,0,0,,,,PENDING
52,US,A1,US 2021/0304019 A1,112-889-645-115-340,2021-09-30,2021,US 202117211691 A,2021-03-24,US 202117211691 A;;US 202063000680 P,2020-03-27,COMPUTER-BASED TECHNIQUES FOR CAPTURING KNOWLEDGE ABOUT COMPUTER-BASED TASKS,"In various embodiments, a knowledge capture application automatically captures knowledge associated with computer-based tasks. While a computer-based task is performed during a computer-based session, the knowledge capture application performs operation(s) on a user utterance to automatically generate a knowledge item. The knowledge capture application performs classification operation(s) on the knowledge item to generate a categorized knowledge item that associates the knowledge item with a first category. Subsequently, the knowledge capture application modifies a first element included in a graphical user interface to visually indicate an actual capture level associated with the first category. The knowledge capture application generates a knowledge dataset based on the first categorized knowledge item for storage or display. Advantageously, automatically generating the knowledge items and visually prompting the user via the actual capture levels during the computer-based session can increase both the comprehensiveness and the quality of the knowledge dataset.",AUTODESK INC,ANDERSON FRASER;;FITZMAURICE GEORGE;;GROSSMAN TOVI;;KROSNICK REBECCA PAIGE;;LASECKI WALTER;;MATEJKA JUSTIN FRANK;;ONEY STEVE,AUTODESK INC (2021-03-23);;GEOTAB INC (2020-07-06),https://lens.org/112-889-645-115-340,Patent Application,yes,0,1,1,1,0,G10L15/26;;G06F9/453;;G06F3/167;;G06N5/02;;G06N5/02;;G06F9/451;;G06F3/167;;G10L2015/088;;G10L15/1815;;G10L25/63;;G10L15/22,G06N5/02;;G06F3/16;;G06F9/451;;G10L15/18;;G10L15/22;;G10L25/63,,0,0,,,,PENDING
53,CN,A,CN 116472463 A,017-881-800-026-875,2023-07-21,2023,CN 202180076097 A,2021-11-03,US 202063112386 P;;US 2021/0072198 W,2020-11-11,"SUBSTRATE PROCESSING SYSTEM TOOL FOR MONITORING, EVALUATING AND RESPONSING BASED ON HEALTH INCLUDING SENSOR MAPPING","A state of health monitoring, assessment and response system includes an interface and a controller. The interface is configured to receive a signal from a sensor disposed in the substrate processing system. The controller includes a state of health index module. The state of health index module is configured to execute an algorithm comprising: obtaining a window and a boundary threshold; monitoring the signal output from the sensor; determining whether the signal has crossed the boundary threshold; updating a state of health index component, wherein the state of health index component is a binary value and transitions between high and low values in response to the signal crossing the boundary threshold; and generating a health status index value based on the health status index component, and reducing the health status index value from 100% to 0% for at least a duration of the window. The controller is configured to execute a countermeasure based on the state of health index value.",LAM RES CORP,BRIGITTE HILL FRASER;;BALDWIN SCOTT;;TANG JUSTIN;;CHOW RAYMOND;;RABE TOR ANDREAS;;STEGER ROBERT J;;ZHU LIN,,https://lens.org/017-881-800-026-875,Patent Application,no,0,0,7,7,0,H01L21/67288;;H01L21/67276;;G05B23/0283;;G05B23/0235;;G05B23/0283;;G05B23/0235;;H01L21/67288;;H01L21/67276;;G01R31/2894;;G01R31/2894;;G05B23/0235;;G05B23/0283;;H01L21/67276;;H01L21/67288,G01R31/28,,0,0,,,,PENDING
54,US,B2,US 11823591 B2,028-000-475-564-317,2023-11-21,2023,US 202117145180 A,2021-01-08,US 202117145180 A,2021-01-08,Emotional management system,"The disclosure herein describes an emotional insight management system that provides user-configured prompts and insights to the user. In some examples, an insights application provides personalized, recurring prompts to encourage users to provide current emotional state updates to a well-being journal. The user's responses over time are aggregated within a historical trends report, which provides emotional response data over time. The insights application generates insights into potential reasons for the user's emotional states on a given day. The system analyzes the user-provided emotion response data with integrated work-related data to identify reasons for the user's mood and make recommendations for actions to be taken by users to reduce stress and improve the user's emotional well-being.",MICROSOFT TECHNOLOGY LICENSING LLC,CHAUHAN VIVEK;;GUO WENDY;;FRASER DANNY LEE;;FAGNAN JUSTIN JOSEPH;;ROBB LEANNA HOLLY;;HUANG CHI;;AUSTIN DARREN GLENN;;ZHANG JINKAI,MICROSOFT TECHNOLOGY LICENSING LLC (2021-01-07),https://lens.org/028-000-475-564-317,Granted Patent,yes,23,0,2,2,0,G06Q10/06395;;G06Q10/103;;G09B7/00;;G06F3/0482;;G06Q10/103;;G06Q10/06395;;G09B7/00,G09B7/00;;G06F3/0482;;G06Q10/0639;;G06Q10/10,,19,4,000-869-162-869-253;;096-352-839-542-609;;120-474-489-479-067;;058-348-463-516-129,10.1145/3173574.3173662;;22390388;;10.1037/a0027377;;10.1016/s1048-9843(02)00145-5;;10.1016/j.jengtecman.2009.06.008,"Williams, et al., “Supporting Workplace Detachment and Reattachment with Conversational Intelligence”, In Proceedings of the CHI Conference on Human Factors in Computing Systems, Apr. 21, 2018, 13 Pages.;;Bolton, Sharon, “Emotion Management in the Workplace”, In Publication Red Globe Press, Jan. 2005, 7 Pages.;;Clark, Timothy R., “8 Ways to Manage Your Team While Social Distancing”, Retrieved from: https://hbr.org/2020/03/8-ways-to-manage-your-team-while-social-distancing, Mar. 24, 2020, 3 Pages.;;Stefano, et al., “Making Experience Count: The Role of Reflection in Individual Learning”, Retrieved from:https://papers.ssm.com/sol3/papers.cfm?abstract_id=2414478, Jun. 14, 2016, 37 Pages.;;Craig, Heather, “17 Emotional Intelligence Tests and Assessments”, Retrieved from: https://positivepsychology.com/emotional-intelligence-tests/, Sep. 1, 2020, 24 Pages.;;Dierdorff, et al., “Research: We're Not Very Self-Aware, Especially at Work”, Retrieved from: https://hbr.org/2015/03/research-were-not-very-self-aware-especially-at-work, Mar. 12, 2015, 7 Pages.;;Eurich, Tasha, “Working with People Who Aren't Self-Aware”, Retrieved from: https://hbr.org/2018/10/working-with-people-who-arent-self-aware, Oct. 19, 2018, 9 Pages.;;Farh, et al., “Emotional Intelligence, Teamwork Effectiveness, and Job Performance: The Moderating Role of Job Context”, In Journal of Applied Psychology, vol. 97, Issue 4, Mar. 2012, pp. 890-900.;;Greenwood, et al., “Research: People Want Their Employers to Talk About Mental Health”, Retrieved from: https://hbr.org/2019/10/research-people-want-their-employers-to-talk-about-mental-health, Oct. 7, 2019, 3 Pages.;;Wigert, et al., “Employee Burnout, Part 1: The 5 Main Causes”, In Workplace, Jul. 12, 2018, 6 Pages.;;Huffington, et al., “Working Below the Surface: The Emotional Life of Contemporary Organizations”, In Publication of Routledge, Apr. 24, 2018, 43 Pages.;;Lieberman, Charlotte, “What Wellness Programs Don't Do for Workers”, Retrieved from: https://hbr.org/2019/08/what-wellness-programs-dont-do-for-workers. Aug. 14, 2019, 3 Pages.;;Moss, Jennifer, “Burnout Is About Your Workplace, Not Your People”, Retrieved from: https://hbr.org/2019/12/burnout-is-about-your-workplace-not-your-people, Dec. 11, 2019, 3 Pages.;;Pescosolido, Anthony T, “Emergent leaders as managers of group emotion”, In Journal of The Leadership Quarterly, vol. 13, Issue 5, Oct. 2002, pp. 583-599.;;Seppälä, Emma, “Good Bosses Create More Wellness than Wellness Plans Do”, Retrieved from: https://hbr.org/2016/04/good-bosses-create-more-wellness-than-wellness-plans-do, Apr. 8, 2016, 4 Pages.;;Seppälä, et al., “Proof That Positive Work Cultures Are More Productive”, Retrieved from: https://hbr.org/2015/12/proof-that-positive-work-cultures-are-more-productive, Dec. 1, 2015, 6 Pages.;;Silvis, Gerlinde, “Emotional boarding using the ‘check-in’”, In Executive MA Thesis, 2015, 55 Pages.;;Smith, Ryan, “How CEOs Can Support Employee Mental Health in a Crisis”, Retrieved from: https://hbr.org/2020/05/how-ceos-can-support-employee-mental-health-in-a-crisis. May 1, 2020, 7 Pages.;;Akgün, et al., “Organizational emotional capability, product and process innovation, and firm performance: An empirical analysis”, In Journal of Engineering and Technology Management, vol. 26, Issue 3, Sep. 1, 2009, pp. 103-130.",ACTIVE
55,US,A1,US 2022/0223064 A1,054-190-875-179-680,2022-07-14,2022,US 202117145180 A,2021-01-08,US 202117145180 A,2021-01-08,EMOTIONAL MANAGEMENT SYSTEM,"The disclosure herein describes an emotional insight management system that provides user-configured prompts and insights to the user. In some examples, an insights application provides personalized, recurring prompts to encourage users to provide current emotional state updates to a well-being journal. The user's responses over time are aggregated within a historical trends report, which provides emotional response data over time. The insights application generates insights into potential reasons for the user's emotional states on a given day. The system analyzes the user-provided emotion response data with integrated work-related data to identify reasons for the user's mood and make recommendations for actions to be taken by users to reduce stress and improve the user's emotional well-being.",MICROSOFT TECHNOLOGY LICENSING LLC,CHAUHAN VIVEK;;GUO WENDY;;FRASER DANNY LEE;;FAGNAN JUSTIN JOSEPH;;ROBB LEANNA HOLLY;;HUANG CHI;;AUSTIN DARREN GLENN;;ZHANG JINKAI,MICROSOFT TECHNOLOGY LICENSING LLC (2021-01-07),https://lens.org/054-190-875-179-680,Patent Application,yes,17,1,2,2,0,G06Q10/06395;;G06Q10/103;;G09B7/00;;G06F3/0482;;G06Q10/103;;G06Q10/06395;;G09B7/00,G09B19/00;;G06F3/0482;;G06Q10/06;;G09B7/00,,0,0,,,,ACTIVE
56,SG,A,SG 11201900080V A,048-910-565-785-314,2019-02-27,2019,SG 11201900080V A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,ADDITIVE CHANNELS,,EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/048-910-565-785-314,Unknown,no,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,PENDING
57,US,B2,US 10852311 B2,092-938-162-229-268,2020-12-01,2020,US 201715648029 A,2017-07-12,US 201715648029 A;;US 201662361274 P,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNGSHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,EMULATE INC (2018-01-10);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/092-938-162-229-268,Granted Patent,yes,22,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/80;;B01L3/00;;C12M1/00;;C12M1/34;;C12M1/42;;C12M3/06;;G01N33/543;;G01N33/86,,64,58,000-518-514-786-546;;149-113-775-110-673;;039-664-515-151-316;;079-740-990-065-460;;033-955-564-406-161;;116-693-543-492-605;;007-065-406-866-886;;012-742-326-331-802;;070-980-838-775-244;;064-886-117-691-499;;018-603-591-056-352;;081-815-779-737-490;;064-484-421-661-911;;070-707-086-277-076;;056-577-811-880-557;;001-230-813-708-728;;055-987-395-896-335;;033-827-137-686-449;;073-060-558-392-596;;076-196-806-192-22X;;034-593-517-365-476;;052-241-791-051-991;;043-182-442-181-460;;135-540-238-738-949;;028-814-177-858-504;;039-185-542-225-036;;012-046-383-546-130;;024-963-732-076-880;;015-780-566-404-51X;;143-518-952-033-136;;019-801-860-310-712;;124-632-538-654-332;;019-066-396-656-841;;004-651-611-520-836;;046-495-576-142-340;;095-202-117-866-900;;000-295-453-168-799;;003-530-287-662-850;;023-257-569-327-007;;041-953-550-492-290;;085-770-264-579-04X;;033-007-116-567-965;;071-914-081-229-25X;;056-862-006-859-803;;113-478-780-821-264;;021-284-947-247-532;;143-518-952-033-136;;028-706-026-410-691;;026-137-400-977-488;;141-124-351-574-59X;;084-172-950-041-796;;032-465-047-469-916;;039-055-633-551-472;;016-822-126-682-355;;135-806-223-397-649;;087-651-379-618-660;;066-969-411-056-900;;051-364-927-511-381,10.1161/01.cir.0000028962.04520.01;;12186789;;10.1055/s-0037-1614982;;9493580;;12632425;;10.1002/art.10856;;pmc4910695;;26014643;;10.1016/j.thromres.2015.05.012;;10.1038/nri2761;;20414204;;10.1016/j.polymer.2010.08.022;;10.2174/138161210794519255;;21247395;;10.1182/blood-2013-08-523860;;24335500;;pmc3945867;;8135876;;12970136;;10.1136/gut.52.10.1435;;pmc1773814;;pmc440614;;15242934;;10.1128/cdli.11.4.635-641.2004;;pmc4105978;;18972135;;10.1007/s00441-008-0706-5;;10.1097/00007890-200111150-00001;;11707732;;10.2174/092986707781389664;;17691955;;10.1161/01.res.0000074030.98009.ff;;12750303;;9468137;;10.1038/35393;;10.1002/art.10273;;12115186;;24113786;;10.1038/nprot.2013.137;;23136042;;pmc8265389;;10.1126/scitranslmed.3004249;;pmc8335790;;10.1126/science.1188302;;20576885;;10.1016/j.cell.2016.02.049;;26967278;;8849381;;10.1002/art.1780390217;;17311994;;10.1182/blood-2006-12-027698;;27464497;;10.1007/s10544-016-0095-6;;pmc4963439;;10.1074/jbc.273.24.14827;;9614084;;10510335;;pmc408556;;10.1172/jci7014;;10.1073/pnas.96.14.8132;;10393960;;pmc22200;;10.1111/j.1774-9987.2005.00221.x;;15828909;;10.1038/9536;;10371508;;10.1097/01.tp.0000135457.69220.5b;;15502729;;pmc377457;;10727447;;10.1172/jci7569;;10.1182/blood-2003-06-2167;;14551140;;15968400;;10.1160/th04-12-0774;;10.1063/1.4935863;;pmc4654733;;26634014;;24404131;;10.1371/journal.pone.0082493;;pmc3880267;;10.2165/00063030-200418020-00003;;15046525;;22388577;;10.1039/c2ib00176d;;10.1161/01.atv.0000031340.68494.34;;12231555;;24898333;;10.3233/bir-140658;;23872531;;pmc9004362;;10.1097/moh.0b013e3283642186;;10.1016/0049-3848(72)90020-5;;10.1016/j.smim.2009.05.012;;19595612;;pmc2753170;;9291241;;10.1016/s0002-9149(97)00572-9;;10609959;;10.1097/00007890-199912150-00026;;10.1097/00062752-200309000-00006;;12913790;;10.4049/jimmunol.0903888;;20585032;;10.1097/01.tp.0000135457.69220.5b;;15502729;;26335795;;10.1186/s13075-015-0757-4;;pmc4558773;;10.1191/0961203304lu1032oa;;15230298;;10.1055/s-0038-1647284;;2125371;;pmc3248292;;10.1172/jci58753;;22156199;;10.1016/j.bpj.2017.01.005;;pmc5340212;;28256231;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3109/09537104.2012.709653;;22873212;;pmc3557050;;23288905;;10.1073/pnas.1209905110;;10.4049/jimmunol.1303239;;24670803;;10.1186/s12872-015-0124-z;;26481314;;pmc4617895;;10.2217/imt.15.54;;26268734;;pmc4575641,"Great Britain Office Action for the Great Britain Patent Application No. GB1711213.7 dated Jan. 15, 2018.;;PCT International Search Report of International Application No. PCT/US2017/041668 dated Sep. 11, 2017.;;André, P. et al. (2002) “Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease,” Circulation 106(8), 896.;;Barstad, R. M. et al. (1998) “Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface,” Thrombosis and Haemostasis 79(2), 302-305.;;Boumpas, D. T. et al. (2003) “A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis,” Arthritis & Rheumatism 48(3), 719-727.;;Branchford, B. R. et al. (2015) “Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis,” Thrombosis Research 136(1), 13-19.;;Chan, A. C. et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10(5), 301-316.;;Chen, S. et al. (2010) “Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials,” Polymer 51(23), 5283-5293.;;Christoph, E. H. et al. (2010) “Targeting the Platelet Integrin GPIIb/IIIa,” Current Pharmaceutical Design 16(37), 4119-4133.;;Cines, D. B. et al. (2014) “Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin,” Blood 123(10), 1596-1603.;;Csomor, K. et al. (1994) “Effect of vintoperol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung 44(1), 36-40.;;Danese, S. et al. (2003) “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” Gut 52(10), 1435-1441.;;Daoussis, D. et al. (2004) “Targeting CD40L: a Promising Therapeutic Approach,” Clinical and Diagnostic Laboratory Immunology 11(4), 635-641.;;Dela Paz, N. G. et al. (2009) “Arterial versus venous endothelial cells,” Cell and Tissue Research 335(1), 5-16.;;Duffau, P. et al. (2010) “Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Science Translational Medicine 2(47), 47ra63.;;Elster, E. A. et al. (2001) “Treatment with the Humanized CD154-Specific Monoclonal Antibody, HU5C8, Prevents Acute Rejection of Primary Skin Allografts in Nonhuman Primates,” Transplantation 72(9), 1473-1478.;;FDA. Eptifibatide for Intravenous Administration, (FDA, Ed.).;;Ferroni, P. et al. (2007) “Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis,” Current Medicinal Chemistry 14(20), 2170-2180.;;Freedman, J. E. (2003) “CD40-CD40L and Platelet Function,” Circulation Research 92(9), 944.;;Henn, V. et al. (1998) “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature 391(6667), 591-594.;;Huang, W. et al. (2002) “The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus,” Arthritis & Rheumatism 46(6), 1554-1562.;;Huh, D. et al. (2013) “Microfabrication of human organs-on-chips,” Nature Protocols 8(11), 2135-2157.;;Huh, D. et al. (2012) “A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4(159), 159ra147.;;Huh, D. et al. (2010) “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328(5986), 1662.;;Ingber, D. E. (2016) “Reverse Engineering Human Pathophysiology with Organs-on-Chips,” Cell 164(6), 1105-1109.;;Inoh, M. et al. (1996) “Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis,” Arthritis & Rheumatism 39(2), 287-291.;;Jackson, S. P. (2007) “The growing complexity of platelet aggregation,” Blood 109(12), 5087-5095.;;Jain, A. et al. (2016) “Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium,” Biomedical Microdevices 18(4), 73.;;Jung, S. M. et al. (1998) “Platelets Interact with Soluble and Insoluble Collagens through Characteristically Different Reactions,” Journal of Biological Chemistry 273(24), 14827-14837.;;Kato, K. et al. (1999) “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” Journal of Clinical Investigation 104(7), 947-955.;;Kenyon, N. S. et al. (1999) “Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154,” Proceedings of the National Academy of Sciences 96(14), 8132-8137.;;Kimura, K. et al. (2005) “Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis,” Therapeutic Apheresis and Dialysis 9(1), 64-68.;;Kirk, A. D. et al. (1999) “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine 5(6), 686-693.;;Koyama, I. et al. (2004) “Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates,” Transplantation 77(3), 460-462.;;Kulkarni, S. et al. (2000) “A revised model of platelet aggregation,” Journal of Clinical Investigation 105(6), 783-791.;;Kuwana, M. et al. (2004) “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura,” Blood 103(4), 1229.;;Langer, F. et al. (2005) “The role of CD40 in CD40L- and antibody-mediated platelet activation,” Thrombosis and Haemostasis 93(6), 1137-1146.;;Lehmann, M. et al. (2015) “On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer,” Biomicrofluidics 9(6), 064106.;;Li, M. et al. (2014) “Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses,” PLoS ONE 9, e82493.;;Liossis, S.-N. C. et al. (2004) “Costimulation Blockade in the Treatment of Rheumatic Diseases,” BioDrugs 18(2), 95-102.;;Meer, A. D. v. d. et al. (2012) “Organs-on-chips: breaking the in vitro impasse,” Integrative Biology 4(5), 461-470.;;Monroe, D. M. et al. (2002) “Platelets and Thrombin Generation,” Arteriosclerosis, Thrombosis, and Vascular Biology 22(9), 1381.;;Muthard, R. W. et al. (2014) “Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow,” Biorheology 51(2-3), 227-237.;;Neeves, K. B. et al. (2013) “The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury,” Current Opinion in Hematology 20(5), 417-423.;;Nishizawa, E. E. et al. (1972) “Collagen-induced pulmonary thromboembolism in mice,” Thrombosis Research 1(3), 233-241.;;Peters, A. L. et al. (2009) “CD40 and autoimmunity: The dark side of a great activator,” Seminars in Immunology 21(5), 293-300.;;Phillips, D. R. et al. (1997) “Clinical pharmacology of eptifibatide,” American Journal of Cardiology 80(4A), 11B-20B.;;Pierson, R. N., 3rd et al. (1999) “Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody,” Transplantation 68(11), 1800-1805.;;Prasad, K. S. S. et al. (2003) “Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences 100(21), 12367-12371.;;Prasad, K. S. S. et al. (2003) “The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease,” Current Opinion in Hematology 10(5), 356-361.;;Robles-Carrillo, L. et al. (2010) “Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice,” Journal of Immunology 185(3), 1577.;;Roth, G. A. et al. (2004) “Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates,” Transplantation 78(8), 1238-1239.;;Shock, A. et al. (2015) “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Research & Therapy 17(1), 234.;;Sidiropoulos, P. I. et al. (2004) “Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients,” Lupus 13(5), 391-397.;;Speiser, W. et al. (1990) “D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness,” Thrombosis and Haemostasis 64(2), 196-201.;;Tsai, M. et al. (2012) “In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology,” Journal of Clinical Investigation 122(1), 408-418.;;Tutwiler, V. et al. (2017) “Interplay of Platelet Contractility and Elasticity of Fibrin/Erythrocytes in Blood Clot Retraction,” Biophysical Journal 112(4), 714-723.;;Vafa, O. et al. (2014) “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods 65(1), 114-126.;;Wakefield, I. et al. (2010) “An Assessment of theThromboembolic Potential of CDP7657, a Monovalent Fab′ PEG Anti-CD40L Antibody, in Rhesus Macaques,” Arthritis & Rheumatism 62(Supplement 10), 1243.;;Westein, E. et al. (2012) “Monitoring in vitro thrombus formation with novel microfluidic devices,” Platelets 23(7), 501-509.;;Westein, E. et al. (2013) “Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner,” Proceedings of the National Academy of Sciences 110(4), 1357-1362.;;Xie, J. H. et al. (2014) “Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases,” Journal of Immunology 192(9), 4083.;;Yau, J. W. et al. (2015) “Endothelial cell control of thrombosis,” BMC Cardiovascular Disorders 15, 130.;;Zhang, T. et al. (2015) “Update on CD40 and CD154 blockade in transplant models,” Immunotherapy 7(8), 899-911.",ACTIVE
58,US,B2,US 10908171 B2,139-573-635-970-131,2021-02-02,2021,US 201715648000 A,2017-07-12,US 201715648000 A;;US 201662361274 P,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNGSHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-01-31),https://lens.org/139-573-635-970-131,Granted Patent,yes,27,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00;;C12M1/00;;C12M1/34;;C12M1/42;;C12M3/06;;G01N33/543;;G01N33/80,,64,58,000-518-514-786-546;;149-113-775-110-673;;039-664-515-151-316;;079-740-990-065-460;;033-955-564-406-161;;116-693-543-492-605;;007-065-406-866-886;;012-742-326-331-802;;070-980-838-775-244;;064-886-117-691-499;;018-603-591-056-352;;081-815-779-737-490;;064-484-421-661-911;;070-707-086-277-076;;056-577-811-880-557;;001-230-813-708-728;;055-987-395-896-335;;033-827-137-686-449;;073-060-558-392-596;;076-196-806-192-22X;;034-593-517-365-476;;052-241-791-051-991;;043-182-442-181-460;;135-540-238-738-949;;028-814-177-858-504;;039-185-542-225-036;;012-046-383-546-130;;024-963-732-076-880;;015-780-566-404-51X;;143-518-952-033-136;;019-801-860-310-712;;124-632-538-654-332;;019-066-396-656-841;;004-651-611-520-836;;046-495-576-142-340;;095-202-117-866-900;;000-295-453-168-799;;003-530-287-662-850;;023-257-569-327-007;;041-953-550-492-290;;085-770-264-579-04X;;033-007-116-567-965;;071-914-081-229-25X;;056-862-006-859-803;;113-478-780-821-264;;021-284-947-247-532;;143-518-952-033-136;;028-706-026-410-691;;026-137-400-977-488;;141-124-351-574-59X;;084-172-950-041-796;;032-465-047-469-916;;039-055-633-551-472;;016-822-126-682-355;;135-806-223-397-649;;087-651-379-618-660;;066-969-411-056-900;;051-364-927-511-381,10.1161/01.cir.0000028962.04520.01;;12186789;;10.1055/s-0037-1614982;;9493580;;12632425;;10.1002/art.10856;;pmc4910695;;26014643;;10.1016/j.thromres.2015.05.012;;10.1038/nri2761;;20414204;;10.1016/j.polymer.2010.08.022;;10.2174/138161210794519255;;21247395;;10.1182/blood-2013-08-523860;;24335500;;pmc3945867;;8135876;;12970136;;10.1136/gut.52.10.1435;;pmc1773814;;pmc440614;;15242934;;10.1128/cdli.11.4.635-641.2004;;pmc4105978;;18972135;;10.1007/s00441-008-0706-5;;10.1097/00007890-200111150-00001;;11707732;;10.2174/092986707781389664;;17691955;;10.1161/01.res.0000074030.98009.ff;;12750303;;9468137;;10.1038/35393;;10.1002/art.10273;;12115186;;24113786;;10.1038/nprot.2013.137;;23136042;;pmc8265389;;10.1126/scitranslmed.3004249;;pmc8335790;;10.1126/science.1188302;;20576885;;10.1016/j.cell.2016.02.049;;26967278;;8849381;;10.1002/art.1780390217;;17311994;;10.1182/blood-2006-12-027698;;27464497;;10.1007/s10544-016-0095-6;;pmc4963439;;10.1074/jbc.273.24.14827;;9614084;;10510335;;pmc408556;;10.1172/jci7014;;10.1073/pnas.96.14.8132;;10393960;;pmc22200;;10.1111/j.1774-9987.2005.00221.x;;15828909;;10.1038/9536;;10371508;;10.1097/01.tp.0000135457.69220.5b;;15502729;;pmc377457;;10727447;;10.1172/jci7569;;10.1182/blood-2003-06-2167;;14551140;;15968400;;10.1160/th04-12-0774;;10.1063/1.4935863;;pmc4654733;;26634014;;24404131;;10.1371/journal.pone.0082493;;pmc3880267;;10.2165/00063030-200418020-00003;;15046525;;22388577;;10.1039/c2ib00176d;;10.1161/01.atv.0000031340.68494.34;;12231555;;24898333;;10.3233/bir-140658;;23872531;;pmc9004362;;10.1097/moh.0b013e3283642186;;10.1016/0049-3848(72)90020-5;;10.1016/j.smim.2009.05.012;;19595612;;pmc2753170;;9291241;;10.1016/s0002-9149(97)00572-9;;10609959;;10.1097/00007890-199912150-00026;;10.1097/00062752-200309000-00006;;12913790;;10.4049/jimmunol.0903888;;20585032;;10.1097/01.tp.0000135457.69220.5b;;15502729;;26335795;;10.1186/s13075-015-0757-4;;pmc4558773;;10.1191/0961203304lu1032oa;;15230298;;10.1055/s-0038-1647284;;2125371;;pmc3248292;;10.1172/jci58753;;22156199;;10.1016/j.bpj.2017.01.005;;pmc5340212;;28256231;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3109/09537104.2012.709653;;22873212;;pmc3557050;;23288905;;10.1073/pnas.1209905110;;10.4049/jimmunol.1303239;;24670803;;10.1186/s12872-015-0124-z;;26481314;;pmc4617895;;10.2217/imt.15.54;;26268734;;pmc4575641,"Great Britain Office Action for the Great Britain Patent Application No. GB1711213.7 dated Jan. 15, 2018.;;PCT International Search Report of International Application No. PCT/US2017/041668 dated Sep. 11, 2017.;;André, P. et al. (2002) “Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease,” Circulation 106(8), 896.;;Barstad, R. M. et al. (1998) “Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface,” Thrombosis and Haemostasis 79(2), 302-305.;;Boumpas, D. T. et al. (2003) “A short decreases hematuria in patients with course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and proliferative lupus glomerulonephritis,” Arthritis & Rheumatism 48(3), 719-727.;;Branchford, B. R. et al. (2015) “Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis,” Thrombosis Research 136(1), 13-19.;;Chan, A. C. et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10(5), 301-316.;;Chen, S. et al. (2010) “Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials,” Polymer 51(23),5283-5293.;;Christoph, E. H. et al. (2010) “Targeting the Platelet Integrin GPIIb/IIIa,” Current Pharmaceutical Design 16(37), 4119-4133.;;Cines, D. B. et al. (2014) “Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin,” Blood 123(10), 1596-1603.;;Csomor, K. et al. (1994) “Effect of vintoperol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung 44(1), 36-40.;;Danese, S. et al. (2003) “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” Gut 52(10), 1435-1441.;;Daoussis, D. et al. (2004) “Targeting CD40L: a Promising Therapeutic Approach,” Clinical and Diagnostic Laboratory Immunology 11(4), 635-641.;;Dela Paz, N. G. et al. (2009) “Arterial versus venous endothelial cells,” Cell and Tissue Research 335(1), 5-16.;;Duffau, P. et al. (2010) “Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Science Translational Medicine 2(47), 47ra63.;;Elster, E. A. et al. (2001) “Treatment Rejection of Primary Skin Allografts with the Humanized CD154-Specific Monoclonal Antibody, HU5C8, Prevents Acute in Nonhuman Primates,” Transplantation 72(9), 1473-1478.;;FDA. Eptifibatide for Intravenous Administration, (FDA, Ed.).;;Ferroni, P. et al. (2007) “Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis,” Current Medicinal Chemistry 14(20), 2170-2180.;;Freedman, J. E. (2003) “CD40-CD40L and Platelet Function,” Circulation Research 92(9), 944.;;Henn, V. et al. (1998) “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature 391(6667),591-594.;;Huang, W. et al. (2002) “The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus,” Arthritis & Rheumatism 46(6), 1554-1562.;;Huh, D. et al. (2013) “Microfabrication of human organs-on-chips,” Nature Protocols 8(11), 2135-2157.;;Huh, D. et al. (2012) “A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4(159), 159ra147.;;Huh, D. et al. (2010) “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328(5986), 1662.;;Ingber, D. E. (2016) “Reverse Engineering Human Pathophysiology with Organs-on-Chips,” Cell 164(6), 1105-1109.;;Inoh, M. et al. (1996) “Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis,” Arthritis & Rheumatism 39(2), 287-291.;;Jackson, S. P. (2007) “The growing complexity of platelet aggregation,” Blood 109(12), 5087-5095.;;Jain, A. et al. (2016) “Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium,” Biomedical Microdevices 18(4), 73.;;Jung, S. M. et al. (1998) “Platelets Interact with Soluble and Insoluble Collagens through Characteristically Different Reactions,” Journal of Biological Chemistry 273(24), 14827-14837.;;Kato, K. et al. (1999) “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” Journal of Clinical Investigation 104(7), 947-955.;;Kenyon, N. S. et al. (1999) “Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154,” Proceedings of the National Academy of Sciences 96(14), 8132-8137.;;Kimura, K. et al. (2005) “Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis,” Therapeutic Apheresis and Dialysis 9(1), 64-68.;;Kirk, A. D. et al. (1999) “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine 5(6), 686-693.;;Koyama, I. et al. (2004) “Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates,” Transplantation 77(3), 460-462.;;Kulkarni, S. et al. (2000) “A revised model of platelet aggregation,” Journal of Clinical Investigation 105(6), 783-791.;;Kuwana, M. et al. (2004) “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura,” Blood 103(4), 1229.;;Langer, F. et al. (2005) “The role of CD40 in CD40L- and antibody-mediated platelet activation,” Thrombosis and Haemostasis 93(6), 1137-1146.;;Lehmann, M. et al. (2015) “On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer,” Biomicrofluidics 9(6), 064106.;;Li, M. et al. (2014) “Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses,” PLoS ONE 9, e82493.;;Liossis, S.-N. C. et al. (2004) “Costimulation Blockade in the Treatment of Rheumatic Diseases,” BioDrugs 18(2), 95-102.;;Meer, A. D. v. d. et al. (2012) “Organs-on-chips: breaking the in vitro impasse,” Integrative Biology 4(5), 461-470.;;Monroe, D. M. et al. (2002) “Platelets and Thrombin Generation,” Arteriosclerosis, Thrombosis, and Vascular Biology 22(9), 1381.;;Muthard, R. W. et al. (2014) “Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow,” Biorheology 51(2-3), 227-237.;;Neeves, K. B. et al. (2013) “The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury,” Current Opinion in Hematology 20(5), 417-423.;;Nishizawa, E. E. et al. (1972) “Collagen-induced pulmonary thromboembolism in mice,” Thrombosis Research 1(3), 233-241.;;Peters, A. L. et al. (2009) “CD40 and autoimmunity: The dark side of a great activator,” Seminars in Immunology 21(5), 293-300.;;Phillips, D. R. et al. (1997) “Clinical pharmacology of eptifibatide,” American Journal of Cardiology 80(4A), 11B-20B.;;Pierson, R. N., 3rd et al. (1999) “Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody,” Transplantation 68(11), 1800-1805.;;Prasad, K. S. S. et al. (2003) “Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences 100(21), 12367-12371.;;Prasad, K. S. S. et al. (2003) “The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease,” Current Opinion in Hematology 10(5), 356-361.;;Robles-Carrillo, L. et al. (2010) “Anti-CD40L Immune Complexes Potently Activate Platelets in Vitro and Cause Thrombosis in FCGR2A Transgenic Mice,” Journal of Immunology 185(3), 1577.;;Roth, G. A. et al. (2004) “Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates,” Transplantation 78(8), 1238-1239.;;Shock, A. et al. (2015) “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Research & Therapy 17(1), 234.;;Sidiropoulos, P. I. et al. (2004) “Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients,” Lupus 13(5), 391-397.;;Speiser, W. et al. (1990) “D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness,” Thrombosis and Haemostasis 64(2), 196-201.;;Tsai, M. et al. (2012) “In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology,” Journal of Clinical Investigation 122(1), 408-418.;;Tutwiler, V. et al. (2017) “Interplay of Platelet Contractility and Elasticity of Fibrin/Erythrocytes in Blood Clot Retraction,” Biophysical Journal 112(4), 714-723.;;Vafa, O. et al. (2014) “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods 65(1), 114-126.;;Wakefield, I. et al. (2010) “An Assessment of theThromboembolic Potential of CDP7657, a Monovalent Fab′ PEG Anti-CD40L Antibody, in Rhesus Macaques,” Arthritis & Rheumatism 62(Supplement 10), 1243.;;Westein, E. et al. (2012) “Monitoring in vitro thrombus formation with novel microfluidic devices,” Platelets 23(7), 501-509.;;Westein, E. et al. (2013) “Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner,” Proceedings of the National Academy of Sciences 110(4), 1357-1362.;;Xie, J. H. et al. (2014) “Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases,” Journal of Immunology 192(9), 4083.;;Yau, J. W. et al. (2015) “Endothelial cell control of thrombosis,” BMC Cardiovascular Disorders 15, 130.;;Zhang, T. et al. (2015) “Update on CD40 and CD154 blockade in transplant models,” Immunotherapy 7(8), 899-911.",ACTIVE
59,US,B2,US 11150255 B2,180-821-835-989-909,2021-10-19,2021,US 201715648182 A,2017-07-12,US 201715648182 A;;US 201662361274 P,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNGSHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/180-821-835-989-909,Granted Patent,yes,20,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/00;;B01L3/00;;C12M1/00;;C12M1/34;;C12M1/42;;C12M3/06;;G01N33/543;;G01N33/80;;G01N33/86,,64,58,000-518-514-786-546;;149-113-775-110-673;;039-664-515-151-316;;079-740-990-065-460;;033-955-564-406-161;;116-693-543-492-605;;007-065-406-866-886;;012-742-326-331-802;;070-980-838-775-244;;064-886-117-691-499;;018-603-591-056-352;;081-815-779-737-490;;064-484-421-661-911;;070-707-086-277-076;;056-577-811-880-557;;001-230-813-708-728;;055-987-395-896-335;;033-827-137-686-449;;073-060-558-392-596;;076-196-806-192-22X;;034-593-517-365-476;;052-241-791-051-991;;043-182-442-181-460;;135-540-238-738-949;;028-814-177-858-504;;039-185-542-225-036;;012-046-383-546-130;;024-963-732-076-880;;015-780-566-404-51X;;143-518-952-033-136;;019-801-860-310-712;;124-632-538-654-332;;019-066-396-656-841;;004-651-611-520-836;;046-495-576-142-340;;095-202-117-866-900;;000-295-453-168-799;;003-530-287-662-850;;023-257-569-327-007;;041-953-550-492-290;;085-770-264-579-04X;;033-007-116-567-965;;071-914-081-229-25X;;056-862-006-859-803;;113-478-780-821-264;;021-284-947-247-532;;143-518-952-033-136;;028-706-026-410-691;;026-137-400-977-488;;141-124-351-574-59X;;084-172-950-041-796;;032-465-047-469-916;;039-055-633-551-472;;016-822-126-682-355;;135-806-223-397-649;;087-651-379-618-660;;066-969-411-056-900;;051-364-927-511-381,10.1161/01.cir.0000028962.04520.01;;12186789;;10.1055/s-0037-1614982;;9493580;;12632425;;10.1002/art.10856;;pmc4910695;;26014643;;10.1016/j.thromres.2015.05.012;;10.1038/nri2761;;20414204;;10.1016/j.polymer.2010.08.022;;10.2174/138161210794519255;;21247395;;10.1182/blood-2013-08-523860;;24335500;;pmc3945867;;8135876;;12970136;;10.1136/gut.52.10.1435;;pmc1773814;;pmc440614;;15242934;;10.1128/cdli.11.4.635-641.2004;;pmc4105978;;18972135;;10.1007/s00441-008-0706-5;;10.1097/00007890-200111150-00001;;11707732;;10.2174/092986707781389664;;17691955;;10.1161/01.res.0000074030.98009.ff;;12750303;;9468137;;10.1038/35393;;10.1002/art.10273;;12115186;;24113786;;10.1038/nprot.2013.137;;23136042;;pmc8265389;;10.1126/scitranslmed.3004249;;pmc8335790;;10.1126/science.1188302;;20576885;;10.1016/j.cell.2016.02.049;;26967278;;8849381;;10.1002/art.1780390217;;17311994;;10.1182/blood-2006-12-027698;;27464497;;10.1007/s10544-016-0095-6;;pmc4963439;;10.1074/jbc.273.24.14827;;9614084;;10510335;;pmc408556;;10.1172/jci7014;;10.1073/pnas.96.14.8132;;10393960;;pmc22200;;10.1111/j.1774-9987.2005.00221.x;;15828909;;10.1038/9536;;10371508;;10.1097/01.tp.0000135457.69220.5b;;15502729;;pmc377457;;10727447;;10.1172/jci7569;;10.1182/blood-2003-06-2167;;14551140;;15968400;;10.1160/th04-12-0774;;10.1063/1.4935863;;pmc4654733;;26634014;;24404131;;10.1371/journal.pone.0082493;;pmc3880267;;10.2165/00063030-200418020-00003;;15046525;;22388577;;10.1039/c2ib00176d;;10.1161/01.atv.0000031340.68494.34;;12231555;;24898333;;10.3233/bir-140658;;23872531;;pmc9004362;;10.1097/moh.0b013e3283642186;;10.1016/0049-3848(72)90020-5;;10.1016/j.smim.2009.05.012;;19595612;;pmc2753170;;9291241;;10.1016/s0002-9149(97)00572-9;;10609959;;10.1097/00007890-199912150-00026;;10.1097/00062752-200309000-00006;;12913790;;10.4049/jimmunol.0903888;;20585032;;10.1097/01.tp.0000135457.69220.5b;;15502729;;26335795;;10.1186/s13075-015-0757-4;;pmc4558773;;10.1191/0961203304lu1032oa;;15230298;;10.1055/s-0038-1647284;;2125371;;pmc3248292;;10.1172/jci58753;;22156199;;10.1016/j.bpj.2017.01.005;;pmc5340212;;28256231;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3109/09537104.2012.709653;;22873212;;pmc3557050;;23288905;;10.1073/pnas.1209905110;;10.4049/jimmunol.1303239;;24670803;;10.1186/s12872-015-0124-z;;26481314;;pmc4617895;;10.2217/imt.15.54;;26268734;;pmc4575641,"Great Britain Office Action for the Great Britain Patent Application No. GB1711213.7 dated Jan. 15, 2018.;;PCT International Search Report of International Application No. PCT/US2017/041668 dated Sep. 11, 2017.;;André, P. et al. (2002) “Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease,” Circulation 106(8), 896.;;Barstad, R. M. et al. (1998) “Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface,” Thrombosis and Haemostasis 79(2), 302-305.;;Boumpas, D. T. et al. (2003) “A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis,” Arthritis & Rheumatism 48(3), 719-727.;;Branchford, B. R. et al. (2015) “Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis,” Thrombosis Research 136(1), 13-19.;;Chan, A. C. et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10(5), 301-316.;;Chen, S. et al. (2010) “Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials,” Polymer 51(23), 5283-5293.;;Christoph, E. H. et al. (2010) “Targeting the Platelet Integrin GPIIb/IIIa,” Current Pharmaceutical Design 16(37), 4119-4133.;;Cines, D. B. et al. (2014) “Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin,” Blood 123(10), 1596-1603.;;Csomor, K. et al. (1994) “Effect of vintoperol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung 44(1), 36-40.;;Danese, S. et al. (2003) “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” Gut 52(10), 1435-1441.;;Daoussis, D. et al. (2004) “Targeting CD40L: a Promising Therapeutic Approach,” Clinical and Diagnostic Laboratory Immunology 11(4), 635-641.;;Dela Paz, N. G. et al. (2009) “Arterial versus venous endothelial cells,” Cell and Tissue Research 335(1), 5-16.;;Duffau, P. et al. (2010) “Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Science Translational Medicine 2(47), 47ra63.;;Elster, E. A. et al. (2001) “Treatment with the Humanized CD154-Specific Monoclonal Antibody, HU5C8, Prevents Acute Rejection of Primary Skin Allografts in Nonhuman Primates,” Transplantation 72(9), 1473-1478.;;FDA. Eptifibatide for Intravenous Administration, (FDA, Ed.).;;Ferroni, P. et al. (2007) “Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis,” Current Medicinal Chemistry 14(20), 2170-2180.;;Freedman, J. E. (2003) “CD40-CD40L and Platelet Function,” Circulation Research 92(9), 944.;;Henn, V. et al. (1998) “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature 391(6667), 591-594.;;Huang, W. et al. (2002) “The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus,” Arthritis & Rheumatism 46(6), 1554-1562.;;Huh, D. et al. (2013) “Microfabrication of human organs-on-chips,” Nature Protocols 8(11), 2135-2157.;;Huh, D. et al. (2012) “A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4(159), 159ra147.;;Huh, D. et al. (2010) “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328(5986), 1662.;;Ingber, D. E. (2016) “Reverse Engineering Human Pathophysiology with Organs-on-Chips,” Cell 164(6), 1105-1109.;;Inoh, M. et al. (1996) “Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis,” Arthritis & Rheumatism 39(2), 287-291.;;Jackson, S. P. (2007) “The growing complexity of platelet aggregation,” Blood 109(12), 5087-5095.;;Jain, A. et al. (2016) “Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium,” Biomedical Microdevices 18(4), 73.;;Jung, S. M. et al. (1998) “Platelets Interact with Soluble and Insoluble Collagens through Characteristically Different Reactions,” Journal of Biological Chemistry 273(24), 14827-14837.;;Kato, K. et al. (1999) “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” Journal of Clinical Investigation 104(7), 947-955.;;Kenyon, N. S. et al. (1999) “Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154,” Proceedings of the National Academy of Sciences 96(14), 8132-8137.;;Kimura, K. et al. (2005) “Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis,” Therapeutic Apheresis and Dialysis 9(1), 64-68.;;Kirk, A. D. et al. (1999) “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine 5(6), 686-693.;;Koyama, I. et al. (2004) “Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates,” Transplantation 77(3), 460-462.;;Kulkarni, S. et al. (2000) “A revised model of platelet aggregation,” Journal of Clinical Investigation 105(6), 783-791.;;Kuwana, M. et al. (2004) “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura,” Blood 103(4), 1229.;;Langer, F. et al. (2005) “The role of CD40 in CD4OL- and antibody-mediated platelet activation,” Thrombosis and Haemostasis 93(6), 1137-1146.;;Lehmann, M. et al. (2015) “On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer,” Biomicrofluidics 9(6), 064106.;;Li, M. et al. (2014) “Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses,” PLoS ONE 9, e82493.;;Liossis, S.-N. C. et al. (2004) “Costimulation Blockade in the Treatment of Rheumatic Diseases,” BioDrugs 18(2), 95-102.;;Meer, A. D. v. d. et al. (2012) “Organs-on-chips: breaking the in vitro impasse,” Integrative Biology 4(5), 461-470.;;Monroe, D. M. et al. (2002) “Platelets and Thrombin Generation,” Arteriosclerosis, Thrombosis, and Vascular Biology 22(9), 1381.;;Muthard, R. W. et al. (2014) “Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow,” Biorheology 51(2-3), 227-237.;;Neeves, K. B. et al. (2013) “The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury,” Current Opinion in Hematology 20(5), 417-423.;;Nishizawa, E. E. et al. (1972) “Collagen-induced pulmonary thromboembolism in mice,” Thrombosis Research 1(3), 233-241.;;Peters, A. L. et al. (2009) “CD40 and autoimmunity: The dark side of a great activator,” Seminars in Immunology 21(5), 293-300.;;Phillips, D. R. et al. (1997) “Clinical pharmacology of eptifibatide,” American Journal of Cardiology 80(4A), 11B-20B.;;Pierson, R. N., 3rd et al. (1999) “Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody,” Transplantation 68(11), 1800-1805.;;Prasad, K. S. S. et al. (2003) “Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences 100(21), 12367-12371.;;Prasad, K. S. S. et al. (2003) “The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease,” Current Opinion in Hematology 10(5), 356-361.;;Robles-Carrillo, L. et al. (2010) “Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice,” Journal of Immunology 185(3), 1577.;;Roth, G. A. et al. (2004) “Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates,” Transplantation 78(8), 1238-1239.;;Shock, A. et al. (2015) “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Research & Therapy 17(1), 234.;;Sidiropoulos, P. I. et al. (2004) “Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients,” Lupus 13(5), 391-397.;;Speiser, W. et al. (1990) “D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness,” Thrombosis and Haemostasis 64(2), 196-201.;;Tsai, M. et al. (2012) “In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology,” Journal of Clinical Investigation 122(1), 408-418.;;Tutwiler, V. et al. (2017) “Interplay of Platelet Contractility and Elasticity of Fibrin/Erythrocytes in Blood Clot Retraction,” Biophysical Journal 112(4), 714-723.;;Vafa, O. et al. (2014) “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods 65(1), 114-126.;;Wakefield, I. et al. (2010) “An Assessment of theThromboembolic Potential of CDP7657, a Monovalent Fab' PEG Anti-CD40L Antibody, in Rhesus Macaques,” Arthritis & Rheumatism 62(Supplement 10), 1243.;;Westein, E. et al. (2012) “Monitoring in vitro thrombus formation with novel microfluidic devices,” Platelets 23(7), 501-509.;;Westein, E. et al. (2013) “Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner,” Proceedings of the National Academy of Sciences 110(4), 1357-1362.;;Xie, J. H. et al. (2014) “Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases,” Journal of Immunology 192(9), 4083.;;Yau, J. W. et al. (2015) “Endothelial cell control of thrombosis,” BMC Cardiovascular Disorders 15, 130.;;Zhang, T. et al. (2015) “Update on CD40 and CD154 blockade in transplant models,” Immunotherapy 7(8), 899-911.",ACTIVE
60,US,B2,US 10228381 B2,074-534-380-223-282,2019-03-12,2019,US 201715648085 A,2017-07-12,US 201715648085 A;;US 201662361274 P,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNGSHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-03-20),https://lens.org/074-534-380-223-282,Granted Patent,yes,20,2,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;C12M1/00;;C12M1/34;;C12M1/42;;C12M3/00;;C12M3/06;;G01N33/50;;G01N33/543;;G01N33/569;;G01N33/86;;G01N35/08,,64,58,000-518-514-786-546;;149-113-775-110-673;;039-664-515-151-316;;079-740-990-065-460;;033-955-564-406-161;;116-693-543-492-605;;007-065-406-866-886;;012-742-326-331-802;;070-980-838-775-244;;064-886-117-691-499;;018-603-591-056-352;;081-815-779-737-490;;064-484-421-661-911;;070-707-086-277-076;;056-577-811-880-557;;001-230-813-708-728;;055-987-395-896-335;;033-827-137-686-449;;073-060-558-392-596;;076-196-806-192-22X;;034-593-517-365-476;;052-241-791-051-991;;043-182-442-181-460;;135-540-238-738-949;;028-814-177-858-504;;039-185-542-225-036;;012-046-383-546-130;;024-963-732-076-880;;015-780-566-404-51X;;143-518-952-033-136;;019-801-860-310-712;;124-632-538-654-332;;019-066-396-656-841;;004-651-611-520-836;;046-495-576-142-340;;095-202-117-866-900;;000-295-453-168-799;;003-530-287-662-850;;023-257-569-327-007;;041-953-550-492-290;;085-770-264-579-04X;;033-007-116-567-965;;071-914-081-229-25X;;056-862-006-859-803;;113-478-780-821-264;;021-284-947-247-532;;143-518-952-033-136;;028-706-026-410-691;;026-137-400-977-488;;141-124-351-574-59X;;084-172-950-041-796;;032-465-047-469-916;;039-055-633-551-472;;016-822-126-682-355;;135-806-223-397-649;;087-651-379-618-660;;066-969-411-056-900;;051-364-927-511-381,10.1161/01.cir.0000028962.04520.01;;12186789;;10.1055/s-0037-1614982;;9493580;;12632425;;10.1002/art.10856;;pmc4910695;;26014643;;10.1016/j.thromres.2015.05.012;;10.1038/nri2761;;20414204;;10.1016/j.polymer.2010.08.022;;10.2174/138161210794519255;;21247395;;10.1182/blood-2013-08-523860;;24335500;;pmc3945867;;8135876;;12970136;;10.1136/gut.52.10.1435;;pmc1773814;;pmc440614;;15242934;;10.1128/cdli.11.4.635-641.2004;;pmc4105978;;18972135;;10.1007/s00441-008-0706-5;;10.1097/00007890-200111150-00001;;11707732;;10.2174/092986707781389664;;17691955;;10.1161/01.res.0000074030.98009.ff;;12750303;;9468137;;10.1038/35393;;10.1002/art.10273;;12115186;;24113786;;10.1038/nprot.2013.137;;23136042;;pmc8265389;;10.1126/scitranslmed.3004249;;pmc8335790;;10.1126/science.1188302;;20576885;;10.1016/j.cell.2016.02.049;;26967278;;8849381;;10.1002/art.1780390217;;17311994;;10.1182/blood-2006-12-027698;;27464497;;10.1007/s10544-016-0095-6;;pmc4963439;;10.1074/jbc.273.24.14827;;9614084;;10510335;;pmc408556;;10.1172/jci7014;;10.1073/pnas.96.14.8132;;10393960;;pmc22200;;10.1111/j.1774-9987.2005.00221.x;;15828909;;10.1038/9536;;10371508;;10.1097/01.tp.0000135457.69220.5b;;15502729;;pmc377457;;10727447;;10.1172/jci7569;;10.1182/blood-2003-06-2167;;14551140;;15968400;;10.1160/th04-12-0774;;10.1063/1.4935863;;pmc4654733;;26634014;;24404131;;10.1371/journal.pone.0082493;;pmc3880267;;10.2165/00063030-200418020-00003;;15046525;;22388577;;10.1039/c2ib00176d;;10.1161/01.atv.0000031340.68494.34;;12231555;;24898333;;10.3233/bir-140658;;23872531;;pmc9004362;;10.1097/moh.0b013e3283642186;;10.1016/0049-3848(72)90020-5;;10.1016/j.smim.2009.05.012;;19595612;;pmc2753170;;9291241;;10.1016/s0002-9149(97)00572-9;;10609959;;10.1097/00007890-199912150-00026;;10.1097/00062752-200309000-00006;;12913790;;10.4049/jimmunol.0903888;;20585032;;10.1097/01.tp.0000135457.69220.5b;;15502729;;26335795;;10.1186/s13075-015-0757-4;;pmc4558773;;10.1191/0961203304lu1032oa;;15230298;;10.1055/s-0038-1647284;;2125371;;pmc3248292;;10.1172/jci58753;;22156199;;10.1016/j.bpj.2017.01.005;;pmc5340212;;28256231;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3109/09537104.2012.709653;;22873212;;pmc3557050;;23288905;;10.1073/pnas.1209905110;;10.4049/jimmunol.1303239;;24670803;;10.1186/s12872-015-0124-z;;26481314;;pmc4617895;;10.2217/imt.15.54;;26268734;;pmc4575641,"André, P. et al. (2002) “Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease,” Circulation 106(8), 896.;;Barstad, R. M. et al. (1998) “Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface,” Thrombosis and Haemostasis 79(2), 302-305.;;Boumpas, D. T. et al. (2003) “A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis,” Arthritis & Rheumatism 48(3), 719-727.;;Branchford, B. R. et al. (2015) “Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis,” Thrombosis Research 136(1), 13-19.;;Chan, A. C. et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10(5), 301-316.;;Chen, S. et al. (2010) “Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials,” Polymer 51(23), 5283-5293.;;Christoph, E. H. et al. (2010) “Targeting the Platelet Integrin GPIIb/IIIa,” Current Pharmaceutical Design 16(37), 4119-4133.;;Cines, D. B. et al. (2014) “Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin,” Blood 123(10), 1596-1603.;;Csomor, K. et al. (1994) “Effect of vintoperol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung 44(1), 36-40.;;Danese, S. et al. (2003) “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” Gut 52(10), 1435-1441.;;Daoussis, D. et al. (2004) “Targeting CD40L: a Promising Therapeutic Approach,” Clinical and Diagnostic Laboratory Immunology 11(4), 635-641.;;Dela Paz, N. G. et al. (2009) “Arterial versus venous endothelial cells,” Cell and Tissue Research 335(1), 5-16.;;Duffau, P. et al. (2010) “Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Science Translational Medicine 2(47), 47ra63.;;Elster, E. A. et al. (2001) “Treatment with the Humanized CD154-Specific Monoclonal Antibody, HU5C8, Prevents Acute Rejection of Primary Skin Allografts in Nonhuman Primates,” Transplantation 72(9), 1473-1478.;;FDA. Eptifibatide for Intravenous Administration, (FDA, Ed.).;;Ferroni, P. et al. (2007) “Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis,” Current Medicinal Chemistry 14(20), 2170-2180.;;Freedman, J. E. (2003) “CD40-CD40L and Platelet Function,” Circulation Research 92(9), 944.;;Henn, V. et al. (1998) “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature 391(6667), 591-594.;;Huang, W. et al. (2002) “The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus,” Arthritis & Rheumatism 46(6), 1554-1562.;;Huh, D. et al. (2013) “Microfabrication of human organs-on-chips,” Nature Protocols 8(11), 2135-2157.;;Huh, D. et al. (2012) “A Human Disease Model of Drug Toxicity—Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4(159), 159ra147.;;Huh, D. et al. (2010) “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328(5986), 1662.;;Ingber, D. E. (2016) “Reverse Engineering Human Pathophysiology with Organs-on-Chips,” Cell 164(6), 1105-1109.;;Inoh, M. et al. (1996) “Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis,” Arthritis & Rheumatism 39(2), 287-291.;;Jackson, S. P. (2007) “The growing complexity of platelet aggregation,” Blood 109(12), 5087-5095.;;Jain, A. et al. (2016) “Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium,” Biomedical Microdevices 18(4), 73.;;Jung, S. M. et al. (1998) “Platelets Interact with Soluble and Insoluble Collagens through Characteristically Different Reactions,” Journal of Biological Chemistry 273(24), 14827-14837.;;Kato, K. et al. (1999) “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” Journal of Clinical Investigation 104(7), 947-955.;;Kenyon, N. S. et al. (1999) “Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154,” Proceedings of the National Academy of Sciences 96(14), 8132-8137.;;Kimura, K. et al. (2005) “Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis,” Therapeutic Apheresis and Dialysis 9(1), 64-68.;;Kirk, A. D. et al. (1999) “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine 5(6), 686-693.;;Koyama, I. et al. (2004) “Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates,” Transplantation 77(3), 460-462.;;Kulkarni, S. et al. (2000) “A revised model of platelet aggregation,” Journal of Clinical Investigation 105(6), 783-791.;;Kuwana, M. et al. (2004) “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura,” Blood 103(4), 1229.;;Langer, F. et al. (2005) “The role of CD40 in CD40L- and antibody-mediated platelet activation,” Thrombosis and Haemostasis 93(6), 1137-1146.;;Lehmann, M. et al. (2015) “On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer,” Biomicrofluidics 9(6), 064106.;;Li, M. et al. (2014) “Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses,” PLoS One 9, e82493.;;Liossis, S.-N. C. et al. (2004) “Costimulation Blockade in the Treatment of Rheumatic Diseases,” BioDrugs 18(2), 95-102.;;Meer, A. D. v. d. et al. (2012) “Organs-on-chips: breaking the in vitro impasse,” Integrative Biology 4(5), 461-470.;;Monroe, D. M. et al. (2002) “Platelets and Thrombin Generation,” Arteriosclerosis, Thrombosis, and Vascular Biology 22(9), 1381.;;Muthard, R. W. et al. (2014) “Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow,” Biorheology 51(2-3), 227-237.;;Neeves, K. B. et al. (2013) “The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury,” Current Opinion in Hematology 20(5), 417-423.;;Nishizawa, E. E. et al. (1972) “Collagen-induced pulmonary thromboembolism in mice,” Thrombosis Research 1(3), 233-241.;;Peters, A. L. et al. (2009) “CD40 and autoimmunity: The dark side of a great activator,” Seminars in Immunology 21(5), 293-300.;;Phillips, D. R. et al. (1997) “Clinical pharmacology of eptifibatide,” American Journal of Cardiology 80(4A), 11B-20B.;;Pierson, R. N., 3rd et al. (1999) “Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody,” Transplantation 68(11), 1800-1805.;;Prasad, K. S. S. et al. (2003) “Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences 100(21), 12367-12371.;;Prasad, K. S. S. et al. (2003) “The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease,” Current Opinion in Hematology 10(5), 356-361.;;Robles-Carrillo, L. et al. (2010) “Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice,” Journal of Immunology 185(3), 1577.;;Roth, G. A. et al. (2004) “Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates,” Transplantation 78(8), 1238-1239.;;Shock, A. et al. (2015) “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Research & Therapy 17(1), 234.;;Sidiropoulos, P. I. et al. (2004) “Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients,” Lupus 13(5), 391-397.;;Speiser, W. et al. (1990) “D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness,” Thrombosis and Haemostasis 64(2), 196-201.;;Tsai, M. et al. (2012) “In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology,” Journal of Clinical Investigation 122(1), 408-418.;;Tutwiler, V. et al. (2017) “Interplay of Platelet Contractility and Elasticity of Fibrin/Erythrocytes in Blood Clot Retraction,” Biophysical Journal 112(4), 714-723.;;Vafa, O. et al. (2014) “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods 65(1), 114-126.;;Wakefield, I. et al. (2010) “An Assessment of theThromboembolic Potential of CDP7657, a Monovalent Fab' PEG Anti-CD40L Antibody, in Rhesus Macaques,” Arthritis & Rheumatism 62(Supplement 10), 1243.;;Westein, E. et al. (2012) “Monitoring in vitro thrombus formation with novel microfluidic devices,” Platelets 23(7), 501-509.;;Westein, E. et al. (2013) “Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner,” Proceedings of the National Academy of Sciences 110(4), 1357-1362.;;Xie, J. H. et al. (2014) “Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases,” Journal of Immunology 192(9), 4083.;;Yau, J. W. et al. (2015) “Endothelial cell control of thrombosis,” BMC Cardiovascular Disorders 15, 130.;;Zhang, T. et al. (2015) “Update on CD40 and CD154 blockade in transplant models,” Immunotherapy 7(8), 899-911.;;Great Britain Office Action for the Great Britain Patent Application No. GB1711213.7 dated Jan. 15, 2018.;;PCT International Search Report of International Application No. PCT/US2017/041668 dated Sep. 11, 2017.",ACTIVE
61,US,B2,US 10989721 B2,059-798-187-746-300,2021-04-27,2021,US 201715648162 A,2017-07-12,US 201715648162 A;;US 201662361274 P,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNGSHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/059-798-187-746-300,Granted Patent,yes,21,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00;;C12M1/00;;C12M1/34;;C12M1/42;;C12M3/06;;G01N33/543;;G01N33/80,,64,59,000-518-514-786-546;;149-113-775-110-673;;039-664-515-151-316;;079-740-990-065-460;;033-955-564-406-161;;116-693-543-492-605;;007-065-406-866-886;;012-742-326-331-802;;070-980-838-775-244;;064-886-117-691-499;;018-603-591-056-352;;081-815-779-737-490;;028-223-942-848-334;;064-484-421-661-911;;070-707-086-277-076;;056-577-811-880-557;;001-230-813-708-728;;055-987-395-896-335;;033-827-137-686-449;;073-060-558-392-596;;076-196-806-192-22X;;034-593-517-365-476;;052-241-791-051-991;;043-182-442-181-460;;135-540-238-738-949;;028-814-177-858-504;;039-185-542-225-036;;012-046-383-546-130;;024-963-732-076-880;;015-780-566-404-51X;;143-518-952-033-136;;019-801-860-310-712;;124-632-538-654-332;;019-066-396-656-841;;004-651-611-520-836;;046-495-576-142-340;;095-202-117-866-900;;000-295-453-168-799;;003-530-287-662-850;;023-257-569-327-007;;041-953-550-492-290;;085-770-264-579-04X;;033-007-116-567-965;;071-914-081-229-25X;;056-862-006-859-803;;113-478-780-821-264;;021-284-947-247-532;;143-518-952-033-136;;028-706-026-410-691;;026-137-400-977-488;;141-124-351-574-59X;;084-172-950-041-796;;032-465-047-469-916;;039-055-633-551-472;;016-822-126-682-355;;135-806-223-397-649;;087-651-379-618-660;;066-969-411-056-900;;051-364-927-511-381,10.1161/01.cir.0000028962.04520.01;;12186789;;10.1055/s-0037-1614982;;9493580;;12632425;;10.1002/art.10856;;pmc4910695;;26014643;;10.1016/j.thromres.2015.05.012;;10.1038/nri2761;;20414204;;10.1016/j.polymer.2010.08.022;;10.2174/138161210794519255;;21247395;;10.1182/blood-2013-08-523860;;24335500;;pmc3945867;;8135876;;12970136;;10.1136/gut.52.10.1435;;pmc1773814;;pmc440614;;15242934;;10.1128/cdli.11.4.635-641.2004;;pmc4105978;;18972135;;10.1007/s00441-008-0706-5;;20811042;;10.1126/scitranslmed.3001001;;10.1097/00007890-200111150-00001;;11707732;;10.2174/092986707781389664;;17691955;;10.1161/01.res.0000074030.98009.ff;;12750303;;9468137;;10.1038/35393;;10.1002/art.10273;;12115186;;24113786;;10.1038/nprot.2013.137;;23136042;;pmc8265389;;10.1126/scitranslmed.3004249;;pmc8335790;;10.1126/science.1188302;;20576885;;10.1016/j.cell.2016.02.049;;26967278;;8849381;;10.1002/art.1780390217;;17311994;;10.1182/blood-2006-12-027698;;27464497;;10.1007/s10544-016-0095-6;;pmc4963439;;10.1074/jbc.273.24.14827;;9614084;;10510335;;pmc408556;;10.1172/jci7014;;10.1073/pnas.96.14.8132;;10393960;;pmc22200;;10.1111/j.1774-9987.2005.00221.x;;15828909;;10.1038/9536;;10371508;;10.1097/01.tp.0000135457.69220.5b;;15502729;;pmc377457;;10727447;;10.1172/jci7569;;10.1182/blood-2003-06-2167;;14551140;;15968400;;10.1160/th04-12-0774;;10.1063/1.4935863;;pmc4654733;;26634014;;24404131;;10.1371/journal.pone.0082493;;pmc3880267;;10.2165/00063030-200418020-00003;;15046525;;22388577;;10.1039/c2ib00176d;;10.1161/01.atv.0000031340.68494.34;;12231555;;24898333;;10.3233/bir-140658;;23872531;;pmc9004362;;10.1097/moh.0b013e3283642186;;10.1016/0049-3848(72)90020-5;;10.1016/j.smim.2009.05.012;;19595612;;pmc2753170;;9291241;;10.1016/s0002-9149(97)00572-9;;10609959;;10.1097/00007890-199912150-00026;;10.1097/00062752-200309000-00006;;12913790;;10.4049/jimmunol.0903888;;20585032;;10.1097/01.tp.0000135457.69220.5b;;15502729;;26335795;;10.1186/s13075-015-0757-4;;pmc4558773;;10.1191/0961203304lu1032oa;;15230298;;10.1055/s-0038-1647284;;2125371;;pmc3248292;;10.1172/jci58753;;22156199;;10.1016/j.bpj.2017.01.005;;pmc5340212;;28256231;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3109/09537104.2012.709653;;22873212;;pmc3557050;;23288905;;10.1073/pnas.1209905110;;10.4049/jimmunol.1303239;;24670803;;10.1186/s12872-015-0124-z;;26481314;;pmc4617895;;10.2217/imt.15.54;;26268734;;pmc4575641,"André, P. et al. (2002) “Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease,” Circulation 106(8), 896.;;Barstad, R. M. et al. (1998) “Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface,” Thrombosis and Haemostasis 79(2), 302-305.;;Boumpas, D. T. et al. (2003) “A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis,” Arthritis & Rheumatism 48(3), 719-727.;;Branchford, B. R. et al. (2015) “Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis,” Thrombosis Research 136(1), 13-19.;;Chan, A. C. et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology 10(5), 301-316.;;Chen, S. et al. (2010) “Surface hydration: Principles and applications toward low-fouling/nonfouling biomaterials,” Polymer 51(23), 5283-5293.;;Christoph, E. H. et al. (2010) “Targeting the Platelet Integrin GPIIb/IIIa,” Current Pharmaceutical Design 16(37), 4119- 4133.;;Cines, D. B. et al. (2014) “Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin,” Blood 123(10), 1596-1603.;;Csomor, K. et al. (1994) “Effect of vintoperol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung 44(1), 36-40.;;Danese, S. et al. (2003) “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” Gut 52(10), 1435-1441.;;Daoussis, D. et al. (2004) “Targeting CD40L: a Promising Therapeutic Approach,” Clinical and Diagnostic Laboratory Immunology 11(4), 635-641.;;Dela Paz, N. G. et al. (2009) “Arterial versus venous endothelial cells,” Cell and Tissue Research 335(1), 5-16.;;Duffau, P. et al. (2010) “Platelet CD154 Potentiates Interferon-a Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus,” Science Translational Medicine 2(47), 47ra63.;;Elster, E. A. et al. (2001) “Treatment with the Humanized CD154-Specific Monoclonal Antibody, HU5C8, Prevents Acute Rejection of Primary Skin Allografts in Nonhuman Primates,” Transplantation 72(9), 1473-1478.;;FDA. Eptifibatide for Intravenous Administration, (FDA, Ed.).;;Ferroni, P. et al. (2007) “Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis,” Current Medicinal Chemistry 14(20), 2170-2180.;;Freedman, J. E. (2003) “CD40-CD40L and Platelet Function,” Circulation Research 92(9), 944.;;Henn, V. et al. (1998) “CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells,” Nature 391(6667), 591-594.;;Huang, W. et al. (2002) “The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus,” Arthritis & Rheumatism 46(6), 1554-1562.;;Huh, D. et al. (2013) “Microfabrication of human organs-on-chips,” Nature Protocols 8(11), 2135-2157.;;Huh, D. et al. (2012) “A Human Disease Model of Drug Toxicity—Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4(159), 159ra147.;;Huh, D. et al. (2010) “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328(5986), 1662.;;Ingber, D. E. (2016) “Reverse Engineering Human Pathophysiology with Organs-on-Chips,” Cell 164(6), 1105-1109.;;Inoh, M. et al. (1996) “Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis,” Arthritis & Rheumatism 39(2), 287-291.;;Jackson, S. P. (2007) “The growing complexity of platelet aggregation,” Blood 109(12), 5087-5095.;;Jain, A. et al. (2016) “Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium,” Biomedical Microdevices 18(4), 73.;;Jung, S. M. et al. (1998) “Platelets Interact with Soluble and Insoluble Collagens through Characteristically Different Reactions,” Journal of Biological Chemistry 273(24), 14827-14837.;;Kato, K. et al. (1999) “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” Journal of Clinical Investigation 104(7), 947-955.;;Kenyon, N. S. et al. (1999) “Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154,” Proceedings of the National Academy of Sciences 96(14), 8132-8137.;;Kimura, K. et al. (2005) “Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis,” Therapeutic Apheresis and Dialysis 9(1), 64-68.;;Kirk, A. D. et al. (1999) “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine 5(6), 686-693.;;Koyama, I. et al. (2004) “Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates,” Transplantation 77(3), 460-462.;;Kulkarni, S. et al. (2000) “A revised model of platelet aggregation,” Journal of Clinical Investigation 105(6), 783-791.;;Kuwana, M. et al. (2004) “Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura,” Blood 103(4), 1229.;;Langer, F. et al. (2005) “The role of CD40 in CD40L- and antibody-mediated platelet activation,” Thrombosis and Haemostasis 93(6), 1137-1146.;;Lehmann, M. et al. (2015) “On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer,” Biomicrofluidics 9(6), 064106.;;Li, M. et al. (2014) “Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses,” PLoS ONE 9, e82493.;;Liossis, S.-N. C. et al. (2004) “Costimulation Blockade in the Treatment of Rheumatic Diseases,” BioDrugs 18(2), 95-102.;;Meer, A. D. v. d. et al. (2012) “Organs-on-chips: breaking the in vitro impasse,” Integrative Biology 4(5), 461-470.;;Monroe, D. M. et al. (2002) “Platelets and Thrombin Generation,” Arteriosclerosis, Thrombosis, and Vascular Biology 22(9), 1381.;;Muthard, R. W. et al. (2014) “Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow,” Biorheology 51(2-3), 227-237.;;Neeves, K. B. et al. (2013) “The use of microfluidics in hemostasis: clinical diagnostics and biomimetic models of vascular injury,” Current Opinion in Hematology 20(5), 417-423.;;Nishizawa, E. E. et al. (1972) “Collagen-induced pulmonary thromboembolism in mice,” Thrombosis Research 1(3), 233-241.;;Peters, A. L. et al. (2009) “CD40 and autoimmunity: The dark side of a great activator,” Seminars in Immunology 21(5), 293- 300.;;Phillips, D. R. et al. (1997) “Clinical pharmacology of eptifibatide,” American Journal of Cardiology 80(4A), 11B-20B.;;Pierson, R. N., 3rd et al. (1999) “Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody,” Transplantation 68(11), 1800-1805.;;Prasad, K. S. S. et al. (2003) “Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling,” Proceedings of the National Academy of Sciences 100(21), 12367-12371.;;Prasad, K. S. S. et al. (2003) “The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease,” Current Opinion in Hematology 10(5), 356-361.;;Robles-Carrillo, L. et al. (2010) “Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice,” Journal of Immunology 185(3), 1577.;;Roth, G. A. et al. (2004) “Thrombophilia Associated with Anti-CD154 Monoclonal Antibody Treatment and its Prophylaxis in Nonhuman Primates,” Transplantation 78(8), 1238-1239.;;Shock, A. et al. (2015) “CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study,” Arthritis Research & Therapy 17(1), 234.;;Sidiropoulos, P. I. et al. (2004) “Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients,” Lupus 13(5), 391-397.;;Speiser, W. et al. (1990) “D-dimer and Tat measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness,” Thrombosis and Haemostasis 64(2), 196-201.;;Tsai, M. et al. (2012) “In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology,” Journal of Clinical Investigation 122(1), 408-418.;;Tutwiler, V. et al. (2017) “Interplay of Platelet Contractility and Elasticity of Fibrin/Erythrocytes in Blood Clot Retraction,” Biophysical Journal 112(4), 714-723.;;Vafa, O. et al. (2014) “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods 65(1), 114-126.;;Wakefield, I. et al. (2010) “An Assessment of theThromboembolic Potential of CDP7657, a Monovalent Fab' PEG Anti-CD40L Antibody, in Rhesus Macaques,” Arthritis & Rheumatism 62(Supplement 10), 1243.;;Westein, E. et al. (2012) “Monitoring in vitro thrombus formation with novel microfluidic devices,” Platelets 23(7), 501-509.;;Westein, E. et al. (2013) “Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner,” Proceedings of the National Academy of Sciences 110(4), 1357-1362.;;Xie, J. H. et al. (2014) “Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases,” Journal of Immunology 192(9), 4083.;;Yau, J. W. et al. (2015) “Endothelial cell control of thrombosis,” BMC Cardiovascular Disorders 15, 130.;;Zhang, T. et al. (2015) “Update on CD40 and CD154 blockade in transplant models,” Immunotherapy 7(8), 899-911.;;Great Britain Office Action for the Great Britain Patent Application No. GB1711213.7 dated Jan. 15, 2018.;;PCT International Search Report of International Application No. PCT/US2017/041668 dated Sep. 11, 2017.",ACTIVE
62,AU,A1,AU 2017/297384 A1,017-644-881-354-90X,2019-01-24,2019,AU 2017/297384 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,,https://lens.org/017-644-881-354-90X,Patent Application,no,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,ACTIVE
63,EP,A2,EP 2425098 A2,054-848-265-269-070,2012-03-07,2012,EP 09764629 A,2009-10-13,US 2009/0060562 W;;US 19604208 P;;US 10491508 P,2008-10-13,"STIRLING ENGINE SYSTEMS, APPARATUS AND METHODS",,INFINIA CORP,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,QNERGY INC. (2014-07-09),https://lens.org/054-848-265-269-070,Patent Application,yes,0,0,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F01C21/06;;F24S23/70,,1,0,,,See references of WO 2010045269A3,DISCONTINUED
64,US,A1,US 2018/0015462 A1,016-313-007-805-783,2018-01-18,2018,US 201715648085 A,2017-07-12,US 201715648085 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-03-20),https://lens.org/016-313-007-805-783,Patent Application,yes,4,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;G01N33/86,,0,0,,,,ACTIVE
65,US,A1,US 2018/0017582 A1,056-152-349-574-926,2018-01-18,2018,US 201715648000 A,2017-07-12,US 201715648000 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-01-31),https://lens.org/056-152-349-574-926,Patent Application,yes,5,2,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00,,0,0,,,,ACTIVE
66,US,A1,US 2018/0017585 A1,049-973-175-702-602,2018-01-18,2018,US 201715648162 A,2017-07-12,US 201715648162 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/049-973-175-702-602,Patent Application,yes,2,4,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00,,0,0,,,,ACTIVE
67,EP,A4,EP 3484621 A4,149-382-893-261-507,2020-09-09,2020,EP 17828363 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,ADDITIVE CHANNELS,,EMULATE INC;;JANSSEN BIOTECH INC,PARK HYOUNG SHIN;;LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/149-382-893-261-507,Search Report,no,1,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,PENDING
68,CA,C,CA 3029905 C,029-151-448-545-449,2021-11-30,2021,CA 3029905 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,USES OF MICROFLUIDIC DEVICES COMPRISING ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/029-151-448-545-449,Granted Patent,no,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,ACTIVE
69,US,A1,US 2018/0017586 A1,028-496-762-008-956,2018-01-18,2018,US 201715648182 A,2017-07-12,US 201715648182 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VA DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/028-496-762-008-956,Patent Application,yes,4,1,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00,,0,0,,,,ACTIVE
70,US,A1,US 2018/0017584 A1,030-460-247-871-875,2018-01-18,2018,US 201715648104 A,2017-07-12,US 201715648104 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NOEMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/030-460-247-871-875,Patent Application,yes,2,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00,,0,0,,,,PENDING
71,AU,B2,AU 2017/297384 B2,036-937-799-011-121,2020-07-23,2020,AU 2017/297384 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,Additive channels,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,,https://lens.org/036-937-799-011-121,Granted Patent,no,4,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,ACTIVE
72,US,A1,US 2018/0015455 A1,034-767-074-555-218,2018-01-18,2018,US 201715648049 A,2017-07-12,US 201715648049 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-09);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/034-767-074-555-218,Patent Application,yes,1,9,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;C12M1/00,,0,0,,,,PENDING
73,WO,A3,WO 2010/045269 A3,187-575-659-255-909,2012-01-12,2012,US 2009/0060562 W,2009-10-13,US 19604208 P;;US 10491508 P,2008-10-13,"STIRLING ENGINE SYSTEMS, APPARATUS AND METHODS","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation (12, X), to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus (18) are described herein. In one aspect, the invention relates to the field alignment of panels (16) and the assembly of a concentrator (14). In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over- insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",INFINIA CORP;;FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,,https://lens.org/187-575-659-255-909,Search Report,yes,4,0,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F03G6/06;;F24S23/70,,2,0,,,"SCHLAICH BERGERMANN UND PARTNER GBR: ""Euro Disch - Stirling: System Description"", 30 June 2001 (2001-06-30), Stuttgart, XP002663416, Retrieved from the Internet <URL:http://pointfocus.com/images/pdfs/eurodish.pdf> [retrieved on 20111114];;THOMAS R. MANCINI: ""Solar-Electric Dish Stirling System Development"", 1 December 1997 (1997-12-01), XP002663417, Retrieved from the Internet <URL:http://mac6.ma.psu.edu/stirling/reports/DE98001305.pdf> [retrieved on 20111114]",PENDING
74,CA,A1,CA 3134381 A1,136-225-698-213-648,2018-01-18,2018,CA 3134381 A,2017-07-12,US 201662361274 P;;CA 3029905 A,2016-07-12,USES OF MICROFLUIDIC DEVICES COMPRISING ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/136-225-698-213-648,Patent Application,no,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N1/00;;B01L3/00;;C12M1/26;;C12Q1/00;;G01N15/10;;G01N21/01,,0,0,,,,PENDING
75,CN,A,CN 102792020 A,033-995-651-943-447,2012-11-21,2012,CN 200980147400 A,2009-10-13,US 2009/0060562 W;;US 10491508 P,2008-10-13,"Stirling engine systems, apparatus and methods","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",INFINIA CORP,PAUL FRASER;;TERRY SMITH;;ROCCO LUONGO;;JUSTIN THURGOOD;;TRENT WETHERBEE;;RAPHAEL MILLERET;;ALLEN PETERSON;;JACK AUGENBLICK;;SCOTT MCCALLUM;;IAN WILLIFORD;;RAY ERBEZNIK;;BEN GYORI;;PATRICK FOX;;HARRY MCVICKER;;TINA DALE,,https://lens.org/033-995-651-943-447,Patent Application,no,6,4,1,15,0,Y02E10/46;;Y02T10/90,F03G6/06,,0,0,,,,DISCONTINUED
76,GB,A,GB 2553898 A,128-136-934-773-184,2018-03-21,2018,GB 201711213 A,2017-07-12,US 201662361274 P,2016-07-12,Additive channels,"A method of adding a reagent to a fluid sample in a microfluidic device comprises providing a fluid sample comprising a first anticoagulant and a microfluidic device comprising at least one microchannel in fluid communication with at least one additive channel wherein the at least one additive channel comprises at least one reagent solution containing a reagent capable of re-activating a coagulation cascade within the sample, and introducing the sample into the microchannel with a portion of the sample contacting the reagent as is moves through the microchannel to create a treated portion. The method may further comprise contacting the treated portion with a second reagent solution comprising a second anticoagulant. Ideally, the sample is blood. The microchannel may comprise an active region comprising endothelial cells. A microfluidic device comprising an input channel, an output channel, test channel 203 and an input additive channel wherein the test channel comprises an input portion in fluid communication with the input channel and input additive channel, an output portion in fluid communication with the output channel and endothelial cells disposed in a portion of the test channel. Alternatively, the input additive channel is replaced by an output additive channel in fluid communication with the output portion of the test channel.",EMULATE INC;;JANSSEN BIOTECH INC,DANIEL LEVNER;;CHRISTOPHER DAVID HINOJOSA;;NORMAN WEN;;JACOB FRASER;;JUSTIN NGUYEN;;RICARDO BARRILE;;GERALDINE HAMILTON;;CATHERINE KARALIS;;HYOUNG SHIN PARK;;ANTONIO VARONE;;ANDRIES VAN DER MEER;;MONICA OTIENO;;DAVID CONEGLIANO,,https://lens.org/128-136-934-773-184,Patent Application,no,5,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;G01N33/49,,0,0,,,,ACTIVE
77,US,A1,US 2018/0017583 A1,158-827-359-054-925,2018-01-18,2018,US 201715648029 A,2017-07-12,US 201715648029 A;;US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,EMULATE INC (2018-01-10);;JANSSEN BIOTECH INC (2018-02-01),https://lens.org/158-827-359-054-925,Patent Application,yes,3,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,G01N33/86;;B01L3/00,,0,0,,,,ACTIVE
78,WO,A2,WO 2010/045269 A2,175-374-006-773-657,2010-04-22,2010,US 2009/0060562 W,2009-10-13,US 19604208 P;;US 10491508 P,2008-10-13,"STIRLING ENGINE SYSTEMS, APPARATUS AND METHODS","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",INFINIA CORP;;FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,,https://lens.org/175-374-006-773-657,Patent Application,yes,0,5,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F01C21/06;;F24S23/70,,0,0,,,,PENDING
79,CA,A1,CA 3029905 A1,036-707-314-187-281,2018-01-18,2018,CA 3029905 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/036-707-314-187-281,Patent Application,no,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,ACTIVE
80,EP,A1,EP 3484621 A1,052-893-081-867-164,2019-05-22,2019,EP 17828363 A,2017-07-12,US 201662361274 P;;US 2017/0041668 W,2016-07-12,ADDITIVE CHANNELS,,EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICAH;;CONEGLIANO DAVID,,https://lens.org/052-893-081-867-164,Patent Application,yes,0,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,0,0,,,,PENDING
81,WO,A1,WO 2018/013654 A1,188-864-081-997-638,2018-01-18,2018,US 2017/0041668 W,2017-07-12,US 201662361274 P,2016-07-12,ADDITIVE CHANNELS,"Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it ""on-chip"" before moving into the experimental region of the chip.",EMULATE INC;;JANSSEN BIOTECH INC,LEVNER DANIEL;;HINOJOSA CHRISTOPHER DAVID;;WEN NORMAN;;FRASER JACOB;;NGUYEN JUSTIN;;BARRILE RICCARDO;;HAMILTON GERALDINE;;KARALIS CATHERINE;;PARK HYOUNG SHIN;;VARONE ANTONIO;;VAN DER MEER ANDRIES;;OTIENO MONICA;;CONEGLIANO DAVID,,https://lens.org/188-864-081-997-638,Patent Application,yes,9,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00,,1,0,,,See also references of EP 3484621A4,PENDING
82,US,A1,US 2010/0180595 A1,061-998-595-761-540,2010-07-22,2010,US 57855409 A,2009-10-13,US 57855409 A;;US 10491508 P;;US 19604208 P,2008-10-13,"STIRLING ENGINE SYSTEMS, APPARATUS AND METHODS","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JACK EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,QNERGY INC (2013-11-07);;INFINIA CORPORATION (2009-12-09),https://lens.org/061-998-595-761-540,Patent Application,yes,98,2,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F03G6/06;;B23P11/00;;F24S23/70,60/641.15;;29/464,0,0,,,,INACTIVE
83,GB,A,GB 2609706 A,007-852-563-490-141,2023-02-15,2023,GB 202206709 A,2022-05-09,US 202117330689 A,2021-05-26,Interacting with semantic video segments through interactive tiles,"Interactive tiles 1020 represent video segments of a segmentation of a video. Each interactive tile 1030 includes a thumbnail 1032 (e.g., the first frame of the video segment represented by the tile) and may include some transcript 1034 from the beginning of the video segment, a visualization of detected faces 1036 in the video segment, and one or more faceted timelines 1040 that visualize a category of detected features (e.g., a visualization of detected visual scenes, audio classifications, visual artifacts). Interacting with a particular interactive tile by clicking or tapping on a visualization of the detected features navigates to a corresponding portion of the video and may add a corresponding video segment to a selection, and/or scrubs through tile thumbnails. A re-segmentation of the video into a search segmentation based on a query may be triggered and the interactive tiles may be broken up to represent smaller units of the video. The interactive tiles may be arranged in a grid or rows and columns.",ADOBE INC,ASEEM AGARWALA;;LUBOMIRA DONTCHEVA;;JOEL RICHARD BRANDT;;JOVAN POPOVIC;;JOY OAKYUNG KIM;;JUSTIN SALAMON;;JUI-HSIEN WANG;;TIMOTHY JEEWUN GANTER;;XUE BAI;;SETH WALKER;;HIJUNG SHIN;;CRISTIN AILIDH FRASER;;LI DINGZEYU,,https://lens.org/007-852-563-490-141,Patent Application,no,5,0,5,21,0,G06F3/0482;;G06F3/04847;;G06F3/0488;;G06V10/82;;G06V20/41;;G11B27/005;;G11B27/34;;G10L15/26;;G10L17/00;;G10L25/51;;G06F3/04847;;G06V10/82;;G06F16/75;;G06F16/7844;;G06F16/7847;;G11B27/102;;H04N21/8456;;H04N21/84;;H04N21/8153;;H04N21/4821;;H04N21/26603;;H04N21/23418;;H04N21/23109;;H04N21/4828;;G06V20/46;;G06V20/49;;G06F3/0485;;G11B27/02;;G11B27/10,G11B27/10;;G11B27/02,,0,0,,,,PENDING
84,US,B2,US 8151568 B2,112-606-324-162-418,2012-04-10,2012,US 57855409 A,2009-10-13,US 57855409 A;;US 10491508 P;;US 19604208 P,2008-10-13,"Stirling engine systems, apparatus and methods","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA;;INFINIA CORP,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,QNERGY INC (2013-11-07);;INFINIA CORPORATION (2009-12-09),https://lens.org/112-606-324-162-418,Granted Patent,yes,98,3,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,B60K16/00;;B60L8/00;;F01K25/00;;F03G6/00;;F03G7/00;;F24S23/70,60/641.15;;60/516;;60/641.8;;60/641.11;;126/684,4,0,,,"Schlaich Bergermann und Partner GbR, ""Euro Disch-Stirling: System Description,"" Stuttgart, Jun. 2011 (9 pgs.).;;Mancini, ""Solar-Electric Dish Stirling System Development,"" URL:http://mac6.ma.psu.edu/stirling/reports/DE98001305.pdf, Dec. 1, 1997 (9 pgs.).;;International Search Report for PCT/US2009/060562, mailed Dec. 1, 2011 (5 pages).;;Written Opinion of the ISR for PCT/US2009/060562, mailed Dec. 1, 2011 (8 pages).",INACTIVE
85,US,B2,US 8869529 B2,136-276-174-842-881,2014-10-28,2014,US 201213422353 A,2012-03-16,US 201213422353 A;;US 57855409 A;;US 10491508 P;;US 19604208 P,2008-10-13,"Stirling engine systems, apparatus and methods","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA;;QNERGY INC,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,QNERGY INC (2013-11-29),https://lens.org/136-276-174-842-881,Granted Patent,yes,103,0,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F03G6/00;;F01B29/10;;F02G1/04;;F03G6/06;;F03G7/00;;F24J2/00;;F24S23/70,60/641.15;;60/517;;126/701;;126/689,4,0,,,"Schlaich Bergermann und Partner GbR, ""Euro Disch-Stirling: System Description,"" Stuttgart, Jun. 2011 (9 pgs.).;;Mancini, ""Solar-Electric Dish Stirling System Development,"" URL:http://mac6.ma.psu.edu/stirling/reports/DE98001305. pdf, Dec. 1, 1997 (9 pgs.).;;International Search Report for PCT/US2009/060562, mailed Dec. 1, 2011 (5 pages).;;Written Opinion of the ISR for PCT/US2009/060562, mailed Dec. 1, 2011 (8 pages).",INACTIVE
86,US,B2,US 11887629 B2,149-430-970-925-05X,2024-01-30,2024,US 202117330689 A,2021-05-26,US 202117330689 A;;US 202017017344 A,2020-09-10,Interacting with semantic video segments through interactive tiles,"Embodiments are directed to interactive tiles that represent video segments of a segmentation of a video. In some embodiments, each interactive tile represents a different video segment from a particular video segmentation (e.g., a default video segmentation). Each interactive tile includes a thumbnail (e.g., the first frame of the video segment represented by the tile), some transcript from the beginning of the video segment, a visualization of detected faces in the video segment, and one or more faceted timelines that visualize a category of detected features (e.g., a visualization of detected visual scenes, audio classifications, visual artifacts). In some embodiments, interacting with a particular interactive tile navigates to a corresponding portion of the video, adds a corresponding video segment to a selection, and/or scrubs through tile thumbnails.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIĆ JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,ADOBE INC (2021-05-14),https://lens.org/149-430-970-925-05X,Granted Patent,yes,62,0,2,21,0,G11B27/34;;G11B27/005;;G10L15/26;;G10L17/00;;G10L25/51;;G06V10/82;;G06V20/41;;G06F3/0482;;G06F3/04847;;G06F3/0488;;G11B27/036;;G06F3/0486;;G06F3/0482,G11B27/00;;G06F3/0482;;G06F3/0486;;G11B27/02;;G11B27/036,,52,2,079-071-231-345-204;;002-146-741-672-029,10.1109/cvpr42600.2020.01248;;10.1117/12.143647,"Chinfat, “E15—The Tool Bar/The Selection Tool—Adobe Premiere Pro CC 2018,” accessed at https://www.youtube.com/watch?v=IJRhzOqrMzA, p. 1 (May 8, 2018).;;“Hierarchical Segmentation of video timeline and matching searh data,” accessed https://www.google.com/search?q=hierarchical+segmentation+of+video+timeline+and+matching+search +data&hl=en&blw=1142&bih=547&tbm=pts&s . . . , accessed on Dec. 2, 2021, pp. 2.;;“Transient oscillation video matching,” accessed at https://www.google.com/search?q=transient+oscillation+video+matching&hl=en&biw=1225&bih=675&tbm=pts&sxsrf=AOaemvJjtgRC6aa4ltvNUFxJa6 . . . , accessed on Dec. 2, 2021, pp. 2.;;Preinterview First Office Action dated Sep. 27, 2021 in U.S. Appl. No. 17/017,366, 5 pages.;;Preinterview first Office Action dated Sep. 30, 2021 in U.S. Appl. No. 17/017,362, 4 pages.;;Restriction Requirement dated Oct. 18, 2021 in U.S. Appl. No. 17/017,344, 5 pages.;;Non-Final Office Action dated Nov. 9, 2021 in U.S. Appl. No. 17/017,344, 9 pages.;;First Action Interview—Office Action dated Dec. 3, 2021 in U.S. Appl. No. 17/017,366, 4 pages.;;Non-Final Office Action dated Dec. 7, 2021 in U.S. Appl. No. 17/017,370, 26 pages.;;First action interview—office action dated Feb. 3, 2022 in U.S. Appl. No. 17/017,362, 3 pages.;;Final Office Action dated Feb. 28, 2022 in U.S. Appl. No. 17/017,370, 32 pages.;;Notice of Allowance dated Mar. 23, 2022 in U.S. Appl. No. 17/017,344, 7 pages.;;Notice of Allowance dated Apr. 6, 2022 in U.S. Appl. No. 17/330,667, 8 pages.;;Corrected Notice of Allowability dated Apr. 25, 2022 in U.S. Appl. No. 17/017,344, 2 pages.;;Alcazar, J.L., et al., “Active Speakers in Context,” Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR), pp. 12465-12474 (2020).;;Co-pending U.S. Appl. No. 16/879,362, filed May 20, 2020.;;Final Office Action dated May 9, 2022 in U.S. Appl. No. 17/017,366, 14 pages.;;Notice of Allowance dated Jul. 13, 2022 in U.S. Appl. No. 17/017,366, 7 pages.;;Non-Final Office Action dated Jul. 29, 2022 in U.S. Appl. No. 17/017,370, 37 pages.;;Final Office Action dated Aug. 15, 2022 in U.S. Appl. No. 17/017,362, 7 pages.;;Preinterview first office action dated Aug. 18, 2022 in U.S. Appl. No. 17/017,353, 5 pages.;;Non-Final Office Action dated Sep. 29, 2022 in U.S. Appl. No. 17/330,677, 12 pages.;;Non-Final Office Action dated Oct. 24, 2022 in U.S. Appl. No. 17/330,702, 9 pages.;;Non-Final Office Action dated Oct. 24, 2022 in U.S. Appl. No. 17/330,718, 10 pages.;;Non-Final Office Action dated Oct. 26, 2022 in U.S. Appl. No. 17/330,702, 8 pages.;;Notice of Allowance dated Nov. 21, 2022 in U.S. Appl. No. 17/017,362, 5 pages.;;First Action Interview Office Action dated Nov. 22, 2022 in U.S. Appl. No. 17/017,353, 4 pages.;;Final Office Action dated Jan. 4, 2023 in U.S. Appl. No. 17/330,677, 12 pages.;;“Apple, Final Cut Pro 7 User Guide”, 2020, Retrieved from Internet URL: https://prohelp.apple.com/finalcutpro_helpr01/English/en/finalcutpro/usermanual/index.html#chapter=7%26section=1), pp. 11 (Year: 2010).;;Notice of Allowance dated Feb. 8, 2023 in U.S. Appl. No. 17/017,366, 5 pages.;;Notice of Allowance dated Feb. 2, 2023 in U.S. Appl. No. 17/017,370, 6 pages.;;Non-Final Office Action dated Feb. 16, 2023 in U.S. Appl. No. 17/969,536, 16 pages.;;Final Office Action dated Mar. 9, 2023 in U.S. Appl. No. 17/330,702, 8 pages.;;Final Office Action dated Mar. 9, 2023 in U.S. Appl. No. 17/330,718, 8 pages.;;Notice of Allowance dated Apr. 18, 2023 in U.S. Appl. No. 17/330,677, 5 pages.;;Shibata, M., “Temporal segmentation method for video sequence”, Proceedings of SPIE, Applications in Optical Science and Engineering, Visual Communications and Image Processing, vol. 1818, pp. 1-13 (1992).;;Swanberg, D., et al., “Knowledge-guided parsing in video databases”, Proceedings of SPIE, IS&T/SPIE's Symposium on Electronic Imaging: Science and Technology, Storage and retrieval for Image and Video Databases, vol. 1908, pp. 1-13 (Apr. 14, 1993).;;McDarris, J., “Adobe Photoshop Tutorial: Every Tool in the Toolbar Explained and Demonstrated”, You Tube, Retrieved from Internet URL: https://www.youtube.com/watch?v=2cQT1ZgvgGl, accessed on Jun. 21, 2023, pp. 3.;;Final Office Action dated Jun. 14, 2023 in U.S. Appl. No. 17/017,353, 34 pages.;;Final Office Action dated Jul. 19, 2023 in U.S. Appl. No. 17/969,536, 18 pages.;;Non Final Office Action dated Jun. 14, 2023 in U.S. Appl. No. 17/805,080, 9 pages.;;Non Final Office Action dated May 19, 2023 in U.S. Appl. No. 17/805,076, 9 pages.;;Non Final Office Action dated Jun. 30, 2023 in U.S. Appl. No. 17/330,702, 7 pages.;;Non Final Office Action dated Jun. 12, 2023 in U.S. Appl. No. 17/330,718, 7 pages.;;Non Final Office Action dated May 18, 2023 in U.S. Appl. No. 17/805,075, 9 pages.;;Notice of Allowance dated Aug. 16, 2023 in U.S. Appl. No. 17/805,076, 5 pages.;;Non-Final Office Action dated Sep. 1, 2023 in U.S. Appl. No. 17/017,353, 32 pages.;;Non-Final Office Action dated Sep. 21, 2023 in U.S. Appl. No. 17/805,075, 5 pages.;;Notice of Allowance dated Oct. 4, 2023 in U.S. Appl. No. 17/330,718, 5 pages.;;Notice of Allowance dated Oct. 18, 2023 in U.S. Appl. No. 17/969,536, 7 pages.;;Notice of Allowance dated Nov. 1, 2023 in U.S. Appl. No. 17/805,080, 5 pages.;;Final Office Action dated Nov. 15, 2023 in U.S. Appl. No. 17/330,702, 7 pages.",ACTIVE
87,US,A1,US 2012/0312017 A1,117-005-374-925-987,2012-12-13,2012,US 201213422353 A,2012-03-16,US 201213422353 A;;US 57855409 A;;US 10491508 P;;US 19604208 P,2008-10-13,"Stirling Engine Systems, Apparatus and Methods","Systems, methods, and apparatus relating to the use of Stirling engine technology to convert heat, such as from solar radiation, to mechanical work or electricity. Apparatus, systems, components, and methods relating to energy converting apparatus are described herein. In one aspect, the invention relates to the field alignment of panels and the assembly of a concentrator. In another aspect, a passive balancer is used in combination with a ring frame and other moving masses to reduce engine forces and vibration on the structure of the energy converting apparatus while maintaining properly constrained alignment of various suspended masses. In yet another aspect, the invention relates to various over-insolation control and management strategy to prevent overheating of the energy converting apparatus or components and subsystems thereof.",FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA;;INFINIA CORP,FRASER PAUL;;SMITH TERRY;;LUONGO ROCCO;;THURGOOD JUSTIN;;WETHERBEE TRENT;;MILLERET RAPHAEL;;PETERSON ALLEN;;AUGENBLICK JOHN EDWARD;;MCCALLUM SCOTT;;WILLIFORD IAN;;ERBEZNIK RAY;;GYORI BEN;;FOX PATRICK;;MCVICKER HARRY;;DALE TINA,QNERGY INC (2013-11-29),https://lens.org/117-005-374-925-987,Patent Application,yes,6,5,7,15,0,F03G6/068;;F03G6/068;;Y02E10/46;;Y02E10/46;;Y02T10/7072;;Y10T29/49895;;Y10T29/49895,F03G6/06;;F02G1/043;;F02G1/055;;F24J2/46;;F24S23/70,60/641.15;;126/701;;126/704;;126/696;;60/516,0,0,,,,INACTIVE
88,GB,A,GB 2567529 A,172-988-524-759-318,2019-04-17,2019,GB 201813027 A,2017-07-12,US 201662361274 P;;GB 201711213 A,2016-07-12,Additive channels,"A microfluidic device 1400 comprising a test channel 1403 with input portion and output portion, endothelial cells disposed within at least one portion of the test channel, and an output additive channel 1409, 1410 in fluidic communication with the output portion of the test channel. The device further comprises an input channel 1401 and an output channel 1406. Ideally, the additive output channel delivers fluid to at least two opposing sides of the test channel. The device may include a porous membrane and back channel 1402, 1404, 1405 wherein the membrane is situated between at least one portion of the test channel and at least one portion of the back channel (see fig 2). A method of using the device comprises flowing a biological sample, preferably a blood sample, through the test channel to ideally test for a thrombotic process, and flowing an anti-coagulation agent into the output additive sample such that the agent contacts at least a portion of the biological sample. The anti-coagulation agent also acts as a sheath fluid, shielding the sample from the device walls to prevent coagulation or clotting due to sample contact with the walls.",EMULATE INC;;JANSSEN BIOTECH INC,DANIEL LEVNER;;NORMAN WEN;;JACOB FRASER;;JUSTIN K NGUYEN;;RICCARDO BARRILE;;GERALDINE HAMILTON;;CATHERINE KARALIS;;HYOUNG SHIN PARK;;ANTONIO VARONE;;ANDRIES VAN DER MEER;;MONICAH OTIENO;;DAVID CONEGLIANO;;CHRISTOPHER DAVID HINOJOSA,,https://lens.org/172-988-524-759-318,Patent Application,no,4,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;C12M1/00;;G01N33/49,,0,0,,,,ACTIVE
89,GB,B,GB 2553898 B,086-106-550-160-099,2021-04-07,2021,GB 201711213 A,2017-07-12,US 201662361274 P,2016-07-12,Additive channels,,EMULATE INC;;JANSSEN BIOTECH INC,DANIEL LEVNER;;NORMAN WEN;;JACOB FRASER;;JUSTIN K NGUYEN;;RICCARDO BARRILE;;GERALDINE HAMILTON;;CATHERINE KARALIS;;HYOUNG SHIN PARK;;ANTONIO VARONE;;ANDRIES VAN DER MEER;;MONICAH OTIENO;;DAVID CONEGLIANO;;CHRISTOPHER DAVID HINOJOSA,,https://lens.org/086-106-550-160-099,Granted Patent,no,6,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;C12M3/00;;G01N33/49;;G01N33/543,,0,0,,,,ACTIVE
90,DE,A1,DE 102022105123 A1,090-244-087-247-386,2022-12-01,2022,DE 102022105123 A,2022-03-04,US 202117330689 A,2021-05-26,Interagieren mit semantischen Videosegmenten durch interaktive Kacheln,"Ausführungsformen betreffen interaktive Kacheln, die Videosegmente einer Segmentierung eines Videos darstellen. Bei einigen Ausführungsformen stellt jede interaktive Kachel ein anderes Videosegment aus einer bestimmten Videosegmentierung (beispielsweise einer Standardvideosegmentierung) dar. Jede interaktive Kachel beinhaltet ein Vorschaubild (beispielsweise das erste Einzelbild des Videosegmentes, das von der Kachel dargestellt wird), ein Transkript ab dem Anfang des Videosegmentes, eine Visualisierung von detektierten Gesichtern in dem Videosegment und einen oder mehrere facettenbestückte Zeitstrahlen, die eine Kategorie von detektierten Merkmalen visualisieren (beispielsweise eine Visualisierung von detektierten visuellen Szenen, Audioklassifizierungen, visuellen Artefakten). Bei einigen Ausführungsformen bewirkt das Interagieren mit einer bestimmten interaktiven Kachel ein Navigieren zu einem entsprechenden Abschnitt des Videos, ein Hinzufügen eines entsprechenden Videosegmentes zu einer Auswahl und/oder ein Wischen durch Kachelvorschaubilder.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,,https://lens.org/090-244-087-247-386,Patent Application,no,1,0,5,21,0,G06F3/0482;;G06F3/04847;;G06F3/0488;;G06V10/82;;G06V20/41;;G11B27/005;;G11B27/34;;G10L15/26;;G10L17/00;;G10L25/51;;G06F3/04847;;G06V10/82;;G06F16/75;;G06F16/7844;;G06F16/7847;;G11B27/102;;H04N21/8456;;H04N21/84;;H04N21/8153;;H04N21/4821;;H04N21/26603;;H04N21/23418;;H04N21/23109;;H04N21/4828;;G06V20/46;;G06V20/49;;G06F3/0485;;G11B27/02;;G11B27/10,H04N21/431;;G06F3/01,,0,0,,,,PENDING
91,US,B2,US 11887371 B2,124-441-908-879-976,2024-01-30,2024,US 202117330718 A,2021-05-26,US 202117330718 A;;US 202017017344 A,2020-09-10,Thumbnail video segmentation identifying thumbnail locations for a video,"Embodiments are directed to a thumbnail segmentation that defines the locations on a video timeline where thumbnails are displayed. Candidate thumbnail locations are determined from boundaries of feature ranges of the video indicating when instances of detected features are present in the video. In some embodiments, candidate thumbnail separations are penalized for being separated by less than a minimum duration corresponding to a minimum pixel separation (e.g., the width of a thumbnail) between consecutive thumbnail locations on a video timeline. The thumbnail segmentation is computed by solving a shortest path problem through a graph that models different thumbnail locations and separations. As such, a video timeline is displayed with thumbnails at locations on the timeline defined by the thumbnail segmentation, with each thumbnail depicting a portion of the video associated with the thumbnail location.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIĆ JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,ADOBE INC (2021-05-14),https://lens.org/124-441-908-879-976,Granted Patent,yes,62,0,2,21,0,G11B27/031;;G11B27/34;;G06V20/49;;G06V40/172;;G06V10/82;;G11B27/10;;G06V20/49;;G06V10/751;;G06V20/46;;G06V40/161,G11B27/00;;G06V10/75;;G06V10/82;;G06V20/40;;G06V40/16;;G11B27/031;;G11B27/10;;G11B27/34,,54,2,079-071-231-345-204;;002-146-741-672-029,10.1109/cvpr42600.2020.01248;;10.1117/12.143647,"Chinfat, “E15—The Tool Bar/The Selection Tool—Adobe Premiere Pro CC 2018,” accessed at https://www.youtube.com/watch?v=IJRhzOqrMzA, p. 1 (May 8, 2018).;;“Hierarchical Segmentation of video timeline and matching searh data,” accessed https://www.google.com/search?q=hierarchical+segmentation+of+video+timeline+and+matching+search+data&hl=en&blw=1142&bih=547&tbm=pts&s . . . , accessed on Dec. 2, 2021, pp. 2.;;“Transient oscillation video matching,” accessed at https://www.google.com/search?q=transient+oscillation+video+matching&hl=en&biw=1225&bih=675&tbm=pts&sxsrf=AOaemvJjtgRC6aa4ltvNUFxJa6 . . . , accessed on Dec. 2, 2021, pp. 2.;;Preinterview First Office Action dated Sep. 27, 2021 in U.S. Appl. No. 17/017,366, 5 pages.;;Preinterview first Office Action dated Sep. 30, 2021 in U.S. Appl. No. 17/017,362, 4 pages.;;Restriction Requirement dated Oct. 18, 2021 in U.S. Appl. No. 17/017,344, 5 pages.;;Non-Final Office Action dated Nov. 9, 2021 in U.S. Appl. No. 17/017,344, 9 pages.;;First Action Interview—Office Action dated Dec. 3, 2021 in U.S. Appl. No. 17/017,366, 4 pages.;;Non-Final Office Action dated Dec. 7, 2021 in U.S. Appl. No. 17/017,370, 26 pages.;;Final Office Action dated May 9, 2022 in U.S. Appl. No. 17/017,366, 14 pages.;;Non-Final Office Action dated Jun. 2, 2022 in U.S. Appl. No. 17/330,689, 9 pages.;;First action interview—office action dated Feb. 3, 2022 in U.S. Appl. No. 17/017,362, 3 pages.;;Final Office Action dated Feb. 28, 2022 in U.S. Appl. No. 17/017,370, 32 pages.;;Notice of Allowance dated Mar. 23, 2022 in U.S. Appl. No. 17/017,344, 7 pages.;;Notice of Allowance dated Apr. 6, 2022 in U.S. Appl. No. 17/330,667, 8 pages.;;Corrected Notice of Allowability dated Apr. 25, 2022 in U.S. Appl. No. 17/017,344, 2 pages.;;Restriction Requirement dated Apr. 26, 2022 in U.S. Appl. No. 17/330,689, 6 pages.;;Notice of Allowance dated Jul. 13, 2022 in U.S. Appl. No. 17/017,366, 7 pages.;;Non-Final Office Action dated Jul. 29, 2022 in U.S. Appl. No. 17/017,370, 37 pages.;;Final Office Action dated Aug. 15, 2022 in U.S. Appl. No. 17/017,362, 7 pages.;;Preinterview first office action dated Aug. 18, 2022 in U.S. Appl. No. 17/017,353, 5 pages.;;Non-Final Office Action dated Sep. 29, 2022 in U.S. Appl. No. 17/330,677, 12 pages.;;Alcazar, J.L., et al., “Active Speakers in Context,” Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR), pp. 12465-12474 (2020).;;Co-pending U.S. Appl. No. 16/879,362, filed May 20, 2020.;;Non-Final Office Action dated Oct. 24, 2022 in U.S. Appl. No. 17/330,702, 9 pages.;;Non-Final Office Action dated Oct. 26, 2022 in U.S. Appl. No. 17/330,702, 8 pages.;;Final Office Action dated Oct. 27, 2022 in U.S. Appl. No. 17/330,689, 8 pages.;;Notice of Allowance dated Nov. 21, 2022 in U.S. Appl. No. 17/017,362, 5 pages.;;First Action Interview Office Action dated Nov. 22, 2022 in U.S. Appl. No. 17/017,353, 4 pages.;;Final Office Action dated Jan. 4, 2023 in U.S. Appl. No. 17/330,677, 12 pages.;;“Apple, Final Cut Pro 7 User Guide”, 2020, Retrieved from Internet URL: https://prohelp.apple.com/finalcutpro_helpr01/English/en/finalcutpro/usermanual/index.html#chapter=7%26section=1), pp. 11 (Year: 2010).;;Notice of Allowance dated Feb. 8, 2023 in U.S. Appl. No. 17/017,366, 5 pages.;;Non-Final Office Action dated Jan. 24, 2023 in U.S. Appl. No. 17/330,689, 13 pages.;;Notice of Allowance dated Feb. 2, 2023 in U.S. Appl. No. 17/017,370, 6 pages.;;Non-Final Office Action dated Feb. 16, 2023 in U.S. Appl. No. 17/969,536, 16 pages.;;Final Office Action dated Mar. 9, 2023 in U.S. Appl. No. 17/330,702, 8 pages.;;Notice of Allowance dated Apr. 18, 2023 in U.S. Appl. No. 17/330,677, 5 pages.;;Shibata, M., “Temporal segmentation method for video sequence”, Proceedings of SPIE, Applications in Optical Science and Engineering, Visual Communications and Image Processing, vol. 1818, pp. 1-13 (1992).;;Swanberg, D., et al., “Knowledge-guided parsing in video databases”, Proceedings of SPIE, IS&T/SPIE's Symposium on Electronic Imaging: Science and Technology, Storage and retrieval for Image and Video Databases, vol. 1908, pp. 1-13 (Apr. 14, 1993).;;McDarris, J., “Adobe Photoshop Tutorial: Every Tool in the Toolbar Explained and Demonstrated”, You Tube, Retrieved from Internet URL: https://www.youtube.com/watch?v=2cQT1ZgvgGI, accessed on Jun. 21, 2023, pp. 3.;;Final Office Action dated Jun. 14, 2023 in U.S. Appl. No. 17/017,353, 34 pages.;;Final Office Action dated Jun. 20, 2023 in U.S. Appl. No. 17/330,689, 13 pages.;;Non Final Office Action dated Jun. 14, 2023 in U.S. Appl. No. 17/805,080, 9 pages.;;Non Final Office Action dated May 19, 2023 in U.S. Appl. No. 17/805,076, 9 pages.;;Non Final Office Action dated Jun. 30, 2023 in U.S. Appl. No. 17/330,702, 7 pages.;;Notice of Allowance dated Aug. 16, 2023 in U.S. Appl. No. 17/805,076, 5 pages.;;Non Final Office Action dated May 18, 2023 in U.S. Appl. No. 17/805,075, 9 pages.;;Final Office Action dated Jul. 19, 2023 in U.S. Appl. No. 17/969,536, 18 pages.;;Non-Final Office Action dated Sep. 1, 2023 in U.S. Appl. No. 17/017,353, 32 pages.;;Non-Final Office Action dated Sep. 21, 2023 in U.S. Appl. No. 17/805,075, 5 pages.;;Final Office Action dated Nov. 15, 2023 in U.S. Appl. No. 17/330,702, 7 pages.;;Notice of Allowance dated Oct. 18, 2023 in U.S. Appl. No. 17/969,536, 7 pages.;;Notice of Allowance dated Nov. 1, 2023 in U.S. Appl. No. 17/805,080, 5 pages.;;Notice of Allowance dated Sep. 11, 2023 in U.S. Appl. No. 17/330,689, 5 pages.",ACTIVE
92,US,A1,US 2022/0076706 A1,146-322-167-755-058,2022-03-10,2022,US 202117330689 A,2021-05-26,US 202117330689 A;;US 202017017344 A,2020-09-10,INTERACTING WITH SEMANTIC VIDEO SEGMENTS THROUGH INTERACTIVE TILES,"Embodiments are directed to interactive tiles that represent video segments of a segmentation of a video. In some embodiments, each interactive tile represents a different video segment from a particular video segmentation (e.g., a default video segmentation). Each interactive tile includes a thumbnail (e.g., the first frame of the video segment represented by the tile), some transcript from the beginning of the video segment, a visualization of detected faces in the video segment, and one or more faceted timelines that visualize a category of detected features (e.g., a visualization of detected visual scenes, audio classifications, visual artifacts). In some embodiments, interacting with a particular interactive tile navigates to a corresponding portion of the video, adds a corresponding video segment to a selection, and/or scrubs through tile thumbnails.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,ADOBE INC (2021-05-14),https://lens.org/146-322-167-755-058,Patent Application,yes,4,1,2,21,0,G11B27/34;;G11B27/005;;G10L15/26;;G10L17/00;;G10L25/51;;G06V10/82;;G06V20/41;;G06F3/0482;;G06F3/04847;;G06F3/0488;;G11B27/036;;G06F3/0486;;G06F3/0482,G11B27/036;;G06F3/0482;;G06F3/0486,,0,0,,,,ACTIVE
93,AU,A1,AU 2022/202672 A1,058-944-950-251-00X,2022-12-15,2022,AU 2022/202672 A,2022-04-22,US 202117330689 A,2021-05-26,INTERACTING WITH SEMANTIC VIDEO SEGMENTS THROUGH INTERACTIVE TILES,"Embodiments are directed to interactive tiles that represent video segments of a segmentation of a video. In some embodiments, each interactive tile represents a different video segment from a particular video segmentation (e.g., a default video segmentation). Each interactive tile includes a thumbnail (e.g., the first frame of the video segment represented by the tile), some transcript from the beginning of the video segment, a visualization of detected faces in the video segment, and one or more faceted timelines that visualize a category of detected features (e.g., a visualization of detected visual scenes, audio classifications, visual artifacts). In some embodiments, interacting with a particular interactive tile navigates to a corresponding portion of the video, adds a corresponding video segment to a selection, and/or scrubs through tile thumbnails. LO z z -J z z L L I z 0 0 Z z z 0 Z 0 o o wJ z OH)lZ i -L 0 > 0 2 ~~ ~ ~ I 0 Z Of LJ L - Z L ~ - m- 0 w - 0- Z ( Z WZ (-9 0 0< F- W - z > Z U) ZU Wz wo COQ o -0 Of LL, LLQ 0u0 U 0 L0 00 zO 0 w 0 IL U) F0 <0 0~ o mo 0 L) F- o LL, (D af F u-U W) Wr 0 L0 m00 ) w) oo < 2iC O I O) Co 0 z 0 z wL IL 0 0) O Of",ADOBE INC,GANTER TIMOTHY JEEWUN;;BAI XUE;;WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;LI DINGZEYU,,https://lens.org/058-944-950-251-00X,Patent Application,no,0,0,5,21,0,G06F3/0482;;G06F3/04847;;G06F3/0488;;G06V10/82;;G06V20/41;;G11B27/005;;G11B27/34;;G10L15/26;;G10L17/00;;G10L25/51;;G06F3/04847;;G06V10/82;;G06F16/75;;G06F16/7844;;G06F16/7847;;G11B27/102;;H04N21/8456;;H04N21/84;;H04N21/8153;;H04N21/4821;;H04N21/26603;;H04N21/23418;;H04N21/23109;;H04N21/4828;;G06V20/46;;G06V20/49;;G06F3/0485;;G11B27/02;;G11B27/10,G06F16/74;;G06F3/0482;;G06F3/04842;;G06F3/04845,,0,0,,,,ACTIVE
94,AU,B2,AU 2022/202672 B2,063-302-148-093-653,2023-10-05,2023,AU 2022/202672 A,2022-04-22,US 202117330689 A,2021-05-26,INTERACTING WITH SEMANTIC VIDEO SEGMENTS THROUGH INTERACTIVE TILES,"Embodiments are directed to interactive tiles that represent video segments of a segmentation of a video. In some embodiments, each interactive tile represents a different video segment from a particular video segmentation (e.g., a default video segmentation). Each interactive tile includes a thumbnail (e.g., the first frame of the video segment represented by the tile), some transcript from the beginning of the video segment, a visualization of detected faces in the video segment, and one or more faceted timelines that visualize a category of detected features (e.g., a visualization of detected visual scenes, audio classifications, visual artifacts). In some embodiments, interacting with a particular interactive tile navigates to a corresponding portion of the video, adds a corresponding video segment to a selection, and/or scrubs through tile thumbnails. LO z z -J z z L L I z 0 0 Z z z 0 Z 0 o o wJ z OH)lZ i -L 0 > 0 2 ~~ ~ ~ I 0 Z Of LJ L - Z L ~ - m- 0 w - 0- Z ( Z WZ (-9 0 0< F- W - z > Z U) ZU Wz wo COQ o -0 Of LL, LLQ 0u0 U 0 L0 00 zO 0 w 0 IL U) F0 <0 0~ o mo 0 L) F- o LL, (D af F u-U W) Wr 0 L0 m00 ) w) oo < 2iC O I O) Co 0 z 0 z wL IL 0 0) O Of",ADOBE INC,GANTER TIMOTHY JEEWUN;;BAI XUE;;WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;LI DINGZEYU,,https://lens.org/063-302-148-093-653,Granted Patent,no,0,0,5,21,0,G06F3/0482;;G06F3/04847;;G06F3/0488;;G06V10/82;;G06V20/41;;G11B27/005;;G11B27/34;;G10L15/26;;G10L17/00;;G10L25/51;;G06F3/04847;;G06V10/82;;G06F16/75;;G06F16/7844;;G06F16/7847;;G11B27/102;;H04N21/8456;;H04N21/84;;H04N21/8153;;H04N21/4821;;H04N21/26603;;H04N21/23418;;H04N21/23109;;H04N21/4828;;G06V20/46;;G06V20/49;;G06F3/0485;;G11B27/02;;G11B27/10,G06F16/74;;G06F3/0482;;G06F3/04842;;G06F3/04845,,0,0,,,,ACTIVE
95,US,A1,US 2022/0076707 A1,090-236-432-670-24X,2022-03-10,2022,US 202117330702 A,2021-05-26,US 202117330702 A;;US 202017017344 A,2020-09-10,SNAP POINT VIDEO SEGMENTATION IDENTIFYING SELECTION SNAP POINTS FOR A VIDEO,"Embodiments are directed to a snap point segmentation that defines the locations of selection snap points for a selection of video segments. Candidate snap points are determined from boundaries of feature ranges of the video indicating when instances of detected features are present in the video. In some embodiments, candidate snap point separations are penalized for being separated by less than a minimum duration corresponding to a minimum pixel separation between consecutive snap points on a video timeline. The snap point segmentation is computed by solving a shortest path problem through a graph that models different snap point locations and separations. When a user clicks or taps on the video timeline and drags, a selection snaps to the snap points defined by the snap point segmentation. In some embodiments, the snap points are displayed during a drag operation and disappear when the drag operation is released.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,ADOBE INC (2021-05-14),https://lens.org/090-236-432-670-24X,Patent Application,yes,3,4,1,21,0,G11B27/031;;G11B27/34;;G10L25/57;;G10L25/78;;G10L17/00;;G10L15/26;;G06V10/82;;G06V20/41;;G06F3/0481;;G06F3/0488;;G06F3/04847;;G06F3/0482;;G11B27/036;;G06F3/0482;;G06F3/0486,G11B27/036;;G06F3/0482;;G06F3/0486,,0,0,,,,PENDING
96,GB,B,GB 2567529 B,123-586-791-054-305,2021-03-31,2021,GB 201813027 A,2017-07-12,US 201662361274 P;;GB 201711213 A,2016-07-12,Additive channels,,EMULATE INC;;JANSSEN BIOTECH INC,DANIEL LEVNER;;NORMAN WEN;;JACOB FRASER;;JUSTIN K NGUYEN;;RICCARDO BARRILE;;GERALDINE HAMILTON;;CATHERINE KARALIS;;HYOUNG SHIN PARK;;ANTONIO VARONE;;ANDRIES VAN DER MEER;;MONICAH OTIENO;;DAVID CONEGLIANO;;CHRISTOPHER DAVID HINOJOSA,,https://lens.org/123-586-791-054-305,Granted Patent,no,4,0,27,27,0,B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;B01L3/502761;;B01L2200/0647;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;B01L3/502746;;B01L2300/14;;B01L3/5027;;B01L3/502715;;G01N33/49;;B01L3/502746;;B01L3/502761;;C12M23/16;;G01N33/4905;;C12M29/10;;G01N33/54366;;C12M3/00;;C12M35/08;;C12M41/46;;G01N33/543;;B01L3/502707;;C12M23/16;;C12M29/04;;C12M29/10;;C12M35/08;;C12M41/46;;G01N33/54366;;B01L2200/027;;B01L2300/0883;;G01N33/80;;B01L3/502715;;B01L3/502761;;B01L2200/0647;;B01L2200/16;;B01L2300/0816;;B01L2300/0867;;B01L2300/0887;;B01L2300/16;;G01N33/86;;G01N2500/10;;B01L3/5023;;B01L2200/02;;B01L2300/0809;;C12M29/00;;B01L3/502746;;B01L2200/0605;;B01L2300/14,B01L3/00;;C12M1/00;;G01N33/49;;G01N33/543,,0,0,,,,ACTIVE
97,US,A1,US 2022/0076026 A1,184-781-605-978-077,2022-03-10,2022,US 202117330718 A,2021-05-26,US 202117330718 A;;US 202017017344 A,2020-09-10,THUMBNAIL VIDEO SEGMENTATION IDENTIFYING THUMBNAIL LOCATIONS FOR A VIDEO,"Embodiments are directed to a thumbnail segmentation that defines the locations on a video timeline where thumbnails are displayed. Candidate thumbnail locations are determined from boundaries of feature ranges of the video indicating when instances of detected features are present in the video. In some embodiments, candidate thumbnail separations are penalized for being separated by less than a minimum duration corresponding to a minimum pixel separation (e.g., the width of a thumbnail) between consecutive thumbnail locations on a video timeline. The thumbnail segmentation is computed by solving a shortest path problem through a graph that models different thumbnail locations and separations. As such, a video timeline is displayed with thumbnails at locations on the timeline defined by the thumbnail segmentation, with each thumbnail depicting a portion of the video associated with the thumbnail location.",ADOBE INC,WALKER SETH;;SHIN HIJUNG;;FRASER CRISTIN AILIDH;;AGARWALA ASEEM;;DONTCHEVA LUBOMIRA;;BRANDT JOEL RICHARD;;POPOVIC JOVAN;;KIM JOY OAKYUNG;;SALAMON JUSTIN;;WANG JUI-HSIEN;;GANTER TIMOTHY JEEWUN;;BAI XUE;;LI DINGZEYU,ADOBE INC (2021-05-14),https://lens.org/184-781-605-978-077,Patent Application,yes,2,0,2,21,0,G11B27/031;;G11B27/34;;G06V20/49;;G06V40/172;;G06V10/82;;G11B27/10;;G06V20/49;;G06V10/751;;G06V20/46;;G06V40/161,G06K9/00;;G06K9/62;;G11B27/10,,0,0,,,,ACTIVE
98,US,A1,US 2017/0148116 A1,139-829-213-122-489,2017-05-25,2017,US 201615359182 A,2016-11-22,US 201615359182 A;;US 201562259030 P,2015-11-23,AUTOMATED SUPERVISION OF CONSTRUCTION OPERATIONS IN AN INTELLIGENT WORKSPACE,"One embodiment of the present invention sets forth a technique for performing tasks associated with a construction project. The technique includes transmitting to a worker, via a mobile computing device worn by the worker, a first instruction related to performing a first task included in a plurality of tasks associated with a construction project, and transmitting to a light-emitting device a command to provide a visual indicator to the worker that facilitates performing the first task, based on an input received from the mobile computing device, determining that the worker has completed the first task of the construction project, selecting, from a database that tracks eligibility of each of the plurality of tasks, a second task included in the plurality of tasks that the worker is eligible to perform, and transmitting to the worker, via the mobile computing device, a second instruction related to performing the second task.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;NOGUEIRA ANDERSON;;BEIRNE NICK;;MATEJKA JUSTIN FRANK;;NAGY DANIL;;LI STEVEN;;LAFRENIERE BENJAMIN;;KERRICK HEATHER;;WHITE THOMAS;;ANDERSON FRASER;;ATHERTON EVAN;;THOMASSON DAVID;;HARSUVANAKIT ARTHUR;;CONTI MAURICE UGO,AUTODESK INC (2016-11-21),https://lens.org/139-829-213-122-489,Patent Application,yes,19,8,2,2,0,G06Q50/08;;G06Q10/06311;;G06Q50/08;;G06Q10/06311,G06Q50/08;;G06Q10/06,,0,0,,,,ACTIVE
99,US,B2,US 11295400 B2,122-091-596-604-42X,2022-04-05,2022,US 201615359182 A,2016-11-22,US 201615359182 A;;US 201562259030 P,2015-11-23,Automated supervision of construction operations in an intelligent workspace,"One embodiment of the present invention sets forth a technique for performing tasks associated with a construction project. The technique includes transmitting to a worker, via a mobile computing device worn by the worker, a first instruction related to performing a first task included in a plurality of tasks associated with a construction project, and transmitting to a light-emitting device a command to provide a visual indicator to the worker that facilitates performing the first task, based on an input received from the mobile computing device, determining that the worker has completed the first task of the construction project, selecting, from a database that tracks eligibility of each of the plurality of tasks, a second task included in the plurality of tasks that the worker is eligible to perform, and transmitting to the worker, via the mobile computing device, a second instruction related to performing the second task.",AUTODESK INC,GROSSMAN TOVI;;FITZMAURICE GEORGE;;NOGUEIRA ANDERSON;;BEIRNE NICK;;MATEJKA JUSTIN FRANK;;NAGY DANIL;;LI STEVEN;;LAFRENIERE BENJAMIN;;KERRICK HEATHER;;WHITE THOMAS;;ANDERSON FRASER;;ATHERTON EVAN;;THOMASSON DAVID;;HARSUVANAKIT ARTHUR;;CONTI MAURICE UGO,AUTODESK INC (2016-11-21),https://lens.org/122-091-596-604-42X,Granted Patent,yes,19,2,2,2,0,G06Q50/08;;G06Q10/06311;;G06Q50/08;;G06Q10/06311,G06Q50/08;;G06Q10/06,,0,0,,,,ACTIVE
100,US,A1,US 2020/0141283 A1,193-224-134-799-420,2020-05-07,2020,US 202016735523 A,2020-01-06,US 202016735523 A;;US 2018/0040965 W;;US 201715642041 A,2017-07-05,Synchronous Belt Drive System,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;MURI JOHN;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/193-224-134-799-420,Patent Application,yes,0,3,2,29,0,F16H7/023;;F16H7/1281;;F16H55/084;;F16H55/171;;F16H7/02;;F16H7/12;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F01L2820/01;;F01L2820/02;;F01L1/024;;F01L2001/0537;;F01L2810/03;;F16G1/28;;F16G1/10;;F01L1/024;;F16H7/023;;F16G1/04;;F16H55/084;;F16H2007/0893;;F16H55/171;;F16H7/1281;;F16H2007/081;;F16H2007/0865;;F16G1/28,F01L1/02;;F16G1/04;;F16G1/28;;F16H7/02;;F16H7/12;;F16H55/08;;F16H55/17,,0,0,,,,ACTIVE
101,US,B2,US 11421561 B2,124-519-080-638-562,2022-08-23,2022,US 202016735523 A,2020-01-06,US 202016735523 A;;US 2018/0040965 W;;US 201715642041 A,2017-07-05,Synchronous belt drive system,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;MURI JOHN;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/124-519-080-638-562,Granted Patent,yes,43,0,2,29,0,F16H7/023;;F16H7/1281;;F16H55/084;;F16H55/171;;F16H7/02;;F16H7/12;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F01L2820/01;;F01L2820/02;;F01L1/024;;F01L2001/0537;;F01L2810/03;;F16G1/28;;F16G1/10;;F01L1/024;;F16H7/023;;F16G1/04;;F16H55/084;;F16H2007/0893;;F16H55/171;;F16H7/1281;;F16H2007/081;;F16H2007/0865;;F16G1/28,F01L1/02;;F16G1/04;;F16G1/28;;F16H7/02;;F16H7/08;;F16H7/12;;F16H55/08;;F16H55/17,,7,0,,,"European Patent Office, International Search Report and Written Opinion of the International Searching Authority, International application No. PCT/US2018/040965, dated Mar. 6, 2019.;;NGF News: Latest News: Belt in Oil (BiO) wins again, Jun. 23, 2016, http://www.ngfglasscord.com/en-gb/news/latest-news/belt-in-oil-bio-wins-again, 1 page, Nippon Sheet Glass Co., Ltd., Tokyo, Japan, copyright 2018.;;Continental: Contitech—Oil pump drive, Drive Belts for Oil Pumps in Passenger Car OEM Equipment, https://www.contitech.de/en-GL/Solutions/Power-Transmission/Passenger-cars-OE/Oil-pump-drive, 2 pages, copyright 2018.;;Dayco Products LLC, Timing Belt-In-Oil (BIO) System, https://www.dayco.com/timing-belt-in-oil-bio-system, 3 pages, Troy, MI, United States.;;Wikipedia: Ford EcoBoost engine, https://en.wikipedia.org/wiki/Ford_EcoBoost_engine, 14 pages.;;NGF News, Latest News: Ford's new Panther two-litre EcoBlue advanced diesel engine uses Belt in Oil Technology, May 17, 2016, http://www.ngfglasscord.com/en-gb/news/latest-news/fords-new-panther-two-litre-ecoblue-advanced-diesel-engine-uses-belt-in . . . , 1 page, Nippon Sheet Glass Co., Ltd, Tokyo, Japan, copyright 2018.;;AutoServiceWorld: AutoServiceWorld News, Jun. 2, 2016, Talking Tech: Keeping things in time, by Jeff Taylor; https://www.autoserviceworld.com/carsmagazine/talking-tech-keeping-things-time/, 6 pages.",ACTIVE
102,BR,A2,BR 112020000200 A2,103-194-606-783-859,2020-07-07,2020,BR 112020000200 A,2018-07-05,US 2018/0040965 W,2018-07-05,sistema de acionamento por correia síncrona,"um sistema de acionamento por correia síncrona tenho: uma correia síncrona com um fio de tração de fibra de alto módulo tal como de vidro, carbono, pbo, ou aramida; uma roda dentada acionadora e pelo menos uma roda dentada acionada, pelo menos uma das quais é uma roda dentada oblonga; e um tracionador tendo: uma base tendo uma porção cilíndrica estendendo-se axialmente com uma superfície radialmente externa e uma porção de recepção, um braço excêntrico engatado pivotavelmente com a superfície radialmente externa, uma mola de torção disposta dentro da porção de recepção, a mola de torção aplicando uma força tensionadora ao braço excêntrico, e uma polia articulada no braço excêntrico. preferivelmente, nenhum dentre o braço excêntrico, a polia ou a mola de torção é axialmente deslocado ao longo de um eixo a-a dos outros. a roda dentada oblonga tem uma superfície denteada e pelo menos uma porção linear disposta entre duas porções arqueadas tendo um raio constante, a porção linear tendo um comprimento predeterminado.",GATES CORP,ANDRZEJ DEC;;CAROL WEBER;;CHARLIE OCHOA;;CINDY COOKSON;;CINDY DECKER;;DOUGLAS D SCHELHAAS;;GUOGONG CHEN;;JENNIFER E PEASE;;JOHN MURI;;JUSTIN PAULSEN;;KARLA J BIER;;KEVIN WARD;;LESLEE BROWN;;MIN GAO;;PATRICK JOSEPH MCNAMEE;;PAUL PEARSON;;SHAWN XIANG WU;;WILLIAM FRASER LACY;;YUDING FENG,,https://lens.org/103-194-606-783-859,Patent Application,no,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,ACTIVE
103,EP,A1,EP 3645842 A1,089-795-181-833-432,2020-05-06,2020,EP 18746393 A,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM,,GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURY JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/089-795-181-833-432,Patent Application,yes,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,DISCONTINUED
104,AU,B2,AU 2018/431021 B2,129-008-561-523-560,2021-08-12,2021,AU 2018/431021 A,2018-07-05,US 2018/0040965 W,2018-07-05,Synchronous belt drive system,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/129-008-561-523-560,Granted Patent,no,6,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,ACTIVE
105,MX,A,MX 2020000131 A,181-555-278-900-111,2020-08-06,2020,MX 2020000131 A,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM.,EMPTY,GATES CORP,FENG YUDING;;GAO MIN;;WU SHAWN XIANG;;SCHELHAAS DOUGLAS D;;DEC ANDRZEJ;;OCHOA CHARLIE;;BIER KARLA J;;BROWN LESLEE;;PEASE JENNIFER E;;MCNAMEE PATRICK JOSEPH;;DECKER CINDY;;WEBER CAROL;;WARD KEVIN;;LACY WILLIAM FRASER;;CHEN GUOGONG;;PEARSON PAUL;;MURI JOHN;;COOKSON CINDY;;PAULSEN JUSTIN,,https://lens.org/181-555-278-900-111,Patent Application,no,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,PENDING
106,CA,A1,CA 3066462 A1,042-263-129-113-013,2020-01-05,2020,CA 3066462 A,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/042-263-129-113-013,Patent Application,no,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,,,0,0,,,,ACTIVE
107,CA,C,CA 3066462 C,049-278-006-554-915,2022-06-21,2022,CA 3066462 A,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/049-278-006-554-915,Granted Patent,no,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02,,0,0,,,,ACTIVE
108,KR,A,KR 20200020943 A,090-931-532-816-853,2020-02-26,2020,KR 20207003367 A,2018-07-05,US 2018/0040965 W,2018-07-05,동기식 벨트 구동 시스템,"동기식 벨트 구동 시스템이, 유리, 탄소, PBO, 또는 아라미드와 같은 고-탄성계수 섬유의 인장 코드를 갖는 동기식 벨트; 구동 스프로킷 및 적어도 하나의 종동 스프로킷으로서, 그들 중 적어도 하나는 오브라운드형 스프로킷인 것인, 구동 스프로킷 및 적어도 하나의 종동 스프로킷; 및 텐셔너로서, 반경 방향 외측 표면 및 수용 부분을 갖는 축 방향으로 연장되는 원통형 부분을 구비하는 베이스부, 상기 반경 방향 외측 표면과 선회식으로 맞물리는 편심 아암, 상기 수용 부분 내부에 배치되는 토션 스프링으로서, 상기 편심 아암에 편향력을 가하는 것인, 토션 스프링, 및 상기 편심 아암에 축 지지되는 풀리를 구비하는 것인, 텐셔너를 구비한다. 바람직하게, 편심 아암, 풀리, 또는 토션 스프링 중의 어느 하나도, 다른 것들로부터 A-A 축을 따라 축 방향으로 변위되지 않는다. 오브라운드형 스프로킷은, 톱니형 표면 및, 일정한 반경을 갖는 2개의 호형 부분 사이에 배치되는 적어도 하나의 선형 부분으로서, 사전결정된 길이를 갖는 것인, 선형 부분을 구비한다.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/090-931-532-816-853,Patent Application,no,2,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F16H7/08;;F01L1/02;;F16H7/02;;F16H35/00;;F16H55/17,,0,0,,,,ACTIVE
109,AU,A1,AU 2018/431021 A1,140-977-858-706-975,2020-01-30,2020,AU 2018/431021 A,2018-07-05,US 2018/0040965 W,2018-07-05,Synchronous belt drive system,,GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/140-977-858-706-975,Patent Application,no,0,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,ACTIVE
110,CN,A,CN 111247316 A,078-826-129-205-658,2020-06-05,2020,CN 201880052133 A,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at leastone of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/078-826-129-205-658,Patent Application,no,6,2,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,ACTIVE
111,WO,A1,WO 2020/009703 A1,099-267-759-975-642,2020-01-09,2020,US 2018/0040965 W,2018-07-05,US 2018/0040965 W,2018-07-05,SYNCHRONOUS BELT DRIVE SYSTEM,"A synchronous belt drive system having: a synchronous belt with a tensile cord of high-modulus fiber such as glass, carbon, PBO, or aramid; a driver sprocket and at least one driven sprocket, at least one of which is an obround sprocket; and a tensioner having: a base having a cylindrical portion extending axially with a radially outer surface and a receiving portion, an eccentric arm pivotally engaged with the radially outer surface, a torsion spring disposed within the receiving portion, the torsion spring applying a biasing force to the eccentric arm, and a pulley journalled to the eccentric arm. Preferably, no one of the eccentric arm, pulley, or torsion spring is axially displaced along an axis A-A from the others. The obround sprocket has a toothed surface and at least one linear portion disposed between two arcuate portions having a constant radius, the linear portion having a predetermined length.",GATES CORP,GAO MIN;;DECKER CINDY;;WEBER CAROL;;SCHELHAAS DOUGLAS D;;WARD KEVIN;;BROWN LESLEE;;LACY WILLIAM FRASER;;CHEN GUOGONG;;FENG YUDING;;PEARSON PAUL;;MURI JOHN;;OCHOA CHARLIE;;BIER KARLA J;;COOKSON CINDY;;PEASE JENNIFER E;;PAULSEN JUSTIN;;MCNAMEE PATRICK JOSEPH;;WU SHAWN XIANG;;DEC ANDRZEJ,,https://lens.org/099-267-759-975-642,Patent Application,yes,12,0,14,29,0,F01L1/02;;F01L1/024;;F16H7/08;;F16H7/0831;;F16H7/12;;F16H7/1218;;F16H2007/081;;F16H2007/0865;;F16H2007/0893;;F16H7/08;;F16H7/023;;F16H35/00;;F16H55/171;;F01L1/024;;F16H2007/081;;F16H2007/0865;;F16H2035/003,F01L1/02;;F16H7/08;;F16H7/12,,0,0,,,,PENDING
112,WO,A1,WO 2021/229486 A1,149-335-398-334-332,2021-11-18,2021,IB 2021054090 W,2021-05-13,US 202063024710 P,2020-05-14,POINT-OF-CARE DEVICE FOR DETECTION OF GENETIC MATERIAL,Provided are systems and methods for detecting target genetic material based on a smartphone devise and application software for the fluorescence detection obtained from the CRISPR-based assay in a low-cost and low-resource matter. Also provided is an example of the system for sensitive and specific detection of SARS-CoV-2.,PAYUNGPORN SUNCHAI,PAYUNGPORN SUNCHAI;;CHANTARAVISOOT NAPHAT;;PISITKUN TRAIRAK;;KHONGNOMNAN KRITSADA;;MAYURAMART ORAPHAN;;NIMSAMER PATTARAPORN;;HANNANTA-ANAN PIMKHUAN;;LUANGKAMCHORN LUMRUNG;;TONGCHAM PHONGSAKHON;;SITTHI-AMORN PITCHAYA;;VACHIRAMON THUCHAKORN;;SAMACOITS AUBIN;;ZAHM UGO;;EARP SAMUEL WILLIAM FRASER;;NOINONGYAO PAVIT;;CAIRNS JUSTIN ASHLEY;;FERRAND SEBASTIEN;;KRAKORNKUL PANGSATORN;;SIRISONGKOL NEERAMPORN;;BAUMGARTEN KEVIN SEAN;;JIRASOPON SHINNAKRIT,,https://lens.org/149-335-398-334-332,Patent Application,yes,5,0,1,1,6,C12N9/22;;C12Q1/701;;C12Q2600/158;;C12Q1/6806,C12Q1/68;;C12N9/22;;G01N21/63,,2,2,074-671-247-540-773;;024-869-466-547-414,32511323;;10.1101/2020.03.19.998724;;pmc7239053;;10.1016/j.scib.2020.04.041;;pmc7198415;;32373393,"DING XIONG, YIN KUN, LI ZIYUE, LIU CHANGCHUN: ""All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus"", BIORXIV, 21 March 2020 (2020-03-21), XP055866744, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.03.19.998724v1.full.pdf> DOI: 10.1101/2020.03.19.998724;;WANG XINJIE, MINGTIAN ZHONG, YONG LIU, PEIXIANG MA, LU DANG, QINGZHOU MENG, WENWEI WAN, XIAODONG MA, JIA LIU, GUANG YANG, ZIFENG Y: ""Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-based detection with naked eye readout, CRISPR/Cas12a-NER"", SCIENCE BULLETIN, vol. 65, 5 May 2020 (2020-05-05), pages 1436 - 1439, XP055866747",PENDING
